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SUMMARY 
Tuberculosis (TB) remains a main public health problem, particularly in people living with 
HIV (PLHIV) in sub-Saharan Africa (SSA). This persistent problem may be an indication 
of underlying problems in national health policies, and their implementation in SSA. The 
Southern African country of Lesotho, with one of the highest TB incidences in the world, 
is facing a catastrophic syndemic of HIV and tuberculosis (TB). The effectiveness of 
isoniazid preventive therapy (IPT), which has the potential to reduce the incidence of TB 
in PLHIV, has not been adequately evaluated since its introduction in 2011. This study 
evaluated the uptake of IPT, its effectiveness and the associated factors in Lesotho, with 
the aim of establishing the necessary policy changes required to prevent the occurrence 
of TB in PLHIV.  
To determine the effectiveness of IPT and the factors underpinning the implementation of 
this intervention in Lesotho, a quantitative evaluation as well as a qualitative study of the 
implementation of IPT was used. The study was therefore based on a triangulation of 
quantitative and qualitative research methods in two phases.  
The qualitative phase of the study identified health system challenges affecting the 
implementation of IPT, based on a cross-sectional qualitative analysis of interview 
responses of healthcare workers and stakeholders of the TB/HIV programmes, which 
included the Ministry of Health officials and support partners, purposively selected for their 
roles in IPT implementation in Lesotho. The rationale of this study phase was based on 
the premise that the rate of initiation of IPT and its effectiveness is largely dependent on 
the quality of implementation of the IPT programme.  
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The qualitative study phase revealed that seven factors in the health system were 
affecting the implementation of IPT in the country, namely poorly decentralised HIV 
services; inefficient monitoring and evaluation systems; ineffective service delivery; 
interrupted supply chains; an undertrained and inadequate health workforce; insufficient 
health system financing; and inefficient health information systems. The implementation 
of IPT was therefore a complex task which needed certain sectors of the health system to 
change. The most important lesson from this is that key health interventions need a ‘health 
system approach’ for success. 
The quantitative phase of the study was a quasi-experimental review of HIV-positive 
medical records randomly selected from eight health institutions in six districts of Lesotho. 
This study phase selected two patient groups, one enrolled into antiretroviral therapy 
(ART) before (2004-2010 cohort), and the other one after the launch of IPT (2011-2016 
cohort), to establish the rate of initiation of IPT and its effectiveness in preventing the 
occurrence of TB in the country. IPT uptake and its effectiveness were evaluated using 
an analytical model based on Cox’s proportional hazards regression analysis, an 
approach often used to determine the relative risk of contracting a disease and the 
associated factors.  
The quantitative study phase included 2 955 randomly selected records that met the 
inclusion criteria set for the study. Overall, 68.8% of the 2 955 patients had received IPT 
over a course of six years (2011-2016), which translated to a sluggish IPT uptake rate of 
20.6 per 100 person-years over the six-year period. Notably, only 135 (6.6%) patients 
defaulted IPT, which is a small proportion. Comparatively, the 2011-2016 cohort had a 
significantly (p=0.000) higher rate of IPT initiation (27.0 per 100 person-years) than the 
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2004-2010 cohort, (15.8 per 100 person-years), implying that patients newly enrolled into 
ART had a higher rate of IPT initiation. Findings indicated that the most significant 
predictors for initiation of IPT were age group, district category and duration of ART. 
Furthermore, based on odds ratios (OR), patients in the sparsely populated districts 
(OR=1.6) and males (OR=2.1) had significantly (p<0.05) higher odds of defaulting IPT, 
compared to those in the densely populated districts and females, respectively. Whereas 
higher defaults in the sparsely populated districts were associated with long distance from 
hospitals and the mountainous terrain associated with these districts, higher rates of 
defaulting by males were most likely due to migrant work in South Africa. 
The TB incidence rate reduced from 2.3 per 100 person-years in 7 985 person-years in 
the 2004-2010 cohort, to 1.6 per 100 person-years in 4 223 person-years in the 2011-
2016 cohort, implying that the IPT intervention had considerably reduced the occurrence 
of TB. However, the use of IPT was not without adverse effects. By proportion, the most 
common side effects to IPT were skin rash (37.2%), peripheral neuropathy (25.4%) and 
liver toxicity (9.4%). In addition, out of 246 patients who had developed TB and were 
discovered during a follow-up, 15.9% of the patients developed TB after exposure to IPT. 
Further findings indicated that prescribing IPT within one year of ART commencement, 
which reduced TB incidences to only 1.3 incidences per 100 person-years, was the most 
effective intervention for preventing the occurrence of TB, compared to other 
commencement timing of IPT intervention. Other TB incidences per 100 person-years by 
timing of IPT were as follows – IPT before ART (1.7), IPT after ART (1.8), no IPT (2.6), 
and IPT 3-5 years after ART initiation (2.3). Gender, baseline WHO clinical stage, district 
category and time to IPT relative to ART commencement emerged as significant 
predictors of TB occurrence. Notably, increasing commencement time for IPT by one six-
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month interval increased the risk of contracting TB by between 6% and 59%, depending 
on the cohort, with the 2011-2016 cohort having a higher risk compared to the 2004-2010 
cohort.  
The findings of this study indicate that the implementation of IPT in Lesotho has notable 
challenges. Clearly, there is a need to improve the rate of IPT initiation in the patient 
groups with the most sluggish rate of IPT uptake, and to improve retention of some patient 
groups with poor adherence to IPT. The findings of this study also indicate that delayed 
IPT commencement after ART initiation significantly affects the effectiveness of IPT. 
Furthermore, the study reveals that IPT is a complex health intervention, and its 
implementation therefore needs a health sector-wide or ‘health systems’ approach. 
KEYWORDS: Effectiveness of IPT; implementation of health interventions; IPT uptake; 
isoniazid preventive therapy; timing of isoniazid preventive therapy; 
tuberculosis  
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CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND TO THE RESEARCH PROBLEM 
Global statistics released by the World Health Organisation (WHO) reveal that one-third 
of the world population had tuberculosis (TB) infection in 2014, making TB the leading 
infectious disease (WHO 2016). Furthermore, TB is the most frequent life-threatening 
opportunistic disease in people living with human immunodeficiency virus (HIV). Of the 
1.5 million people who died from TB in 2013 alone, 360 000 were HIV-positive (WHO 
2014). The sub-Saharan region accounts for 74% of the annual 1.2 million people living 
with HIV who develop TB globally (Hermans, Grant, Chihota, Lewis, Vynnycky, 
Churchyard & Fielding 2016). People living with HIV (PLHIV) in the sub-Saharan region 
therefore constitute the largest reservoir of TB globally. Thus, the control of latent TB 
infection is an important step towards reducing HIV/TB-associated deaths, and ultimately 
TB elimination (Sandgren, Noordegraaf-Schouten, Van Kessel, Stuurman, Oordt-Speets 
& Van der Werf 2016). 
TB, which is caused by a bacterium known as Mycobacterium tuberculosis (MTB), is an 
ancient contagious disease, known to the early Greeks as phthisis and to the Romans as 
tabes (Boslaugh 2012). TB usually attacks the lungs but can also attack the brain, spine, 
and other parts of the body (Gengenbacher & Kaufmann 2012). The finding of evidence 
of TB infection in Egyptian mummies and the remains of Neolithic man in Germany 
(Bartels, 1907), France (Maczel, 2001), Italy (Formicola, 1987), and Denmark (Boslaugh 
2012) is empirical evidence that the prevention and control of TB has eluded mankind for 
millennia, thus making this disease an important example for studying the failure and 
effectiveness of public health interventions. 
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MTB, which has one of the most reinforced cell walls of all known pathogenic bacteria 
genera (Gengenbacher & Kaufmann 2012), is one of the most difficult organisms to cure, 
thus making preventive interventions critical to the success of TB control. Due to their 
capacity to remain dormant and avoid host defences, MTB pose a threat to HIV-positive 
people. The organism is known to reactivate and cause tuberculosis when the immune 
system is weakened by HIV (Gengenbacher & Kaufmann 2012).  
Empirical evidence of the effectiveness of isoniazid preventive therapy (IPT), which was 
recommended by the WHO (2004) as part of its Three I’s strategy for the prevention of 
TB in PLHIV, remains so scarce that it is difficult to judge the success or failure of this 
intervention. Notwithstanding the initial empirical evidence of the success of IPT in 
eradicating MTB from the body and in reducing the risk of progression to active TB disease 
in high TB burden settings (WHO 2004), the initiation and completion rates for IPT are 
frequently suboptimal and vary greatly within and across different populations, including 
those with high TB incidence rates (Sandgren et al. 2016). The variation in outcomes 
therefore necessitates more population studies of this intervention. 
Besides the safety concern for IPT, particularly liver toxicity (Woldehanna & Volmink, 
2004; Rangaka, Wilkinson, Boulle, Glynn, Fielding, Van Cutsem, Wilkinson, Goliath, 
Mathee & Goemaere 2014), the unknown optimal treatment duration and the durability of 
its protection are the most critical concerns with IPT. The optimal treatment duration, 
which has not been established for a very long time (Comstock 1999; Fitzgerald, Morse, 
Pape & Johnson 2000), remains a contentious issue. Several treatment durations have 
been tried, including nine months (Comstock 1999), six months (Johnson, Okwera, Hom, 
Mayanja, Mutuluuza Kityo, Nsubuga, Nakibali, Loughlin, Yun, Mugyenyi, Vernon, 
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Mugerwa, Ellner & Whalen 2001); and 36 months (Fitzgerald et al. 2000; Martinson, 
Barnes, Msandiwa, Moulton, Gray, McIntyre, Hausler, Ram & Chaisson 2009; Samandari, 
Agizew, Nyirenda, Tedla, Sibanda, Shang, Mosimaneotsile, Motsamai, Bozeman, Davis, 
Talbot, Moeti, Moffat, Kilmarx, Castro & Wells 2011). These authors warned that the 
duration of protection depends on the background TB prevalence and infection control 
strategies. Among gold miners in a high TB burden setting in South Africa, the durability 
of protection by IPT is reportedly lost within 6 to twelve months, with the loss being 
conceptually attributed to reactivation of persistent latent infection (Hermans et al. 2016). 
Houben, Sumner, Grant and White (2014) emphasised the need for more evidence of the 
effectiveness of IPT in different settings, including limited resource settings. 
The efficacy of IPT when used concurrently with antiretroviral drugs also needs more 
empirical evidence, particularly in countries with a high HIV and TB burden 
(Charalambous, Grant, Innes, Hoffmann, Dowdeswell, Pienaar, Fielding & Churchyard 
2010; Lawn, Wood, De Cock, Kranzer, Lewis & Churchyard 2010; Fielding, Grant, Hayes, 
Chaisson, Corbett & Churchyard 2011). Lawn et al. (2010) and Golub, Saraceni, 
Cavalcante, Pacheco, Moulton, King, Efron, Moore, Chaisson and Durovni (2007) note 
that the risk of tuberculosis reinfection remains several times higher in patients with a 
lower CD4 count level, compared to those with higher CD4 levels. Noting that poor 
immune recovery is common in countries where HIV patients start ART at very low levels 
of CD4 counts due to late diagnosis of HIV, there is still a need for further research in 
these settings to determine patient groups in need of extended IPT or other interventions. 
In addition, given that IPT has been demonstrated to be more effective in patients with a 
positive tuberculin skin test compared to those with a negative tuberculin skin test 
(Churchyard, Scano, Grant & Chaisson 2007), more evidence of the effectiveness of IPT 
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in settings without tuberculin screening tests (TST) for latent tuberculosis, such as in 
Lesotho, is therefore crucial.  
Poor implementation strategies may be negatively affecting IPT efficacy in developing 
countries. Apparently, ineffective implementation of health interventions at national scale 
is not uncommon in developing countries, despite the availability of theoretical and 
conceptual frameworks for effective and sustainable implementation of health 
interventions (Barker, Reid & Schall 2016; Iwelunmor, Blackstone, Veira, Nwaozuru, 
Airhihenbuwa, Munodawafa, Kalipeni, Jutal, Shelley & Ogedegbe 2016; MacDonald, 
Pauly, Wong, Schick-Makaroff, Van Roode, Strosher, Kothari, Valaitis, Manson & O’Briain 
2016). Of note, Iwelunmor et al. (2016) and Yellappa, Lefèvre, Battaglioli, Devadasan and 
Van der Stuyft (2017) postulate that the prevailing healthcare worker shortages, weak 
health systems and limited resources in sub-Saharan Africa call for careful implementation 
of health interventions, prioritising sustainability as a core component of health 
interventions in this region.  
Thus, the critical evaluation of health interventions such as IPT requires reliable guiding 
frameworks (WHO 2009). The evaluation of the implementation of the IPT intervention in 
this study is based on two theoretical frameworks which are often used for evaluating the 
effectiveness of health interventions: firstly, the WHO framework for evaluating 
interventions (WHO 2007), and secondly, a framework for evaluating the implementation 
of best practices in health interventions by Spencer, Schooley, Anderson, Kochtitzky, 
DeGroff, Devlin and Mercer (2013).  
The investigation of the effectiveness of IPT in high TB/HIV settings, based on sound 
scientific methodologies, thus remain critical for purposes of providing more evidence to 
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support its continued use or the need for a policy shift. Without evaluations of health 
interventions, the possibility of inappropriate use of resources remains ever present. Also, 
given that the failure of the IPT intervention may emanate from poor implementation 
strategies of an otherwise effective intervention, such investigations should therefore also 
include the evaluation of the implementation strategies themselves.  
1.2 STUDY RATIONALE 
The uptake and effectiveness of IPT, which was recommended by the WHO (2004) for 
the prevention of TB in PLHIV, is not well studied in the high HIV/TB-burden setting of 
Lesotho, where it was introduced in 2011 (Government of Lesotho 2013). By mid-2017, 
only one study on the use of IPT among pregnant HIV-positive women in Lesotho 
appeared in the literature (Tiam, Machekano, Gounder, Maama-Maime, Ntene-Sealiete, 
Sahu, Isavwa, Oyebanji, Ahimbisibwe, Mokone, Barnes, Chaisson, Guay & Kassaye 
2014). Lesotho is one of ten countries in the world which did not provide data for this 
indicator in 2014 (WHO 2014). Furthermore, given that the country has the second highest 
adult HIV prevalence rate in the world - estimated at 23.5% (UNAIDS 2016), and the third 
highest TB incidence rates globally, which is estimated at 852 per 100 000 population 
(WHO 2015), Lesotho remains an important research and knowledge gap for this health 
intervention. The need to address these knowledge gaps is therefore imperative. 
This study sought to answer the following research questions: (1) What is the rate of IPT 
initiation and retention in PLHIV, and what factors influence this rate in Lesotho? (2) How 
effective is IPT in preventing the occurrence of tuberculosis and reducing the prevalence 
of TB in the context of Lesotho? (3) What contextual factors within the health system of 
Lesotho affect the implementation of IPT as a health intervention?  
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1.3 AIM AND OBJECTIVES 
1.3.1 Aim 
The overarching aim of the study was to investigate the rate of initiation and retention on 
IPT, its effectiveness and the health system challenges affecting its implementation in 
Lesotho. 
1.3.2 Study objectives 
The specific objectives of this study were: 
 To assess the rate of initiation and retention of patients on IPT, and to determine the 
predictors of poor uptake of the drug. 
 To evaluate the effectiveness of IPT in preventing the occurrence of TB in PLHIV, the 
occurrence of adverse reactions, and to determine the factors associated with poor 
outcomes of IPT. 
 To investigate the health system challenges that are affecting the implementation of 
IPT intervention in PLHIV in Lesotho. 
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CHAPTER TWO: LITERATURE REVIEW 
2.1 MYCOBACTERIUM TUBERCULOSIS AND ITS PATHOGENICITY  
Tuberculosis (TB) remains one of the world’s deadliest communicable diseases, and the 
most frequent life-threatening opportunistic disease in people living with human 
immunodeficiency virus (HIV). In 2014, about 9.0 million people developed TB, and 1.5 
million died from this disease worldwide, 360 000 of whom were HIV-positive (WHO 2014).  
TB is caused by Mycobacterium tuberculosis (MTB), a slow growing, non-spore-forming 
bacterium that belongs to the genus Mycobacterium (Gengenbacher & Kaufmann 2012). 
The genus includes other pathogenic mycobacteria such as Mycobacterium leprae, which 
causes leprosy, Mycobacterium africanum, which causes less virulent forms of TB, and 
Mycobacterium bovis, which is another human pathogen contracted mainly from cattle.  
MTB has a mean generation time of 18 to 24 hours at 37°C under optimal conditions of 
oxygen and nutrients, implying that the organism can form visible colonies much longer 
than other bacteria (Gengenbacher & Kaufmann 2012). The organism forms white to light 
yellow pigmented colonies on Löwenstein-Jensen medium within three to four weeks 
under aerobic-to-facultative anaerobic conditions.  
The organism has a Gram positive cell wall (see Figure 2.1) that is reinforced by 
peptidoglycans, polysaccharides, glycolipids and lipids (Kieser & Rubin 2014). The lipids 
are unusual and are characterised by long-chain fatty acids such as mycolic acids, which 
reinforce the cell wall. Mycolic acids are long chains of β-unsaturated, branched fatty 
acids, which contribute to the non-permeability and rigidity of the cell envelope. The cell 
envelope, being the most distinctive feature of this organism, has been extensively studied 
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for drug targets. Isoniazid, ethionamide, ethambutol and cycloserine are all drugs whose 
mechanisms of action are dependent on interfering with the synthesis of the cell wall 
components (Kieser & Rubin 2014). 
 
Figure 2.1 The ultrastructure of Mycobacterium tuberculosis cell wall  
NAG=N-acetyl glucosamine; NAM=N-acetyl muramic acid; GalN=non-N-acetylated 
galactosamine; Source (Kieser & Rubin 2014). 
The various virulence factors of MTB, which are critical for its pathogenicity, are either 
protein in nature or glyconjugate cell wall components. Although work on unravelling the 
molecular mechanisms underlying these processes is still in progress, understanding 
these mechanisms is a crucial step towards finding anti-tuberculosis drugs and reliable 
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biomarkers for TB diagnosis. Table 2.1a and 2b present the virulence factors of MTB and 
their pathogenicity mechanisms. 
Table 2.1a Virulence factors of Mycobacterium tuberculosis and their pathogenicity 
Factor (Gene) Mechanism of pathogenicity 
Proteins  
 Immunomodulation 
ESAT-6 (esxA) and CFP-10 (esxB) T cell stimulation, elicitation of DTH Downregulate 
ROS production in macrophages. Block TLR2-
mediated signaling 
 Pore formation, apoptosis, cytolysis 
α-crystallin (acr) Antigenic; potential role in triggering latency 
Antigen 85 complex (fbpA, fbpB, fbpC) Antigenic; mediates attachment to macrophages 
 Intracellular survival/metabolism 
Erp (erp) Required for intracellular growth 
Cholesterol transporter (Mce4) Main cholesterol uptake system, important for survival 
during chronic phase 
Enzymes and lipid carriers (Igr locus) Cholesterol metabolism; important for growth 
Isocitrate lyase (Icl1) Allows shift to use of fatty acids as main carbon source; 
important for chronicity and persistence 
 Protection against ROI and RNI 
Catalase-peroxidase-peroxynitritase 
(KatG) 
 
Alkyl-hydroperoxide reductase (ahpC)  
Superoxide dismutases (sodA, sodC)  
Nitric oxide reductase (noxR3)  
CFP-10=culture filtrate protein–10; DC=dendritic cell; DTH=delayed-type hypersensitivity; ESAT-6=early 
secretory antigenic target–6; IFN=interferon; IL=interleukin; NAD=nicotinamide adenine dinucleotide; RNI= 
reactive nitrogen intermediates; ROI=reactive oxygen intermediates; ROS=reactive oxygen species; 
TLR2=Toll-like receptor 2; Source (Sakamoto 2012).  
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Table 2.1b  Virulence factors of Mycobacterium tuberculosis and their pathogenicity 
(continued) 
Factor (Gene) Mechanism of pathogenicity 
 Intracellular survival, protective granulomas and 
host cell damage 
Cell wall components   
Lipoarabinomannan Mannose-capped  Inhibition of DC maturation; induction of IL-10. 
Inhibition of phagolysosomal fusion 
 Protection against ROI; inhibition of protein kinase C 
activity; block transcription of IFN-g-inducible genes 
Mycolic acids Role in granuloma formation, macrophage activation. 
Required for mycobacterial survival 
 Biofilm formation 
Table 2.1 (continued)  
Glycopeptidolipids Biofilm formation 
Trehalose dimycolate Granuloma formation, pro-inflammatory, cachexia, 
 Decrease in NAD 
 Damage to host cell membranes  
Damage to mitochondria induction of apoptosis 
 Inhibition of phagosomal-lysosomal fusion 
Phenolic glycolipids Immunosuppression 
Sulpholipids Increase macrophage infectivity, impair macrophage  
 activation by inhibiting phagosomal maturation, 
blocking priming by IFN-g 
CFP-10=culture filtrate protein–10; DC=dendritic cell; DTH=delayed-type hypersensitivity; ESAT-6=early 
secretory antigenic target–6; IFN=interferon; IL=interleukin; NAD=nicotinamide adenine dinucleotide; RNI= 
reactive nitrogen intermediates; ROI=reactive oxygen intermediates; ROS=reactive oxygen species; 
TLR2=Toll-like receptor 2; Source (Sakamoto 2012). 
MTB’s pathogenicity success, as noted by Sakamoto (2012) and Gengenbacher and 
Kaufmann (2012), is based on three important capacities, namely: (1) immunomodulation 
– its capacity to re-program macrophages after initial phagocytosis to prevent its 
destruction; (2) intracellular survival/metabolism – the capacity to protect itself against 
reactive nitrogen intermediates (RNI) and reactive oxygen intermediates (ROI), and its 
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capability to minimise metabolism and terminate replication allows the bacterium to 
remain dormant and avoid host defences and drug treatment; and (3) MTB’s cell wall 
components – which initiate the formation of protective granulomas and cause damage to 
host cells. 
2.2 PROPERTIES AND MECHANISM OF ACTION OF ANTI-TUBERCULOSIS 
DRUGS  
2.2.1 History of anti-tuberculosis drugs and current treatment practices  
Mycobacterium tuberculosis is one of the most difficult bacteria to treat. For generations, 
TB treatment has required prolonged combination chemotherapy with several drugs 
working in synergy (see Figure 2.2 for the chemical structures of the common anti-
tuberculosis drugs). The order of these discoveries puts the discovery of isoniazid, an 
important drug used to treat or prevent the occurrence of TB, into perspective. Of note is 
the fact that the drug isoniazid has been in use for the treatment of TB for more than 60 
years. The discovery of INH was a significant milestone, as INH was highly active, 
inexpensive, and less prone to side effects.  
Chronologically, anti-tuberculosis drugs were discovered beginning with streptomycin 
(1944); para-aminosalicylic acid (PAS) (1946); isoniazid (INH) and pyrazinamide (PZA) 
(1952); ethionamide (ETH) and Prothionamide (PTH) (1956); and ethambutol (EMB) 
(1961). More anti-tuberculosis drugs were discovered in the 1960s, including cycloserine; 
kanamycin; amikacin; capreomycin; and rifampicin (RIF), which is the drug of choice for 
treatment of TB since the 1970s. Fluoroquinolones, important second-line drugs for the 
treatment of drug-resistant TB, were developed in the 1980s. 
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Figure 2.2 Chemical structures of some common anti-tuberculosis drugs  
   Source (Zhang 2005).  
The current six-month TB chemotherapy recommended by the WHO, known as the 
directly observed treatment short-course (DOTS), comprises an intensive two-month 
treatment phase with four drugs, namely INH, RIF, PZA and EMB, followed by a 
continuation phase with INH and RIF for another four months (WHO 2010). For multi-drug 
resistant TB (MDR-TB), the WHO recommends DOTS-Plus, which means DOTS plus 
second-line TB drugs such as aminoglycosides, polypeptides and fluoroquinolones, 
among others (WHO 2010). While amikacin and kanamycin are most effective, 
aminoglycosides capreomycin is the most commonly used polypeptide drug, and likewise, 
ciprofloxacin is the most common fluoroquinolone used to treat TB (Hu, Zhang, Zhao, 
Gao, Feng, Lv, Xu & Wu 2017).  
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2.2.2 Properties and mechanism of action of common anti-tuberculosis drugs 
Table 2.2 presents the properties, mechanisms of action and targets of common anti-
tuberculosis drugs. Isonicotinic acid hydrazide (INH) or isoniazid, is a synthetic drug of 
which the primary target of inhibition is the synthesis pathway of cell wall mycolic acids 
(Zhang 2005). Specifically, the drug targets the enoyl ACP reductase enzyme in this 
pathway. The loss of acid fastness in MTB exposed to INH has been demonstrated as the 
most critical laboratory evidence of the effect of INH on mycolic acid synthesis, and MTB 
can only kill actively-dividing mycobacteria (Hu et al. 2017). INH being a prodrug, its active 
form, isonicotinic acyl radical, reacts with NAD to form INH-NAD composite, which not 
only inhibits the enoyl ACP reductase enzyme, but also damages DNA, carbohydrates, 
and lipids, and inhibit NAD metabolism in mycobacteria (Zhang 2005). It is therefore not 
surprising that significant changes in the NADH/NAD ratio due to mutations in NAD 
dehydrogenase II may cause resistance to INH, although mutations in the gene KatG, 
which is involved in INH activation, is the main mechanism of INH resistance (Hu et al. 
2017). 
Ethionamide (ETH) is a prodrug that is activated by a monooxygenase enzyme EtaA. It 
inhibits the same target InhA as INH in the mycolic acid synthesis pathway (Vale, Gomes 
& Santos 2013). Ethambutol (EMB) interferes with the biosynthesis of arabinogalactan, a 
major polysaccharide of mycobacterial cell wall, specifically inhibiting the polymerization 
of cell wall arabinan of arabinogalactan and of lipoarabinomannan (Chakraborty & Rhee 
2015). Cycloserine (CS) inhibits the synthesis of cell wall peptidoglycan by blocking the 
action of D-alanine racemase (Alr), an enzyme involved in the conversion of L-alanine to 
an important substrate, D-alanine (Kolyva & Karakousis 2012). 
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Table 2.2 Properties, mechanisms of action and targets of anti-tuberculosis drugs  
Drug (year of 
discovery) MIC
a 
(g/ml) 
Effect on 
bacterial cell 
Mechanisms of action Targets 
Isoniazid (1952) 0.01–0.2 Bactericidal Inhibition of mycolic acid synthesis and other effects 
on DNA, lipids, carbohydrates, and NAD 
metabolism 
Multiple targets, including acyl 
carrier protein reductase (InhA) 
Rifampicin (1966) 0.05–0.5 Bactericidal Inhibition of RNA synthesis RNA polymerase β subunit 
Pyrazinamide 
(1952) 
20–100 
pH 5.5 
or 6.0 
Bacteriostatic/ 
Bactericidal 
Disruption of membrane transport and energy 
depletion 
Membrane energy metabolism 
Ethambutol (1961) 1–5 Bacteriostatic Inhibition of cell wall arabinogalactan synthesis Arabinosyl transferase 
Streptomycin 
(1944) 
2–8 Bactericidal Inhibition of protein synthesis Ribosomal S12 protein and16S 
rRNA 
Kanamycin (1957) 1–8 Bactericidal Inhibition of protein synthesis 16S rRNA 
Quinolones 
(1963) 
0.2–4 Bactericidal Inhibition of DNA synthesis DNA gyrase 
Ethionamide 
(1956) 
0.6–2.5 Bacteriostatic Inhibition of mycolic acid 
synthesis 
Acyl carrier protein reductase 
(InhA) 
PAS (1946) 1–8 Bacteriostatic Inhibition of folic acid and iron metabolism? Unknown 
Cycloserine (1952) 5–20 Bacteriostatic Inhibition of peptidoglycan  
synthesis 
D-alanine racemasec  
aMIC=minimum inhibitory concentration; PAS=para-aminosalicylic acid; Source (Zhang 2005). 
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Rifampicin (RIF) is a broad-spectrum anti-TB drug that impedes RNA synthesis through 
binding to DNA-dependent RNA polymerase of MTB (Kolyva & Karakousis 2012). Of note 
is the fact that RIF can inhibit both actively growing and dormant MTB. Fluoroquinolones, 
particularly nalidixic acid, ciprofloxacin, ofloxacin, levofloxacin, and sparfloxacin, are 
important MDR-TB second-line drugs that inhibit DNA synthesis by targeting the DNA 
gyrase enzyme (Zhang 2005).  
Aminoglycoside anti-TB drugs, particularly streptomycin (SM), interfere with protein 
synthesis through inhibiting initiation of mRNA translation, resulting in misreading of the 
genetic code (Zhang 2005).  
Pyrazinamide (PZA), a prodrug that requires conversion to its active form, pyrazinoic acid, 
has no clear activity against MTB at normal culture conditions, but is important for 
shortening the duration of TB therapy to six months (Kolyva & Karakousis 2012). 
Nevertheless, PZA is believed to facilitate the reduction of the membrane potential in MTB, 
thus de-energising the membrane and affecting membrane transport (Zhang 2005). 
2.3 EPIDEMIOLOGY OF TB IN LESOTHO AND TREATMENT GUIDELINES 
2.3.1 The prevalence and incidence of TB in Lesotho 
In 2015, Lesotho, with a TB incidence rate in the general population estimated at 852 per 
100 000 population (WHO 2015), was amongst the top three nations with the highest rates 
of TB worldwide, with the two other nations, South Africa and Swaziland, having TB 
incidence rates above 700 per 100 000 population. By 2018, despite improvement in the 
incidence rate from 852 to 665 per 100 000 population (WHO 2018), Lesotho continued 
to have the highest TB incidence in the regional grouping of countries in Southern Africa 
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known as Southern African Development Community (SADC). According to latest WHO 
(2018) figures, other countries with high TB incidence rate per 100 000 population in the 
SADC region were South Africa (567), Mozambique (551), Namibia (423) and Zambia 
(361). Of note, TB incidences per 100 000 population in Swaziland (308), Botswana (300), 
Zimbabwe (221) and Malawi (133) depict significant improvement in these countries 
(WHO 2018). 
Government of Lesotho (GoL) (2013b) attributes the high magnitude of TB in Lesotho to 
the high HIV prevalence, which is estimated at 23% among adults. Notably, TB is most 
prevalent in correctional institutions in the country, in migrant mineworkers and factory 
workers who live in overcrowded settings (GoL 2013b). About 75% of patients with TB in 
Lesotho are co-infected with HIV (WHO 2014). The main drivers of the high TB infection 
rate include poverty, poor nutrition, overcrowding and poor ventilation in the homes (GoL 
2013b). 
2.3.2 ART and TB guidelines in Lesotho: rationale and challenges  
The current ART guidelines in Lesotho recommend a combination of three antiretroviral 
(ARV) drugs in all HIV-positive patients. the first line treatment for adults consists of two 
nucleoside reverse transcriptase inhibitors (NRTI) and one non-nucleoside reverse 
transcriptase inhibitor (NNRTI) used according to a rationale shown in Table 2.3 (GoL 
2013a). 
Selecting regimens that are compatible with TB therapy in HIV-positive people co-infected 
with TB presents several challenges, particularly in Lesotho where the number of 
treatment options is severely limited. For example, for children younger than three years, 
regimens based on protease inhibitor (PI) are the preferred first line option, but 
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interactions between rifampicin and LPV/r or NVP mean that co-treatment in children 
under three years is challenging (GoL 2013a). Rifampicin reduces concentrations of LPV/r 
or NVP since it induces the cytochrome P450 enzymes (Wilson, Cotton, Bekker, Meyers, 
Venter & Maartens 2008). HIV patients co-infected with TB therefore may need to be given 
other regimens at an added expense. 
Table 2.3 Current first-line and second-line ART drugs recommended for adults in 
Lesotho 
First-line ART Preferred first-line regimens Alternative first-line regimens 
Adults 
TDF + 3TC + EFV 
AZT + 3TC + EFV 
including pregnant and AZT + 3TC + NVP 
breastfeeding women and TDF + 3TC + NVP 
adults with TBand HBV *ABC + 3TC + EFV (or NVP) 
coinfection 
Adolescents AZT+3TC+EFV 
(10 to 19 years) ≥35 kg AZT+3TC+NVP 
 TDF + 3TC +NVP 
*ABC + 3TC + EFV (or NVP) 
   Children (3 to 9 years) and 
Adolescents <35 kg 
 
ABC + 3TC + EFV 
AZT + 3TC + EFV ABC 
+ 3TC + NVP AZT + 
3TC + NVP 
Children 
< 3 years 
 
ABC+ 3TC + LPV/r 
AZT + 3TC + LPV/r 
ABC + 3TC + NVP AZT 
+ 3TC + NVP 
ABC=abacavir; AZT=zidovudine; 3TC=lamivudine; LPV/r=lopinavir/ritonavir; NVP=nevirapine; 
EFV=efavirenz; TDF=tenofovir; Source (GoL 2013a). 
Switching to second-line ART drugs is recommended in cases where treatment failure as 
assessed by clinical and CD4 count is suspected or confirmed by viral load tests. Table 
2.4 outlines the second-line drug options available in Lesotho. However, both access to 
viral load tests and access to second-line ARVs in Lesotho is limited (GoL 2013a). These 
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limitations imply that the capacity to prove explicitly that a patient needs second-line 
therapy before switching to second- and third-line drugs is greatly curtailed. Third-line 
drugs for Lesotho include darunavir, ritonavir, raltegravir and etravirine (GoL 2013a). 
Table 2.4 Recommended second-line drug options for Lesotho 
 Children First-line ART regimen Second-line ART regimen 
 
LPV/r-based 
first-line 
regimen 
Younger  than 
3 years 
ABC + 3TC + LPV/r No  change 
AZT + 3TC + LPV/r 
3 years and 
older 
ABC + 3TC + LPV/r AZT + 3TC + EFV 
AZT + 3TC + LPV/r ABC + 3TC + EFV 
NNRTI-based 
first-line 
regimen All ages 
ABC + 3TC + EFV (or NVP) AZT + 3TC + LPV/r 
TDF + 3TC + EFV (or NVP) 
AZT + 3TC + EFV (or NVP) ABC + 3TC + LPV/r 
ABC=abacavir; AZT=zidovudine; 3TC=lamivudine; LPV/r=lopinavir/ritonavir; NVP=nevirapine; 
EFV=efavirenz; TDF=tenofovir; Source (GoL 2013a). 
2.3.3 IPT guidelines  
Isoniazid preventive therapy (IPT) was launched in Lesotho in 2011 (GoL 2013b) as part 
of the WHO’s Three I’s programme, which comprised intensified case finding (ICF), 
Isoniazid preventive therapy (IPT) and tuberculosis infection control (IC), (Kranzer, 
Houben, Glynn, Bekker, Wood & Lawn 2010). According to the national IPT guidelines, a 
six-month course of IPT is recommended in all HIV-positive persons over one year of age 
in whom active TB and other contraindications have been excluded (GoL 2013a). These 
contraindications include active hepatitis, alcoholism and severe peripheral neuropathy. 
Other contraindications include epilepsy and kidney failure. The main aim of this 
recommendation is to treat latent TB infection and reduce the risk of progression to active 
TB. The rationale behind the recommendation by the GoL (2013a) is based on the fact 
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that the risk of contracting TB is particularly high during the first six months after ART 
initiation. However, the screening of active TB is based on symptoms, clinical signs and 
X-rays. Tuberculin skin tests are not available to diagnose latent TB infection.  
The Lesotho guidelines for IPT also recommend that IPT be given to all eligible HIV-
positive patients, irrespective of CD4 counts, WHO clinical status, ART status and ART 
regimen (GoL 2013a).  
With respect to liver function, IPT is recommended in patients with alanine 
aminotransferase (ALT) levels up to two to five times the upper limit of the normal range, 
with monthly monitoring of liver function. Of note, in Lesotho, is that ALT is regarded as 
normal if the level is below 40 IU/L in males and below 31 IU/L in females (GoL 2013a). 
However, IPT is contraindicated if ALT is more than five times the upper limit of the normal 
range, that is, ALT levels greater than 200 IU/L. However, recommendations stipulate that 
routine laboratory monitoring of liver function tests, including ALT, without indications for 
liver disease, is not mandatory.  
IPT is regarded to be safe during pregnancy, including during breastfeeding. In addition, 
all HIV-positive infants <12 months and children with possible exposure to TB in the 
households should also be initiated on IPT after ruling out contraindications, and with 
relevant dosage titrations applied (GoL 2013a).  
IPT dosages as stated by GoL (2013a) should not be more than 300mg/day in adults and 
children for six months. However, in children, a dosage of 10 mg/kg body weight is 
recommended. In addition, the IPT recommendation stipulates that an IPT treatment 
course has to be restarted if there is a treatment interruption of three months or less. 
Pyridoxine phosphate or vitamin B6 has to be given concurrently with IPT to prevent the 
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occurrence of peripheral neuropathy. The effectiveness of the six-month treatment 
duration without further IPT is not clear in Lesotho, the main challenge being that the 
threat of reinfection may continue after IPT, particularly in patients with low immune 
recovery (Lawn, Wood, De Cock, Kranzer, Lewis & Churchyard 2010).  
2.4 EARLY EVIDENCE OF IPT EFFECTIVENESS IN PEOPLE LIVING WITH HIV 
2.4.1 Optimum duration of IPT treatment 
Early evidence of IPT treatment in HIV-infected patients with latent tuberculosis proved 
that IPT reduces their lifetime risk of active tuberculosis to 4% or less (Fitzgerald, Morse, 
Pape & Johnson 2000). However, Fitzgerald et al. (2000), one of the earliest research 
teams on IPT efficacy, note that the protection was dependent on the duration of therapy, 
with longer durations of IPT treatment up to 36 months associated with protection for up 
to 40 months on average. Short treatment durations of six months were only associated 
with short protection for six months on average. Comstock (1999) reviewed the data from 
clinical trials conducted mostly in the United States of America (USA), and found 
inconclusive evidence for the efficacy of the six-month course of IPT; and recommended 
that the optimal protection from IPT appears to be obtained by at least nine months of 
treatment (Figure 2.3). 
It is also important to note that historically, trials included other curative anti-tuberculosis 
drugs such as rifampicin and pyrazinamide. However, six-month treatment with IPT alone 
proved to have a better effect, though less sustained than other regimens containing 
rifampicin or pyrazinamide (Johnson, Okwera, Hom, Mayanja, Mutuluuza Kityo, Nsubuga, 
Nakibali, Loughlin, Yun, Mugyenyi, Vernon, Mugerwa, Ellner & Whalen 2001). 
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Contrastingly, the rifampicin and pyrazinamide regimens provided less efficacious and 
narrower therapeutic-to-safety indices. Of note, the term “therapeutic index” refers to the 
therapeutic window relative to the safety window, and, in practice, the therapeutic index 
is obtained by comparing the amount of a therapeutic agent required to achieve 
therapeutic effect to the amount that causes toxicity. 
 Figure 2.3 Tuberculosis case rates by duration of IPT treatment in the clinical trials 
The tuberculosis case rates are in per cent (%); Dots represent observed whilst the 
continuous line represents the fitted line. Source: (Comstock 1999). 
Based on these and possibly other studies, the WHO (2004) recommended routine use 
of IPT for prophylaxis against TB for prophylaxis in 2004. However, the WHO (2004) 
recommendation did not state the maximum period that IPT was to be taken due to a lack 
of evidence, but only recommended that IPT may be used for six up to nine months. In 
addition, the WHO (2004) acknowledged that the effectiveness of this therapy in 
developing countries is less clear because, at that time, there was inconclusive evidence 
about its effectiveness. However, the WHO (2004) believed that the results of upcoming 
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studies assessing the effectiveness of concurrent IPT and ART needed to be monitored 
closely in order to inform the adopted policy on IPT. To date, the duration for IPT has 
remained contentious, with some authors recommending six, nine or twelve months 
(Getahun, Granich, Sculier, Gunneberg, Blanc, Nunn & Raviglione 2010). Two trials from 
Botswana and South Africa have recommended durations of up to 36 months (Martinson, 
Barnes, Msandiwa, Moulton, Gray, McIntyre, Hausler, Ram & Chaisson 2009; Samandari, 
Agizew, Nyirenda, Tedla, Sibanda, Shang, Mosimaneotsile, Motsamai, Bozeman, Davis, 
Talbot, Moeti, Moffat, Kilmarx, Castro & Wells 2011); although the protection has since 
been seen to decline rapidly (Samandari, Agizew, Nyirenda, Tedla, Sibanda, 
Mosimaneotsile, Motsamai, Shang, Rose & Shepherd 2015). 
2.4.2 The effectiveness of IPT in the African setting 
Notable studies of historical importance prior to general acceptance in routine use in 
African settings include the one by Grant, Charalambous, Fielding, Day, Corbett, 
Chaisson, De Cock, Hayes and Churchyard (2005) and Rangaka, Wilkinson, Boulle, 
Glynn, Fielding, Van Cutsem, Wilkinson, Goliath, Mathee and Goemaere (2014) in South 
Africa. IPT reduced tuberculosis incidence by between 38%, and by 60% in HIV-infected 
adults with no history of tuberculosis. However, tuberculosis incidence remained high 
despite IPT. By the end of the study, IPT had reduced the incidence of tuberculosis from 
11.9 to 9.0 per 100 person-years. 
Further studies reflected in a review by Churchyard, Scano, Grant and Chaisson (2007) 
further motivated researchers to accept IPT for routine use, including during ART (Figure 
2.4). However, Churchyard et al. (2007) warned that reinfection is an important problem 
in African settings, having noticed disappointing results in a Zambian IPT trial (Quigley, 
© Central University of Technology, Free State
 31 
Mwinga, Hosp, Lisse, Fuchs, Porter & Godfrey-Faussett 2001). This review by 
Churchyard et al. (2007) also demonstrates that the benefits of IPT are much better for 
patients who have had a positive tuberculin skin sensitivity test, which is based on purified 
protein derivative (PPD), compared to those whose PPD results are negative or unknown.  
 
Figure 2.4 Efficacy of IPT: Results of meta-analysis review 
PPD = purified protein derivative; Source: (Churchyard et al. 2007). 
2.4.3 The problem of short-term protection against tuberculosis 
The main challenge facing IPT is that it provides short-lived protection. Randomised 
controlled trials have shown IPT provides short-term protection against tuberculosis, 
which is quickly lost after cessation of therapy, because IPT does not effectively cure 
Mycobacterium tuberculosis infection, and also does not prevent reinfection (Houben, 
Sumner, Grant & White 2014). Therefore, there is a need to find a better prophylactic 
drugs for preventing TB in PLHIV.   
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2.4.4 The joint effect of ART and IPT 
The joint effect of ART and IPT on the risk of contracting tuberculosis is an interesting 
phenomenon. Generally, the risk of tuberculosis has an antithetical relationship to the 
level of immunity, as depicted in Figure 2.5 (Havlir, Getahun, Sanne & Nunn 2008). The 
use of antiretroviral drugs, with the main purpose of limiting HIV replication, increases the 
CD4 count levels, and reduces the risk of tuberculosis infection. However, it is important 
to note that, although ART significantly reduces the risk of tuberculosis, it does not reduce 
the risk entirely (Getahun et al. 2010). Havlir et al. (2008) reviewed the effect of ART on 
the risk of tuberculosis infection, and concluded from nine studies that ART reduces the 
risk of tuberculosis infection, but not entirely.  
 Figure 2.5 The risk of tuberculosis infection relative to CD4 count 
Source: (Havlir et al. 2008). 
In recent times, more researchers have continued to study the joint effect of IPT and ART. 
From the studies, it is now generally accepted that antiretroviral therapy used concurrently 
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with IPT further reduces the incidence of TB compared to ART alone, due to restoration 
of immunity (Charalambous, Grant, Innes, Hoffmann, Dowdeswell, Pienaar, Fielding & 
Churchyard 2010; Lawn et al. 2010; Fielding, Grant, Hayes, Chaisson, Corbett & 
Churchyard 2011). Charalambous et al. (2010) and Fielding et al. (2011) observed that 
mortality was significantly lower in cohorts taking IPT and ART concurrently. However, as 
Lawn et al. (2010) note, in HIV-positive patients presenting with advanced 
immunodeficiency with very low CD4 counts, it is necessary to delay concurrent IPT until 
completion of the first few months of antiretroviral therapy, when active tuberculosis has 
been excluded. Lawn et al. (2010) further note that the risk of tuberculosis infection 
remains several times higher in those with poor immune recovery than in patients with 
higher CD4 levels. Golub, Saraceni, Cavalcante, Pacheco, Moulton, King, Efron, Moore, 
Chaisson and Durovni (2007) confirm this theory, and also note that the reduction in the 
relative risk of infection with TB is dependent on the CD4 count level at which IPT is given 
together with ART. Patients with better immunity levels as indicated by CD4 counts had 
better outcomes compared with patients with low CD4 counts (below 350 cells/cm3). 
These observations raise a concern in many limited resource settings, including Lesotho, 
where a significant proportion of patients still start ART at very low levels of CD4 counts 
due to late diagnosis of HIV. Therefore, further evaluations of antiretroviral treatment 
outcomes following the use of IPT in limited resource settings is important. 
2.4.5 The effectiveness of IPT in settings without access to the tuberculin skin 
test and other biomarkers 
It is important to note that in resource-limited settings such as Lesotho, IPT is given 
without prior screening for latent TB using tuberculin skin test (TST) such as the purified 
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protein derivative (PPD) test. This may be due to many factors, including scarcity of 
resources and the need to confirm the results with more reliable tests. However, the 
effectiveness of this approach is still unclear.  
In practice, positive PPD tests have to be confirmed by other tests that are less influenced 
by previous Bacillus Calmette–Guérin (BCG) vaccination such as the QuantiFERON-TB 
Gold™ which is based on quantifying interferon-gamma released by T-lymphocytes when 
exposed to certain Mycobacterium tuberculosis antigens (Altet, Dominguez, De Souza-
Galvao, Jimenez-Fuentes, Mila, Solsona, Soriano, Latorre, Lara, Cantos, Ferrer, Orcau, 
Ruiz-Manzano & Cayla 2015), and the T-SPOT.TB™ test, which is a type of Enzyme-
Linked ImmunoSpot (ELISPOT) assay which enumerates anti-mycobacterial T-cells that 
produce interferon-gamma in a sample of blood (Leung, Yam, Ho, Yew, Chan, Law, Lee, 
Chang, Tai & Tam 2015). Thus, the PPD test in limited resource settings remains 
unavailable for routine use until other cheaper and more accurate tests become available. 
Meanwhile, the proportion of latent tuberculosis in limited resource settings remain 
speculative, and opportunities to halt the spread of TB continue to be missed. 
In recent years, researchers have tried other options to confirm latent TB diagnosis. For 
example, Kasempimolporn, Thaveekarn, Kerdpanich, Skulpichetrat, Saekhow, 
Boonchang, Bharnthong and Sitprija (2015) compared the diagnostic performance of the 
strip test with the tuberculin skin test and interferon-gamma release assay. The strip test 
did not appear to be useful for the diagnosis of active TB in comparison with the interferon-
gamma release assay. Further efforts in this regard are therefore required.  
Chegou, Heyckendorf, Walzl, Lange and Ruhwald (2014) also reviewed some of the 
markers that are currently being tested, including recent advances in the development of 
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other antigens specific to Mycobacterium tuberculosis such as ESAT-6 and CFP-10 
(Weldingh & Andersen, 2008; Wu, Zhang, Zhang, Zhang, Zhu & Shi 2008). It is not clear 
which of these markers will eventually prove to be useful in humans. Limited 
understanding of pathogenic mechanisms through which Mycobacterium tuberculosis 
causes disease may be one reason for the delayed success in finding better markers 
(Gengenbacher & Kaufmann 2012). Consequently, more research on the mechanisms 
that cause mycobacterial latency and activation is necessary.  
Molecular screening of tuberculosis is perhaps one of the recent successes in the 
diagnosis of latent tuberculosis. The GeneXpert molecular technique couples rapid 
confirmation of Mycobacterium tuberculosis with a sensitivity test for rifampicin (Walters, 
Goussard, Bosch, Hesseling & Gie 2014). This technique is particularly important in 
children where prior confirmation of Mycobacterium tuberculosis infection and rifampicin 
sensitivity is invaluable. Therefore, molecular techniques offer a glimmer of hope for the 
diagnosis of latent tuberculosis in settings with a high TB burden in the future, as the 
technology becomes more affordable. 
2.5 THE SAFETY OF IPT 
2.5.1 Liver toxicity 
The safety of IPT is another ongoing debate, with liver toxicity being the most serious 
concern. The source of INH hepatotoxicity is believed to be the acetylation of INH by the 
liver enzyme N-acetyltransferase 2 (NAT2), which produces two hepatotoxic metabolites, 
acetylhydrazine and isonicotinic acid (Tostmann, Boeree, Aarnoutse, De Lange, Van Der 
Ven & Dekhuijzen 2008).  
© Central University of Technology, Free State
 36 
Early clinical trials in HIV-positive patients indicate that IPT is less hepatotoxic than other 
regimens based on rifampicin and pyrazinamide (Woldehanna & Volmink 2004). 
Saukkonen, Cohn, Jasmer, Schenker, Jereb, Nolan, Peloquin, Gordin, Nunes, Strader, 
Bernardo, Venkataramanan and Sterling (2006) recommend that patients on INH should 
have liver function tests such as ALT monitored, particularly in chronic alcohol consumers, 
patients on concomitant hepatotoxic drugs, active viral hepatitis such as hepatitis B 
sufferers, and other pre-existing liver disease. Daily alcohol consumption increases the 
risk of hepatitis by more than four times (Saukkonen et al. 2006). It is also important to 
note that active hepatitis B, but not quiescent hepatitis B, is a significant factor to IPT 
hepatotoxicity (Saukkonen et al. 2006). However, this finding needs to be verified in other 
settings.  
IPT toxicity poses a risk in African settings due to limited laboratory tests for monitoring 
toxicity of the drug. Notwithstanding that ALT and hepatitis B screening tests for liver 
function are available in rural settings of African countries, the tests are sometimes not 
performed due to cost constraints. Viral hepatitis is rampant in these settings. For 
example, Mugomeri et al. (2015) found that in one cohort of 304 HIV-positive patients in 
Lesotho, 10.5% had HBV/HIV coinfection by laboratory values. Therefore, hepatitis B 
screening and liver function tests are important to reduce IPT toxicity. 
Studies of the dynamics of IPT toxicity during IPT treatment have noted that about 60% 
of toxicity cases are reported in the first three months of treatment, with about 80% of the 
cases occurring in the first six months (Saukkonen et al. 2006). Additional risk factors to 
IPT toxicity include older age (above 50). However, more adverse drug reaction profiles 
and their risk factors need to be reviewed in limited resource settings.  
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Another safety concern related to hepatotoxicity, is the potential effect of INH on 
cytochrome P450 isoenzymes. Given that INH inhibits several cytochrome P450 
isoenzymes, which metabolise many antiretroviral drugs (Wen, Wang, Neuvonen & 
Backman 2002), Rangaka et al. (2014) warns that increased antiretroviral drug 
concentrations reaching toxic proportions are highly possible in patients taking ARVs and 
IPT concurrently. 
2.5.2 Peripheral neuropathy and other concerns 
INH is associated with peripheral neuropathy (PN), a condition which affects the sensory 
and motor nerves leading to loss of nerve function (Mafukidze, Calnan & Furin 2016). 
However, it is important to note that TB itself, comorbid conditions such as HIV disease, 
malnutrition, or diabetes mellitus and their treatment, and anti-TB drugs such as 
ethambutol, may also cause PN. ARVs, particularly stavudine, didanosine and zidovudine 
and drugs for drug-resistant TB namely, cycloserine, high-dose INH, ethionamide and 
linezolid have also been associated with PN (Mafukidze et al. 2016).  
While withdrawal of the offending agent is the most effective treatment for PN, use of 
analgesics and serotonin reuptake inhibitors may also reverse the effects of PN. 
Fortunately, vitamin supplementation is known to prevent the occurrence of PN in patients 
on INH (Lawn et al. 2010). In the African setting, vitamin supplementation with pyridoxine 
phosphate or vitamin B6 given has become the standard practice for preventing PN in 
HIV-positive patients taking IPT (Rangaka et al. 2014).	
INH is also associated with skin rash typical of drug-induced hypersensitivity (Rangaka et 
al. 2014). Furthermore, INH may be a cause of cutaneous ichthyosis, characterised by 
keratinization and generalised scaly lesions (Kouismi, Bourkadi & Iraqi 2013). 
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2.5.3 Safety of IPT in children 
As IPT became standard treatment in HIV-positive patients, its use was extended to 
children where safety concerns had delayed its use for some years. Gray, Zar and Cotton 
(2009), Frigati, Kranzer, Cotton, Schaaf, Lombard and Zar (2011) and Schaaf, Cotton, 
Boon and Jeena (2013) found IPT to be significantly (p<0.05) associated with low 
incidence of TB among children on ART. However, their recommendations came with 
warnings. IPT was only justifiable in cases where there was evidence of prior exposure to 
TB. According to the same authors, screening of active TB is therefore mandatory before 
IPT is used in children. However, it is also important to note that, whereas the PPD test is 
useful in adults, the same test has limited utility in children. Gray et al. (2009) report that 
the PPD test may not be useful in children as it is not sufficiently sensitive in children.  
Recently, Lala, Parbhoo, Verwey, Khan, Dangor, Moore, Pettifor and Martinson (2014) 
evaluated the effect of topical calcipotriol or zinc as enhancers on the tuberculin skin tests 
in hospitalised South African children. Topical calcipotriol or zinc did not significantly 
improve the performance of the tuberculin skin test in children. Therefore, the screening 
of active tuberculosis remains the most important test before administering IPT in children.  
2.6 IPT AND THE THREAT OF DRUG RESISTANCE 
One of the early stumbling blocks to the widespread use of IPT was the potential to 
develop drug resistance. However, a review by Balcells, Thomas, Godfrey-Faussett and 
Grant (2006) revealed that the overall relative risk for developing drug resistance was 
1.45%, with a 95% confidence interval between 0.85 and 2.47. Van Halsema, Fielding, 
Chihota, Russell, Lewis, Churchyard and Grant (2010) studied the characteristics of TB 
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in gold miners previously exposed to IPT in South Africa. The authors report that, although 
the occurrence of IPT drug resistance is relatively more common among patients pre-
exposed to IPT, tuberculosis has similar prevalence of drug resistance to background 
treatment outcomes. However, as Balcells et al. (2006) note, numerous limitations in the 
studies - including small sample sizes and incomplete data - limit the generalisation of the 
findings. Therefore, the risk of developing drug resistance to IPT remains possible.  
The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-
resistant tuberculosis (XDR-TB) pose a threat, particularly in high TB-burden settings such 
as Lesotho. Fortunately, new affordable molecular diagnostic methods to detect this 
resistance are now available (N’guessan, Assi, Ouassa, Ahui-Brou, Tehe, Keita Sow, 
Guei, Kouakou & Dosso 2014). These methods detect mutations in the rpoB and inhA 
genes of Mycobacterium tuberculosis - changes that are attributed to rifampin. INH 
resistance, on the other hand, is usually due to mutations in the katG gene (N’guessan et 
al. 2014).  
The sensitivity of GeneXpert™ molecular assays for INH resistance detection is generally 
lower than for the detection of rifampicin resistance. While the sensitivity for INH ranges 
from 73% to 92%, the sensitivity for rifampicin ranges from 92% to 99% (N’guessan et al. 
2014). For this reason, the GeneXpert™ technique is generally used to detect resistance 
to rifampicin. 
Adherence to preventive drugs is much more complicated than adherence to curative 
drugs. When patients are asked to take a preventive drug, their adherence is likely to 
depend on their level of loyalty and understanding of the condition they are preventing. It 
is therefore possible that some patients may see additional drugs (e.g. INH) to their other 
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antiretroviral drugs as extra inconvenience. According to Churchyard et al. (2007), rates 
of adherence to IPT in South Africa, Zambia and Malawi ranged between 24% and 59%. 
Most patients cited adverse effects of the drug INH, lack of money for transport to collect 
the IPT and a perception that IPT was not effective. 
2.7 THEORETICAL FRAMEWORKS FOR EVALUATING THE EFFECTIVENESS OF 
HEALTH INTERVENTIONS 
2.7.1 The WHO framework for evaluating the effectiveness of health 
interventions  
Empirical evaluation of the effectiveness of health interventions is integral to evidence-
based practice. Such evaluations are also meant to ensure that treatment outcomes meet 
quality of care standards (Long 2011). Further, the evaluation of health interventions is 
key to health sector reforms, particularly to address policy concerns such as health 
disparities. However, the implementation of health interventions in developing countries 
is often poor due to poor consideration of service delivery strategies, infrastructure and 
technology during conceptualisation and early stages (Hickey, Odeny, Petersen, 
Neilands, Padian, Ford, Matthay, Hoos, Doherty & Beryer 2017).  
The need for evaluations is critical throughout the implementation stages of health 
interventions. Barker, Reid and Schall (2016) emphasise that health interventions should 
be implemented in four sequential steps, namely: (1) setting-up – prepare the ground for 
introduction and testing of the intervention that will be taken to full scale; (2) developing 
the scalable unit – early testing phase; (3) testing of scale-up – tests the intervention in 
different settings and contexts where the intervention will be implemented in full scale; 
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and (4) full scale implementation – rapid unfolding or replicating the intervention to a full 
number of sites. 
It is therefore not surprising that the implementation of IPT, which is a complex TB/HIV 
collaborative activity, needs to be carefully conceptualised and requires constant 
monitoring of its effectiveness. According to the WHO (2009), such monitoring and 
evaluation of health interventions: 
“…provides the means to assess the quality, effectiveness, coverage and delivery of 
services and promotes a learning culture within programmes to ensure continual health 
improvement.” 
Evaluation is defined as a rigorous, scientifically-based collection of information about 
intervention activities, characteristics, and outcomes that determine the merit or worth of 
the intervention (WHO 2009). Therefore, evaluation studies provide empirical evidence 
for improving programmes or interventions.  
The monitoring and evaluation of TB/HIV activities have to ensure that patients receive 
optimal care from both programmes (WHO 2009). Nevertheless, impact evaluation of 
interventions in TB/HIV programmes can rarely be attributed to a single intervention. 
Therefore, the evaluation of particular interventions requires rigorous designs that assess 
the combined effects of a number of interventions (WHO 2009). 
The process of evaluating the effectiveness of interventions has to be based on a reliable 
theoretical framework. The WHO health system framework for evaluating the 
effectiveness of health interventions is such a framework (WHO 2007). The framework is 
invaluable for evaluating the extent to which the set goals of a community or country are 
being met, based on the locally defined core values of a health system.  
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Notably, the framework of the WHO (2007) takes into account local perceptions of what 
should constitute the health system of the local community. In basic terms, a health 
system is defined as the aggregate of commitments or resources which any national 
society invests in the health concerns of its inhabitants (Field 1973). However, the WHO 
(2007) goes on to define health system goals as defined targets for improving health and 
health equity, in a responsive, financially sound and resource-efficient way. Moreover, the 
need to increase greater access to and coverage of effective health interventions without 
compromising the quality and safety of the interventions are other goals listed as desirable 
attributes for any health system (WHO 2007).  
These attributes constitute what is known as the “six building blocks of a health system”, 
as depicted in Figure 2.6. The WHO (2007) stresses the need to ensure the existence of 
multiple, dynamic relationships within the health framework. To improve the outcomes of 
any health intervention, all the six building blocks should be addressed proportionately in 
terms of four indicators, namely access, coverage, quality and safety. Therefore, the art 
of evaluating health interventions is based on evaluating the dynamic relationships and 
equilibrium among these indicators. In addition, to evaluate these four indicators 
objectively, there is need to review the theoretical frameworks that are important for 
developing and implementing best practices in health interventions. 
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Figure 2.6 Theoretical framework for evaluating the effectiveness of health 
interventions 
Source: (WHO 2007). 
2.7.2 Framework for evaluating the implementation of best practices in health 
interventions  
To understand how best practice frameworks are developed, it is important to review the 
theories that guide such missions. Historically, the evaluation of drug interventions has 
been carried out in 4 phases beginning with evaluation of safe dosages in phase 1 and 
efficacy in phase 2. If a drug is deemed safe for human trials, it is then evaluated for 
efficacy on a wider scale in phase 3, and finally for effectiveness through surveillance in 
phase 4 (Chen 2010). To ensure validity of these evaluations, methodical approaches 
have to be adopted. The model proposed by Campbell and Stanley (1963) over 50 years 
ago for evaluating health interventions based on internal and external validity is still in use 
today. Internal validity asks whether, in specific experimental instances, the intervention 
can make a significant difference, whilst external validity on the other hand, asks whether 
an experimental effect is capable of generalisation, and if so, to what populations, settings, 
or treatment and measurement variables (Spencer, Schooley, Anderson, Kochtitzky, 
DeGroff, Devlin & Mercer 2013).  
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The evaluation of health interventions is critical to their success or failure. Aarons, Sklar, 
Mustanski, Benbow and Brown (2017) discuss conceptual conditions critical for success 
of health interventions when scaled out to contexts that are different from the setting where 
the intervention was originally tested, and concludes that, although shorter timeframes of 
“translation” to new contexts is possible, the implementation of health interventions needs 
to be critically evaluated whenever they are transferred to new environments.  
Internal and external validity of health interventions are equally important. However, 
Spencer et al. (2013) argues that, internal validity being the fundamental basis of 
developing best practices for health interventions, seems to be more important. The 
implications of this argument is that the development of best practice frameworks should 
consider, first and foremost, what adaptations are needed for the intervention in question 
to make a significant difference in local settings. Thereafter, the process should review 
how best to generalise the findings to other populations with similar clinical and 
demographic variables.  
The process of determining a particular framework of best practice requires continual 
development and refinement throughout the implementation of the intervention. Of note, 
the term “best practice” refers to a particular practice that gives maximum efficiency and 
effectiveness. As Spencer et al. (2013) note, the process of developing best practices also 
needs a critical review of better practices in use. By definition, better practices are those 
practices that have been tried and tested and have good chances of making a better public 
health impact within a particular setting (Spencer et al. 2013). It is against this background 
that Spencer et al. (2013) presents an alternative framework for developing best practices 
for implementing health interventions. 
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The hallmark of the approach put forward by Spencer et al. (2013) is the evaluation of 
qualitative and quantitative evidence of better practices in local settings. More importantly, 
Spencer et al. (2013) classifies the qualitative and quantitative evidence into five groups 
of elements, namely: effectiveness, reach, feasibility, sustainability, and transferability. 
Transferability refers to the extent to which the practice can be applied to or adapted to 
various contexts. Figure 2.7 shows the conceptual framework for developing best 
practices as put forward by Spencer et al. (2013).  
 
Figure 2.7 Theoretical framework for developing and implementing best practices in 
health interventions 
Source: (Spencer et al. 2013). 
Note that the order in which these elements appear in the conceptual framework is 
important. According to Spencer et al. (2013), the relative order of the elements implies 
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that other issues such as sustainability and transferability are not only more important but 
challenging to resolve during the development of best practice frameworks. Villeval, 
Bidault, Shoveller, Alias, Basson, Frasse, Génolini, Pons, Verbiguié and Grosclaude 
(2016) also concur that, unless health interventions are well evaluated and described, 
they are difficult to transfer to new contexts or country regions. Importantly, Spencer et al. 
(2013) recommend that the quality of evidence from the evaluation be ranked into 4 levels, 
ranging from weak to rigorous. 
The strength of the framework by Spencer et al. (2013) is that it is based on multiple 
frameworks of evaluation. These include the integrative validity model; the systematic 
evaluation framework; and sound assessment methods. Systematic evaluation refers to 
consistent evaluation of the existing health interventions. The integrative validity model is 
an evaluation framework which prioritises the stakeholders’ views and concerns during 
the evaluation process (Chen 2010). In addition, the integrative validity model includes 
elements such as the reach, effectiveness, adoption, and implementation during 
evaluation. 
It is also important to note that this conceptual framework of developing best practices 
brings together aspects of impact and quality to formulate reliable criteria for evaluating 
public health interventions. In addition, the conceptual framework by Spencer et al. (2013) 
simplifies the process of formulating research questions that can be used for collecting 
evidence during the evaluations.  
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CHAPTER THREE: METHODS 
3.1 STUDY SETTING  
Lesotho, located 29.6100° South and 28.2336° East, is completely surrounded by South 
Africa with about 2.2 million people, and an estimated gross domestic product (GDP) per 
capita of US$1 000, which puts the country into the low-income countries tier (BOS 2017). 
The country is divided into ten administrative districts, five of which are considered scale-
up districts for HIV/TB programmes, due to the fact that these districts are densely 
populated and have the highest rates of HIV and TB. The scale-up districts occupy the 
densely populated lowlands of the country, while the other five districts occupy the 
mountainous sparsely populated highlands (PEPFAR Lesotho 2016). The government of 
Lesotho, through the Ministry of Health (MoH) and in partnership with implementing 
partners, adopted and implemented the 6-month IPT guidelines of the WHO in 2011 (GoL 
2013).  
Study participants were sampled from three district hospitals in three sparsely populated 
(non-scale-up) districts, and five district hospitals from three densely inhabited (scale-up) 
districts of the country (Figure 3.1). Of the eight hospitals selected, six started giving IPT 
in 2011, while the remaining two hospitals each commenced in 2012 and 2014 
respectively.  
3.2 STUDY DESIGN 
The study was based on a triangulation of quantitative and qualitative research methods, 
an approach often adopted to improve the reliability of the study findings (Rehle, Saidel, 
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Mills & Magnani 2001). The overall conceptual framework of the study is presented in 
Figure 3.2. 
   
Figure 3.1  Data collection sites 
Densely populated districts included in the study were Maseru, Berea and Mohale’s Hoek, 
while sparsely populated districts sampled were Mokhotlong, Thaba Tseka and Qacha’s 
Nek; GOVT=government; HC=health centre; HOSP=hospital; M. HOEK= Mohale’s Hoek.  
The study was conducted in two phases. Phase 1, which was based on in-depth cross 
sectional qualitative interviews with key informants involved in the implementation of IPT 
in Lesotho, identified contextual constraints within the national health system that affected 
the implementation of IPT in PLHIV within Lesotho. Key informants were sampled from 
among health workers and stakeholders of the TB/HIV programmes which included the 
Ministry of Health officials and support partners.  
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Figure 3.2  Conceptual framework for evaluating the effectiveness of IPT
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Phase 2, which was based on a retrospective cohort analyses of patient records 
randomly selected from the register of ART patients at eight purposively selected 
health institutions, evaluated the rate of initiation and retention of PLHIV on IPT and 
the effectiveness of IPT in preventing the occurrence of TB. Figure 3.3 outlines the 
overall study design and the procedures followed in the study. 
3.3 STUDY POPULATION AND SAMPLING  
3.3.1 Phase 1  
Phase 1 was based on interviews with key informants purposively sampled for their 
roles in the provision of HIV/TB services and their knowledge about the subject in 
question from among health workers at the health institutions, officials at the Ministry 
of Health of Lesotho and implementing partners involved in TB/HIV programmes.  
The healthcare workers targeted in this phase included all those involved in the 
implementation of IPT in the ART centres, TB wards, pharmacies, laboratories, and 
administrative staff at each health institution. The target population at each of the eight 
health institutions was estimated at about five, implying that the total target population 
in the health institutions was 40. 
3.3.2 Phase 2  
3.3.2.1 Target population  
The target population for the study was HIV-positive people enrolled in HIV care 
between 2004 and 2016 in the selected eight health institutions. Patients were 
categorised into two groups, with the first group comprising patients enrolled on ART 
before IPT was launched in Lesotho (2004-2010 cohort), and the second group 
consisting of the patients enrolled on ART from 2011 onwards (2011-2016 cohort).  
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Figure 3.3  Study design schematic layout 
 
Evaluate implementation based on frameworks: 
 WHO (2007) – Evaluating health interventions  
 Spencer et al. (2013) - Evaluating best practices  
 Model rate of initiation on IPT  
 Model time to TB event   
 Determine adverse reactions to IPT 
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3.3.2.2 Sample size calculation  
This study phase, which required an acceptable minimum sample size of patients’ 
records to reconstruct the occurrence of TB with or without exposure to IPT, was 
determined based on three criteria, namely: (1) the target population, (2) the minimum 
relative precision acceptable for the study, and (3) the confidence interval of the 
estimated occurrence. The minimum sample size was calculated following standard 
WHO guidelines for estimating incidences of disease conditions with a specified 
relative precision (Lwanga & Lemeshow 1991).  
The calculated minimum number of patients’ records, based on a minimum relative 
precision of 10% and a significance level of 5% (Lwanga & Lemeshow 1991) was 385 
at each hospital, or 3 080 in the eight hospitals. However, more patient records were 
required to account for losses due to exclusion criteria and incomplete records, and 
this was estimated at 40%, implying that at least 4 620 patient files were required. 
3.3.2.3 Sampling technique 
Patient records were sampled based on a sampling frame, with the list of all patient 
records representing the sampling frame. Patients’ records were then selected using 
a stratified random sampling technique from the sampling frame to ensure proportional 
representation of all patient groups, including gender and age groups, and to avoid 
bias, as noted by Lohr (2010).  
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3.4 INCLUSION AND EXCLUSION CRITERIA 
3.4.1 Phase 1  
3.4.1.1 Inclusion criteria  
The inclusion criteria for phase 1 of the study were: 
(i)     key informants included nurses, doctors, pharmacists, laboratory personnel, 
HIV counsellors and administrators involved in TB/HIV treatment at the selected 
health centres; 
(ii)     Ministry of Health officials involved in TB/HIV programmes; 
(iii)     officials working with support partners and non-governmental organisations who 
were involved in TB/HIV interventions in Lesotho. 
3.4.1.2 Exclusion criteria  
(i)     The study excluded health workers, officials working at Government support 
partner organisations, and Government officials not involved in TB/HIV 
programmes. 
3.4.2 Phase 2 
3.4.2.1 Inclusion criteria 
(i)     Records of all HIV-positive patients, exposed or unexposed to IPT;  
(ii)     the study included children and infants, adult men and women, geriatric patients 
and pregnant women; and 
(iii)     the study also included participants with any duration of antiretroviral treatment 
for HIV, implying that no participants were to be excluded on the grounds of 
treatment duration. 
3.4.2.2 Exclusion criteria 
(i)     Patients contraindicated for IPT, and who were therefore not supposed to be 
initiated on IPT, were excluded from the study, including HIV-positive patients 
with acute or chronic liver disease; those with signs and symptoms suggestive 
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of active hepatitis and kidney failure; patients known to be heavy alcohol 
consumers; those with symptoms of severe peripheral neuropathy; and patients 
with a history of epilepsy or convulsions; and 
(ii)     patient-initiated antiretroviral treatment outside the time frames set for the study, 
that is, before January 2004, and those with less than six months’ follow-up 
data, were also excluded.  
3.5 DATA COLLECTION  
Phase 1 of the study collected data through semi-structured questionnaires shown in 
Appendices A1 and A2, and data were captured into the Microsoft Access® database 
(see Appendix A3). A data capture form for phase 2 is presented in Appendix B. Phase 
2 data was also captured in the database to improve the quality of data entry.  
The data collection forms and the questionnaires for phases 1 and 2 were pilot-tested 
with 10 individuals who were not to be included in the final data analysis. Data were 
collected from January 2016 to October 2016 from the paper-based ART, IPT and TB 
registers, with the assistance of data collectors who were trained during the piloting 
phase. 
3.6 DATA ANALYSIS 
3.6.1 Phase 1 
Data for phase 1 were analysed according to standard guidelines for analyzing 
qualitative data. With the help of two native speakers of the vernacular language 
(Sesotho) who were also competent to communicate in English language, data were 
manually transcribed from Sesotho to English using open coding before analysis. 
Thematic coding was carried out manually, and the barriers to the effective 
implementation of the IPT intervention were tallied and classified into four theme 
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categories according to the adopted conceptual framework for developing and 
implementing best practices in health interventions by Spencer, Schooley, Anderson, 
Kochtitzky, DeGroff, Devlin and Mercer (2013). Each main theme was further classified 
into six theme categories or typologies according to the WHO criteria for benchmarking 
the effectiveness of the implementation of health interventions (WHO 2007). 
3.6.2 Phase 2 
Data analyses for phase 2, whose main aim was to determine the rate of initiation for 
IPT and its effectiveness, was based on statistical modelling in Stata version 13.1 
(StataCorp, Texas, USA), with the modelling being based on Cox’s proportional hazard 
regression. Firstly, the probability of IPT initiation was modelled, considering time to 
IPT as the dependent variable. Secondly, the relative risk of developing TB with or 
without IPT were also modelled, with time to TB as the dependent variable. In both 
models, patient characteristics associated with the dependent outcome were factored 
into the model to identify the most influential factors.  
The justification of the model used in the analyses was based on theoretical guidelines 
commonly applied in the modelling of event occurrences (Singer & Willett 2003). 
Kleinbaum and Klein (2005) define and explain the advantages of using Cox’s 
proportional hazard model, noting that Cox’s model estimates the hazard (ht) at a 
specified time for an individual i with certain characteristics: 
݄ሺݐ௜௝ሻ ൌ ݊	݁ݒ݁݊ݐݏ	݆݊	ܽݐ	ݎ݅ݏ݇	݆ 
where “n events j” represents the number of individuals who experience the target event in 
time period j, and “n at risk j” represents the number of individuals at risk during time period j. 
Patient characteristics constituted predictor variables that were modeled to predict an 
individual’s hazard of having an ‘event’. In this study, the hazard was the initiation of 
the IPT event, and in the second, the hazard was the occurrence of TB, while in both 
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instances, time to event referred to the duration in months from the initial time of 
observation for each patient. The overall duration of observation in this study was 
subdivided into constantly spaced six-month intervals (Singer & Willett 2003), to study 
the effect of time on the rate of initiation for IPT and the occurrence of TB.  
It is important to note that, although Cox’s hazard regression model is somewhat 
similar to logistic regression models (Kleinbaum & Klein 2005), Cox’s model is often 
preferred over logistic models because it works better in cases where the baseline 
hazard is not specified. The key difference between these models is that logistic 
regression estimates odds ratio, while Cox’s model estimates relative risks of 
occurrence for given phenomena.  
 3.7 ETHICAL ASPECTS 
The study was approved by the Ministry of Health of Lesotho prior the collection of 
data (see Appendix E). In addition, the study was approved by the Ethical Review 
Board for the Central University of Technology. To safeguard patient information 
privacy, the researchers observed standard ethical principles (World Medical 
Association 2015), including informing key informants about the purpose of the study 
(Appendix C1 and C2), and obtaining written consent from key informants (Appendix 
D1 and D2). To maintain privacy, all information collected from the medical records 
was treated as confidential, and fictitious patient identifier codes were used to identify 
the patients. 
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CHAPTER FOUR: MODELLING THE RATE OF INITIATION OF 
ISONIAZID PREVENTIVE THERAPY IN A HIGH 
HIV/TB-BURDEN SETTING OF LESOTHO 
ABSTRACT 
Background: Tuberculosis (TB) remains a public health problem, particularly in 
people living with HIV (PLHIV). Efforts to reduce TB incidence using isoniazid 
preventive therapy (IPT) have been curtailed by a poor rate of uptake of this 
intervention. This study modelled the rate of initiation of IPT and the associated factors 
in the sub-Saharan country of Lesotho, which has one of the highest TB incidences in 
the world. The aim was to identify patient groups that need IPT scale-up in the country. 
Methods: This longitudinal retrospective study modelled the rate of initiation of IPT in 
randomly sampled medical records of PLHIV based on Cox’s proportional hazards 
function. Differences in the periods of enrollment into HIV care were controlled by 
considering 2011, the year when IPT was launched, as the base year for follow up, 
and stratifying the medical records into the 2004-2010 cohort (before the launch of IPT) 
and the 2011-2016 cohort (after the launch of IPT).  
Results: Out of 2 955 patients included in the final analysis, 68.8% had received IPT 
by the study exit time. The overall rate of IPT initiation was 20.6 per 100 person-years, 
with 135 (6.6%) defaults. Compared to the 2004-2010 cohort, the 2011-2016 had a 
significantly (p=0.000) higher rate of initiation (15.8 versus 27.0 per 100 person-years, 
respectively). Age group, district category and duration of ART emerged as the most 
significant predictors of IPT initiation. Patients in the sparsely populated districts [Odds 
ratio (OR)=1.6; p=0.000] and males [OR=2.1; p=0.006] had higher rates of defaulting 
IPT compared to those in the densely populated districts, and females, respectively.  
Conclusion: These findings indicate a slow rate of implementation of a key health 
intervention for TB in PLHIV. Significant factors associated with disparities in the 
initiation and defaulting of IPT in this study are important for policy review.  
Keywords: Cox’s proportional hazards function; isoniazid preventive therapy; 
Lesotho; PLHIV; tuberculosis; uptake of health interventions 
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4.1 INTRODUCTION 
4.1.1 Background  
Human immunodeficiency virus (HIV) and tuberculosis (TB) have become a global 
syndemic responsible for nearly 25% of all HIV-associated deaths (WHO 2018). Of the 
1.3 million people who died from TB in 2017 alone, 300 000 were HIV-positive (WHO 
2018). In addition, the WHO (2018) notes that the incidence of TB in 2013 was about 
133 cases per 100 000 global population. Despite the effectiveness of isoniazid, also 
known as isonicotinylhydrazine (INH), recommended by the WHO (2004) for the 
prevention of TB in people living with HIV (PLHIV), having been demonstrated to be 
effective when given in combination with antiretroviral therapy (ART) in many countries 
including, but not limited to Ethiopia, Brazil, Cambodia, Botswana and South Africa, 
the rate of initiation of IPT has generally been slow (Dowdy, Golub, Saraceni, Moulton, 
Cavalcante, Cohn, Pacheco, Chaisson & Durovni 2014; Tedla, Nguyen, Sibanda, 
Nyirenda, Agizew, Girde, Rose & Samandari, 2015; Ayele, Mourik & Bonten 2016; 
Sumner, Houben, Rangaka, Maartens, Boulle, Wilkinson & White 2016). This includes 
developing countries categorised by the World Health Organization (WHO 2015) as 
high TB-burden settings.  
The reasons for the slow implementation vary from country to country (Temprano 
ANRS 12136 Study Group 2015). In some countries, poor healthcare delivery systems 
and a lack of adequate means to exclude a pre-existing TB infection prior to treatment 
initiation are some of the most cited reasons for the slow rate of initiation of IPT 
(Assebe, Reda, Wubeneh, Lerebo & Lambert, 2015; Tadesse, Gebre, Daba, Gashu, 
Habte, Hiruy, Negash, Melkieneh, Jerene, Haile, Kassie, Melese & Suarez 2016). Jena 
and Harinath (2015) also cited skepticism by healthcare professionals about potential 
drug resistance. In addition, underestimation of the potential public health impact of 
IPT by HIV/TB programme managers has also been reported as a barrier to IPT uptake 
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(Guwatudde, Debanne, Diaz, King & Whalen 2004; Ayele, Van Mourik & Bonten 2015). 
Furthermore, some countries were not convinced of the benefits of IPT, and deferred 
the implementation of IPT altogether for many years. For example, the Ivory Coast had 
not implemented IPT by 2014 (Temprano ANRS 12136 Study Group 2015).  
The uptake of health interventions, preventive therapies included, particularly in 
developing countries, are often sluggish (Ostermann, Brown, De Bekker-Grob, 
Mühlbacher & Reed 2017). It is important to note that barriers to scaling up health 
interventions in developing countries are diverse, and studies on these barriers have 
recently become a significant mini-branch of science known as implementation science 
(Yamey, 2012; Bragge, Grimshaw, Lokker & Colquhoun 2017). Realising the challenge 
of translating knowledge into policy and practice, the main focus within this science 
has been on studying the “know-do gap” – the gap between what is known and what 
gets implemented (Pablos‐Mendez & Shademani 2006). As such, some causes of the 
know-do gap applicable to the sluggish IPT uptake in developing countries include 
inexperience in evidence-based problem-solving and learning approaches among 
programme leaders; lack of ownership of knowledge by potential adopters; lack of 
evaluation; and continuous improvement strategies (Pablos‐Mendez & Shademani 
2006). The slow uptake of IPT in developing countries is therefore a symptom of a 
range of problems in the health systems of these countries. Therefore, assessments 
of barriers to IPT uptake in developing countries are an important proxy for gaging the 
efficiency of the respective national health systems.  
Lesotho is a small country completely surrounded by the Republic of South Africa, with 
a territory of only about 30 000 square kilometres, and a population of about 2.2 million 
(GoL, 2013). The United Nations (2009) notes that Lesotho is a poor country, with 40% 
of its population living below the official poverty line of US$1.25 per day. The country, 
with a 23.5% adult HIV prevalence rate, has the second highest prevalence rate of HIV 
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worldwide (UNAIDS 2016), and with the TB incidence rate in the general population 
estimated at 852 per 100 000 population (WHO 2015), the country is amongst the top 
three nations with the highest rates of TB worldwide. 
INH preventive therapy (IPT) was introduced to Lesotho in 2011 (GoL 2013). However, 
since the programme was launched, information on the rate of initiation of IPT and the 
associated factors has remained obscure (GoL 2013). To put this obscurity into 
perspective, the country is one of the ten countries in the world which did not provide 
data for the IPT indicator to the WHO repository in 2014 (WHO 2014).  
This study assessed the rate of initiation of IPT and retention in HIV-infected patients 
in the high TB-burden setting of Lesotho since its launch. The study also determined 
the predictors of poor uptake of this intervention, with the aim of identifying patient 
groups that need IPT scale-up in the country.  
4.2 METHODS 
4.2.1 Study design  
This longitudinal retrospective cohort study modelled the probability of IPT initiation 
associated with characteristics of PLHIV in Lesotho, considering time to IPT as the 
dependent variable. The study made recourse to statistical principles of the Cox’s 
proportional hazard regression, based on data extracted from randomly sampled ART 
records of patients enrolled into ART between 2004 and 2016.   
The study fitted Cox’s proportional hazards regression to the probability of IPT 
initiation, assuming a fairly constant rate of IPT initiation over the study follow-up time. 
One previous study reports that, with minimal calibrations, data on time to IPT initiation 
generally fits an exponential curve which can be modeled by Cox’s proportional 
hazards function (Dowdy et al. 2014).  
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4.2.2 Study population  
The target population for the study was HIV-positive people enrolled in HIV care 
between 2004 and 2016 in the selected eight health institutions, all of which were 
district hospitals with at least 2 000 patients on ART. For purposes of analysing the 
effect of the duration of ART on IPT initiation, patients were categorised into two 
groups, with the first group comprising patients enrolled on ART before IPT was 
launched in Lesotho (2004-2010 cohort), while the second group consisted of patients 
enrolled on ART from 2011 onwards (2011-2016 cohort). In addition, the study 
population was divided into sparsely and densely populated district categories, based 
on population density. ART records of HIV-positive children, adolescents and adults, 
including geriatric patients and pregnant women were selected using stratified 
systematic random sampling across eight health facilities, to ensure proportional 
representation of all patient categories including gender, age groups and period of 
enrolment. 
4.2.3 Sample size calculation 
The minimum sample size was calculated following standard guidelines for estimating 
incidence with a specified relative precision (Lwanga  & Lemeshow 1991). The 
minimum number of patients’ records, based on a minimum relative precision of 10% 
and a significance level of 5% (Lwanga & Lemeshow 1991), was 385 at each hospital, 
or 3 080 in the eight hospitals. However, more patient records were required to account 
for losses due to exclusion criteria and incomplete records. An ample buffer for this 
loss was estimated at 40%, implying that at least 4 620 patient files were required. In 
addition, the minimum sample size per hospital was proportionally adjusted for slight 
differences in the study populations at the hospitals following statistical rules for 
stratified systematic random sampling.  
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Data were collected from January to October 2016 from the paper-based ART, IPT 
and TB registers. To improve the quality of data entry, a Microsoft Access database 
application tool was used to capture data from the files. Data were captured into the 
database tool in six-month discrete intervals.  
4.2.4 Patient sampling and data collection 
File selection was based on a sampling frame. The sampling frame was prepared from 
the ART attendance registers by drawing a list of all the patients enrolled into HIV care 
since 2004. The total number of files to be sampled per hospital was obtained by 
dividing the total number of patients enrolled in HIV care by the proportional target 
sample size for the hospital. For example, in a hospital with 2 000 patients enrolled 
and a target sample size of 350, one in six patients was systematically selected by 
sampling every 6th patient from the patient register.  
4.2.5 Final sample selection criteria 
Overall, 4 122 patient files were collected. Of the 4 122 patients, 1 167 were excluded 
according to the following exclusion criteria: transfer-in (118), past TB cases (337); on 
TB treatment at enrolment, or were diagnosed with TB within one month of enrolment 
(482); less than six months of follow-up time, or died before the IPT programme was 
launched (131); or insufficient information (99) (see Figure 4.1). Therefore, the final 
sample size was 2 955. 
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Figure 4.1  Exclusion criteria for the patients  
Insufficient information referred to patient files with grossly missing data; past TB= 
having a diagnosis of TB before enrolment into HIV care; TB=tuberculosis. 
4.2.6 Patient data and outcome measures 
For purposes of evaluating the associations between patient characteristics and time 
to IPT (in months), which was the main outcome variable, demographic, baseline 
clinical data and ART follow-up information were needed. Thus, demographic 
information including gender, date of birth and marital status of the patients meeting 
the selection criteria were collected from the records. Their clinical data, including 
dates of HIV diagnosis, enrolment into HIV care, ART and IPT initiation; baseline 
indicators including CD4 count, viral load, patient ART status and WHO clinical staging; 
ART and IPT regimens and check-up information at each visit; adherence records; and 
laboratory monitoring data were also extracted from the records. Time-variant 
variables, including age, were calculated according to the time at enrolment into HIV 
care. Patients late for their scheduled appointments by more than a month, and those 
who did not return for ART services were classified as drop-outs.  
Time to IPT was calculated by subtracting the date of enrolment into HIV care from the 
date that IPT was prescribed. Patient treatment outcomes were assessed by median 
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CD4 and viral load values. The duration of the period before ART commencement (in 
years), known as the Pre-ART period, was calculated by subtracting the date of HIV 
diagnosis from that of ART commencement.  
Furthermore, the proportion of patients who defaulted IPT was calculated, and the 
factors associated with the defaulting were assessed using logistic regression analysis. 
4.2.7 Data preparation  
Data for IPT initiation in the Microsoft Access database were verified and exported to 
Stata version 13.1 for further cleaning and analysis (StataCorp, Texas, USA). Data 
were formatted for survival analysis as discrete-time survival data, with the interval 
date as the time variable. The occurrence of IPT event defined the ‘failure’ outcome, 
and the scale for the time variable was set in years. To obtain comparable follow-up 
times, patients enrolled before IPT were declared to have entered the risk set in 2011, 
the year that IPT was launched in the country. For purposes of calculating Cox’s 
proportional hazards ratios, entry times into the risk set were delayed by one month for 
all the patients to calibrate for inconsistencies at first entry into the risk set. The date 
of enrolment into HIV care, and the exit date, marked the left and right censoring times 
respectively.  
4.2.8 Modelling patient characteristics associated with IPT initiation 
This analysis modelled the rate of IPT initiation and identified patient characteristics 
associated with IPT initiation through the Cox’s hazard regression function (Kleinbaum 
& Klein 2005). The method was applied taking the hazard as a probability that an 
individual with certain characteristics would receive IPT in a specified time.   
Breslow’s correction for tied data was used to correct the assumption that survival 
times in the study were distinct (Kleinbaum & Klein 2005). Follow-up times were 
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subdivided into six-month discrete intervals due to observation gaps for the patients 
(Singer & Willett 2003).  
To assess the patient characteristics associated with IPT initiation, descriptive 
statistics of the data were summarised by cross-tabulating the patient characteristics 
with IPT initiation outcome with the Chi-square values, indicating the significance of 
the differences. Patient characteristics were further analysed using cumulative 
probability distribution plots and univariate Kaplan-Meier curves to determine their 
suitability in the model of IPT initiation. Further, Wilcoxon’s log-rank test and Cox’s 
regression analysis were used to determine equality across strata for categorical 
variables and continuous variables, respectively. Predictors with p-values <0.2 were 
included in the IPT initiation model.  
The variable “period of enrolment” was selected a priori as a strata variable to control 
for differences in the periods of enrollment into HIV care. The year 2011, when IPT 
was launched, was set as the base year for follow up, and medical records were 
stratified into the 2004-2010 cohort (before the launch of IPT) and the 2011-2016 
cohort (after the launch of IPT). Nine predictors, namely, age, gender, baseline CD4 
count, duration of pre-ART, patient ART status, baseline WHO clinical stage, duration 
of ART, adherence to ART, and district category were selected into the model and 
excluded using the stepwise method. Three variables, namely age group, district 
category, and duration of ART remained in the model. 
The model was tested for predictor interaction, and two variables, duration of ART and 
district category had significant interactions (p<0.005). The models with and without 
the interaction variables were compared using the likelihood ratio (Lrtest), and the 
difference was found to be significant (Chi (3)=10.0; p=0.006), implying that the bigger 
model with the interaction terms was superior to the one without.  
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The unstratified model was checked for proportionality using the Schoenfeld and 
scaled Schoenfeld residuals (Phtest) test. One categorical variable, duration of ART, 
significantly (p=0.032) violated the proportionality assumption. However, this variable 
was retained in the model, and the anomaly was corrected by the subsequent stratified 
analysis. 
4.2.9 Ethical aspects 
The study was approved by the Ministry of Health of Lesotho (see Appendix E). To 
safeguard patient information privacy, the researchers observed standard ethical 
principles (World Medical Association 2015). To maintain privacy, all information 
collected from the medical records was treated as confidential, and fictitious patient 
identifier codes were used to identify the patients.  
4.3 RESULTS 
4.3.1 Patient characteristics by IPT initiation 
In total, 2 955 patients were included in the final analysis. By proportion, 68.8% of the 
patients received IPT during follow up, while 31.2% had not received the drug at the 
exit time for the study. Tables 4.1a – 4.1c present the characteristics of the patients 
and their IPT initiation outcomes.  
Females had a higher rate of IPT initiation compared to males (71.8% females versus 
63.1% males; t=23.5; p<0.001) (See Table 4.1a). The rate of initiation of IPT varied 
significantly (t=30.8; p<0.001) by age groups. The 65-84 (75.0%) and 0-9 (40.4%) age 
groups had the highest and the least rates of IPT initiation, respectively. IPT initiation 
rates differed significantly (t=24.7; p<0.001) by marital status, with the widowed 
(74.5%) and the single (62.3%) having the highest and least rates, respectively.  
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Overall, the densely populated districts, which constituted 64.7% patients, had 
significantly (t=28.1; p<0.001) higher rates (72.1%) of IPT initiation, compared to the 
sparsely inhabited ones (62.8%). Two densely populated districts, Berea (87.6%) and 
Maseru (70.2%), had the highest initiation rates, while Mohale’s Hoek (44.7%), a 
densely populated district, and two sparsely populated districts, Qacha’s Nek (54.3%), 
and Thaba Tseka (55.0%), had the least rates (Table 4.1a).  
Of note, the cohort enrolled into HIV care from 2011 to 2016 (59.1%) significantly 
(p<0.001) outnumbered that of the period from 2004 to 2010 (Table 4.1b). The total 
IPT initiation in the 2004-2010 period (73.7%) was significantly higher (t=23.1; 
p<0.001) than in the latter period (65.4%). The majority (58.6%) of the patients were 
prescribed with Tenofovir/ lamivudine/ efavirenz for baseline ART. 
Patients who entered into HIV care through the Adolescents Department (100%) and 
the HIV Testing and Counselling Department (89.8%) had the highest proportion of 
IPT initiation, while the proportion initiated was below 60% in the self-refer (55.6%) and 
the under-five (50.0%) entry points (Table 4.1b).  
At the time the study was terminated (Table 4.1b), 84.4% patients were still continuing 
ART; the other patients were drop-outs (9.0%), had died (4.1%), or had transferred out 
(2.6%). Patients with poor adherence had slightly higher overall initiation of IPT 
(73.0%) compared to those with good adherence (70.5%). 
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Table 4.1a Associations between patient characteristics and IPT initiation in PLHIV 
in Lesotho 
   Received IPT while in HIV care 
 Total No Yes Chi-square (p-value)
 Column% (n)  Row% (n) Row% (n)  
Total 100 (2 955)  31.2 (922) 68.8 (2 033)  
Gender      
Female 65.7 (1 942)  28.2 (548) 71.8 (1 394) 23.5 (0.000) 
Male 34.3 (1 013)  36.9 (374) 63.1 (639) 
Age (years)         
0-9 1.8 (52)  59.6 (31) 40.4 (21) 30.8 (0.000) 
9-18 1.3 (38)  42.1 (16) 57.9 (22) 
18-25 9.1 (269)  33.5 (90) 66.5 (179) 
25-35 34.8 (1 027)  32.7 (336) 67.3 (691) 
35-45 27.9 (824)  27.4 (226) 72.6 (598) 
45-55 16.1 (477)  29.1 (139) 70.9 (338) 
55-65 7.6 (224)  32.6 (73) 67.4 (151) 
65-84 1.5 (44)  25 (11) 75 (33) 
Marital status      
Married 59.3 (1 752)  32.2 (564) 67.8 (1188) 24.7 (0.000) 
Divorced 0.4 (11)  27.3 (3) 72.7 (8) 
Separated 6.5 (193)  26.9 (52) 73.1 (141) 
Widowed 15.5 (458)  25.5 (117) 74.5 (341) 
Cohabiting 0.2 (6)  33.3 (2) 66.7 (4) 
Single 14.9 (440)  37.7 (166) 62.3 (274) 
(-) 3.2 (95)  18.9 (18) 81.1 (77) 
District         
Berea 18.3 (540)  12.4 (67) 87.6 (473) 235.9 (0.000) 
Maseru 38.7 (1 145)  29.8 (341) 70.2 (804) 
Mohale’s Hoek 7.7 (228)  55.3 (126) 44.7 (102) 
Mokhotlong 11.4 (336)  20.2 (68) 79.8 (268) 
Qacha’s Nek 10.2 (302)  45.7 (138) 54.3 (164) 
Thaba Tseka 13.7 (404)  45 (182) 55 (222) 
District category     
Dense 64.7 (1 913)  27.9 (534) 72.1 (1 379) 27.3 (0.000) 
Sparse 35.3 (1 042)  37.2 (388) 62.8 (654) 
(-)=missing information; n=number of patients; 
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Table 4.1b Associations between patient characteristics and IPT initiation in PLHIV 
in Lesotho (continued) 
   Received IPT while in HIV care 
 Total No Yes Chi-square (p-value) 
 Column% (n)  Row% (n) Row% (n)  
Total 100 (2 955)  31.2 (922) 68.8 (2 033)  
Period of enrolment into HIV care    
2011-2016 59.1 (1 745)  34.6 (604) 65.4 (1 141) 23.1 (0.000)
2004-2010 40.9 (1 210)  26.3 (318) 73.7 (892)  
Entry point     
Adolescent clinic 0.4 (12)  0 (0) 100 (12) 50 (0.000) 
HTC 4 (118)  10.2 (12) 89.8 (106) 
MCH 9.1 (268)  29.5 (79) 70.5 (189) 
OPD 77.7 (2 295)  31.2 (717) 68.8 (1 578) 
Self-refer 7.9 (232)  44.4 (103) 55.6 (129) 
Under-five clinic 0.2 (6)  50 (3) 50 (3) 
Hospital ward 0.8 (24)  33.3 (8) 66.7 (16) 
Baseline regimen      
TDF+3TC+EFV 58.6 (1 732)   30.2 (523) 69.8 (1 209) 22.2 (0.005) 
AZT+3TC+EFV 23.8 (704)  35.1 (247) 64.9 (457)  
AZT+3TC+NVP 5.9 (173)  27.2 (47) 72.8 (126)  
D4T+3TC+NVP 4.1 (120)  24.2 (29) 75.8 (91)  
D4T+3TC+EFV 2.8 (84)  27.4 (23) 72.6 (61)  
TDF+3TC+NVP 2.2 (65)  26.2 (17) 73.8 (48)  
ABC+3TC+NVP 1.1 (32)  37.5 (12) 62.5 (20)  
ABC+3TC+EFV 1 (29)  55.2 (16) 44.8 (13)  
ABC+3TC+kaletra 0.5 (16)  50 (8) 50 (8)  
Patient status         
Drop-out 9 (265)  48.7 (129) 51.3 (136) 185.9 (0.000) 
Dead 4.1 (121)  78.5 (95) 21.5 (26)  
Transfer out 2.6 (76)  35.5 (27) 64.5 (49)  
ART continuing 84.4 (2 493)  26.9 (671) 73.1 (1 822)  
ART=antiretroviral therapy; ABC=abacavir; AZT=zidovudine; 3TC=lamivudine; kaletra=lopinavir/ritonavir; 
NVP=nevirapine; EFV=efavirenz; TDF=tenofovir; BL=baseline; HTC=HIV testing and counselling; MCH=mother 
and child health; OPD=outpatient department.  
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Table 4.1c Associations between patient characteristics and IPT initiation in PLHIV 
in Lesotho (continued) 
   Received IPT while in HIV care 
 Total  No Yes Chi-square (p-value)
 Column% (n)  Row% (n) Row% (n)  
Total 100 (2 955)  31.2 (922) 100 (2 955)  
Adherence to ART    
Good 79.1 (2 336)  32.3 (755) 67.7 (1 581) 6.5 (0.011) 
Poor 20.9 (619)  27 (167) 73 (452) 
Treatment failure    
No 98.4 (2 909)  31.5 (916) 68.5 (1 993) 7.2 (0.007) 
Yes 1.6 (46)  13 (6) 87 (40) 
BL CD4 count    
1-100 21.6 (639)  35.1 (224) 64.9 (415) 19.5 (0.000) 
101-350 58 (1 714)  28.1 (481) 71.9 (1 233) 
351-500 12.1 (357)  37.3 (133) 62.7 (224) 
501-1512 8.3 (245)  34.3 (84) 65.7 (161) 
BL WHO Clinical stage    
I 35.5 (1 049)  30.1 (316) 69.9 (733) 46.5 (0.000) 
II 41.3 (1 219)  30.9 (377) 69.1 (842) 
III 17.5 (516)  26.6 (137) 73.4 (379) 
IV 5.8 (171)  53.8 (92) 46.2 (79) 
Median viral load    
Tnd* 9.1 (268)  24.3 (65) 75.7 (203) 14.7 (0.005) 
Low 1.3 (38)  34.2 (13) 65.8 (25) 
High 2.1 (61)  31.1 (19) 68.9 (42) 
Very high 2.8 (84)  17.9 (15) 82.1 (69) 
(-) 84.7 (2 504)  32.3 (810) 67.7 (1 694) 
Length of pre-ART (years)     
<1 72 (2 127)  29.9 (636) 70.1 (1 491) 28.8 (0.000) 
01-2 9.1 (269)  26.4 (71) 73.6 (198) 
03-5 11.6 (344)  33.4 (115) 66.6 (229) 
>5 7.3 (215)  46.5 (100) 53.5 (115) 
ART=antiretroviral therapy; *Tnd=target not detected; WHO= World Health Organization; n=number of patients; 
CD4 counts are in cells/mm3; viral load ranges in copies/mm3 are as follows: tnd (0-50); low (50-500); high (500-10 
000); and very high (>10 000). 
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Only 1.6% of the patients had treatment failure (Table 4.1c). Patients with treatment 
failure had significantly (t=7.2; p=0.007) higher initiation of IPT, compared to those with 
no regimen change due to treatment failure (87.0% versus 68.5%).  
IPT initiation significantly (t=28.4; p<0.001) varied with the length of pre-ART time, with 
the highest initiation (73.6%) occurring in those exposed to ART 1-2 years of testing 
positive, and the least (53.5%) occurring in those with a pre-ART time of more than 
five years (Table 4.1c). Baseline stage III had the highest initiation of IPT (73.4%); the 
least was baseline stage IV with an initiation of 46.2%. The 101-350 CD4 count 
category had the highest initiation of IPT (71.9%), while the 351-500 category had the 
least. Overall, IPT initiation varied significantly (t=19.4; p<0.001).  
IPT initiation significantly (t=14.7; p=0.005) varied with median viral load categories 
(Table 4.1c). Patients with very high median viral load had the highest initiation (82.1%) 
of IPT, while those with low median viral load had the least (65.8%). However, 84.6% 
patients had missing data for the median viral load. 
4.3.2 Associations between incident IPT initiation and predictor variables 
Tables 4.2a and 4.2b present the overall incident IPT cases, and the cases stratified 
by period of enrolment. Overall, 2,033 incident IPT cases in 9 728 person-years of 
observation occurred out of the 2 955 patients in the study. The overall rate of IPT 
initiation was 20.6 per 100 person-years. The effective follow-up time since IPT was 
launched in 2011 ranged from 0.5 to 5.8 years (mean=3.5; median=4.1; interquartile 
range (IQR): 1.4–5.6). With the data stratified by period of enrolment, the median time 
to IPT for the patients enrolled before 2011 was higher than that of the patients enrolled 
on ART after 2011 (4.8 versus 2.5 years, respectively). Compared to patients enrolled 
before 2011, patients enrolled after 2011 had a significantly (p=0.000) higher initiation 
rate (15.8 versus 27.0 per 100 person-years, respectively).  
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Table 4.2a Associations between predictors and IPT initiation stratified by period of enrolment into HIV care 
  Overall Enrolment period 2004-2010  Enrolment period 2011-2016 
  %IPT 
cases (n) 
IPT 
cases/ 
100 PYs* 
Total
(n) 
IPT cases 
Row % 
(n) 
Person
-years 
IPT 
cases/ 
100 PYs* 
Chi-square; 
p-value 
 Total 
(n) 
IPT cases  
Row % (n) 
Per-
son-
years 
IPT 
cases/ 
100 PYs* 
Chi-squared;  
p-value 
 Total 69 (2 033) 20.6 1210 74 (892) 5 641 15.8   1 745 65 (1141) 4 223 27.0 300 (0.000)* 
Gender              
 Female 72 (1 394) 21.1 798 77 (613) 3 740 16.4 1.5 (0.226)  1 144 68 (781) 2 856 27.3 1.8 (0.176) 
 Male 63 (639) 19.6 412 68 (279) 1 901 14.7   601 60 (360) 1367 26.3  
Age              
 Children 40 (21) 10.7 31 42 (13) 135 9.6 3.1 (0.373)  21 38 (8) 61 13.2 4.3 (0.23) 
 Adolescents 60 (33) 28.2 12 42 (5) 43 11.7   43 65 (28) 74 37.6  
 Adult 69 (1 876) 20.7 1116 75 (839) 5 217 16.1   1 587 65 (1 037) 3 849 26.9  
 Elderly 71 (103) 21.2 51 69 (35) 246 14.2   94 72 (68) 239 28.4  
District category             
 Dense 72 (1 379) 20.5 922 75 (691) 4 266 16.2 0.9 (0.336)  991 69 (688) 2 452 28.1 2.9 (0.091) 
 Sparse 63 (654) 20.8 288 70 (201) 1 375 14.6   754 60 (453) 1772 25.6  
Patient status              
 Drop-outs 51 (136) 17.4 146 53 (77) 540 14.3 9.5 (0.024)  119 50 (59) 239 24.6 8.1 (0.045) 
 Dead 21 (26) 15.0 73 23 (11) 116 9.5   48 31 (15) 57 26.3  
 Transfer out 64 (49) 18.2 29 93 (21) 135 15.5   47 60 (28) 133 21.0  
 ART cont. 73 (1 822) 21.1 962 81 (783) 4 848 16.2   1531 68 (1 039) 3 794 27.4  
Adherence              
 Good 68 (1 581) 21.7 843 75 (620) 3 864 16.0 0.2 (0.642)  1 493 68 (961) 3 420 28.1 1.1 (0.29) 
 Poor 73 (452) 17.5 367 74 (272) 1 777 15.3   252 71 (180) 802 22.4  
*100 PYs = 100 person years; ART=antiretroviral therapy; BL=baseline; IPT=isoniazid preventive therapy; n=number of patients; TB=tuberculosis; 
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Table 4.2b Associations between predictors and IPT initiation stratified by period of enrolment into HIV care (continued) 
  Overall Enrolment period 2004-2010  Enrolment period 2011-2016 
  %IPT 
cases (n) 
IPT 
cases/ 
100 PYs* 
Total
(n) 
IPT cases 
Row % 
(n) 
Person
-years 
IPT 
cases/ 
100 PYs* 
Chi-square; 
p-value 
 Total 
(n) 
IPT cases  
Row % (n) 
Per-
son-
years 
IPT 
cases/ 
100 PYs* 
Chi-squared;  
p-value 
 Total 69 (2 033) 20.6 1210 74 (892) 5 641 15.8   1 745 65 (1141) 4 223 27.0 300 (0.000)* 
Treatment failure             
 No 69 (1 993) 19.1 1176 73 (860) 5 471 18.9 2.1 (0.144)  1 733 65 (1 133) 4 184 27.1 0.2 (0.649) 
 Yes 87 (40) 20.6 34 94 (32) 169 15.7   12 67 (8) 40 20.2  
BL CD4              
 1-100 65 (413) 18.9 321 71 (229) 1 449 15.8 2.4 (0.515)  318 59 (186) 757 24.6 2.7 (0.313) 
 101-350 72 (1 232) 19.9 757 76 (567) 3 582 15.8   957 70 (666) 2 602 25.6  
 351-500 60 (214) 26.2 81 76 (62) 379 16.3   276 59 (162) 477 34.0  
 501-1572 66 (161) 26.0 51 67 (34) 231 14.6   194 65 (127) 387 32.8  
BL WHO stage             
 I 70 (733) 24.4 246 80 (196) 1 192 16.4 4.2 (0.240)  803 67 (537 1 813 29.6 12.4 (0.006) 
 II 69 (842) 18.7 609 71 (430) 2 848 15.1   610 67 (412) 1 664 24.7  
 III 73 (379) 19.6 295 76 (224) 1 355 16.5   221 70 (155) 577 26.8  
 IV 46 (79) 19.1 60 70 (42) 245 17.1   111 33 (37) 169 21.9  
Duration of pre-ART             
 <1 70 (1 491) 20.7 892 74 (663) 4 151 15.9 1.9 (0.602)  1 235 67 (828) 3 050 27.2 4.5 (0.213) 
 1-2 74 (198) 21.1 121 76 (92) 561 16.4   148 72 (106) 377 28.1  
 3-5 67 (229) 19.2 135 76 (102) 654 15.6   209 56.4 (127) 538 23.6  
 >5 53 (115) 21.6 62 56 (35) 273 12.8   153 46.6 (80) 258 31.0  
Duration of ART (Years)             
 0-2 45 (329) 59.4 59 2 (1) 40 2.4 24 (0.000)  678 48.4 (328) 514 63.8 9.4 (0.024) 
 3-4 67 (479) 23.7 63 32 (20) 191 10.4   654 70.2 (459) 1830 25.1  
 5-6 81 (570) 17.6 313 76 (239) 1 499 15.9   388 85.3 (331) 1 745 19.0  
 >6 82 (655) 16.2 775 81 (632) 3 909 16.1   25 92.0 (23) 134 17.1  
*100 PYs = 100 person years; tnd=target not detected; WHO= World Health Organization; CD4 counts are in cells/mm3
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Five variables, namely gender, patient status, antiretroviral treatment failure, baseline 
WHO clinical stage and duration on ART, had considerable association (p<0.300) with 
IPT initiation in the patients enrolled on ART before 2011 (see Tables 4.2a and 4.2b). 
However, for the patients enrolled on ART after 2011, more variables namely, gender, 
age, district category and patient status had substantial influence (p<0.300) on IPT 
initiation. Other variables with sizable effect (p<0.300) on IPT initiation for the patients 
enrolled on ART after 2011 were adherence, baseline WHO clinical stage, duration on 
pre-ART and duration on ART. 
Figures 4.2 and 4.3 depict the predictive effect of selected variables in Table 4.2 on 
IPT initiation, based on the Kaplan-Meier failure function of time to IPT initiation per 
predictor variable. Period of enrolment and district category displayed disproportionate 
distribution attributes contraindicated for the use of Cox’s proportional hazards 
function, which justified the need for stratified analysis with period of enrolment as the 
strata variable to correct this anomaly.  
Significant (p<0.2) categorical predictor variables that had distinct plots were: (1) 
gender; (2) marital status; (3) district; (4) geographic location; (5) period of enrolment 
into HIV care; (6) baseline WHO clinical stage; (7) adherence to ART; (8) patient status 
at exit time of the study; and (9) history of past TB infection on first visit. For continuous 
predictors, significant (p<0.2) predictors (in Table 4.2) that also had distinct plots 
(Figures 4.2 and 4.3) were: (1); age (2) baseline CD4 count; (3) median CD4 count; 
(4) median viral load; and (5) duration of pre-ART. 
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Figure 4.2 Kaplan-Meier function of time to IPT initiation by predictor variables (A-D) 
Age group (C) and duration of ART (D) were important determinants of IPT initiation, while gender (B) was not. Note that period of enrolment was 
disproportionate, which justified the need for stratified analysis.  
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Figure 4.3 Kaplan-Meier function of time to IPT initiation by predictor variables (E-H) 
Baseline WHO clinical stage (E), Median viral load (F), District category (G) and adherence (H) were all important predictors of IPT initiation; tnd=target not 
detected; viral load ranges in copies/mm3 are as follows; tnd (0-50); low (50-500); high (500-10000); and very high (>10000).
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4.3.3 Associations between patient characteristics and defaulting IPT 
Table 4.3 presents the associations between patient characteristics and defaulting IPT. 
The gender, and district density categories were significantly (p<0.050) associated with 
defaulting IPT by Chi-square test. The baseline CD4 count was only marginally 
significant (t=7.6; p=0.056). However, in univariate logistic regression analysis (see 
Table 4.4), males [OR: 1.7; 95% CI: 1.2-2.4; p=0.006] and the sparsely populated 
district category [OR: 2.1; 95% CI: 1.5-3.0; p=0.000] had significantly higher odds of 
defaulting IPT compared to females and densely populated geographic location, 
respectively. In addition, baseline CD4 count category 351-500 cells/mm3 [OR: 2.1; 
95% CI: 1.2-3.8; p=0.010] and baseline WHO clinical stage IV [OR: 2.4; 95% CI: 1.2-
4.8; p=0.016] also had significantly higher odds of defaulting IPT, compared to baseline 
CD4 count category 1-100 cells/mm3 and baseline WHO clinical stage I. However, in 
multiple logistic regression analysis, the sparsely populated district category [adjusted 
OR: 1.6; 95% CI: 1.1-2.3; p=0.000] and gender [adjusted OR: 2.1; 95% CI: 1.5-3.0; 
p=0.006] were the most influential in determining defaulting of IPT. Baseline CD4 count 
category 351-500 cells/mm3 [OR: 2.2; 95% CI: 1.2-4.0; p=0.013] and baseline WHO 
clinical stage IV [OR: 2.5; 95% CI: 1.2-5.1; p=0.015] were also significant in multiple 
logistic regression analysis. 
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Table 4.3  Association between patient characteristics and IPT defaulting  
Patient Characteristic & Defaulted IPT
Subcategory Total (n) No. Yes Chi-square; p-value  
 Row% (n) Row% (n)
Total 2,033 93.4 (1898) 6.6 (135)
Age   0-9 21 100 (21) 0 (0) 4.1; 0.765
9-18 22 90.9 (20) 9.1 (2)  
18-25 179 94.4 (169) 5.6 (10)  
25-35 691 93.8 (648) 6.2 (43)  
35-45 598 92.6 (554) 7.4 (44)  
45-55 338 92.3 (312) 7.7 (26)  
55-65 151 94 (142) 6 (9)  
65-84 33 97 (32) 3 (1)  
Gender 
Female 1,394 94.4 (1316) 5.6 (78) 7.8; 0.005
Male 639 91.1 (582) 8.9 (57)  
Geographic location 
Dense 1,379 95 (1310) 5 (69) 18.5; 0.000
Sparse 654 89.9 (588) 10.1 (66)  
Period enrolled into HIV care 
2011-2016 1,141 93.2 (1063) 6.8 (78) 0.2; 0.689
2004-2010 892 93.6 (835) 6.4 (57)  
Baseline WHO clinical stage 
1 733 93.6 (686) 6.4 (47) 7.6; 0.056
2 842 93.3 (786) 6.7 (56)  
3 379 94.5 (358) 5.5 (21)  
4 79 86.1 (68) 13.9 (11)  
BL CD4 count
1-100 415 94.2 (391) 5.8 (24) 13.1; 0.004
101-350 1,233 94.3 (1163) 5.7 (70)  
351-500 224 88.4 (198) 11.6 (26)  
501-1512 161 90.7 (146) 9.3 (15)  
IPT=isoniazid preventive therapy; ART=antiretroviral therapy; BL=baseline; n=number of patients; WHO= World Health Organization; CD4 are in cells/mm3.
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Table 4.4 Logistic regression of predictors associated with IPT defaulting  
Patient Characteristic   Defaulted IPT Chi-square Univariate  Multivariate  
Subcategory Total (n)  Row% (n) p-value Unadjusted OR (95% CI)  Adjusted OR (95% CI) p-value 
Gender         
Female 1 394 5.6 (78) 7.8; 0.005 base (1)  base (1)  
Male 639 8.9 (57) 1.7 (1.2-2.4) 0.006 1,7 (1.5-3.0) 0.006 
Geographic location        
Dense 1 379 5 (69) 18.5; 0.000 base (1)  base (1)  
Sparse 654 10.1 (66) 2.1 (1.5-3.0) 0.000 1.6 (1.1-2.3) 0.000 
Period enrolled into HIV care       
2011-2016 1 141 6.8 (78) 0.2; 0.689 base (1)    
2004-2010 892 6.4 (57) 1.1 (0.8-1.5)  0.689 Excluded - 
Baseline WHO clinical stage       
1 733 6.4 (47) 7.6; 0.056 base (1) base (1)   
2 842 6.7 (56) 1.0 (0.7-1.6) 0.848 1.3 (0.9-2.1) 0.174 
3 379 5.5 (21) 0.9 (0.5-1.5) 0.566 1.1 (0.6-2.0) 0.688 
4 79 13.9 (11) 2.4 (1.2-4.8) 0.016 2.5 (1.2-5.1) 0.015 
BL CD4 count        
1-100 415 5.8 (24) 13.1; 0.004 base (1) base (1)   
101-350 1 233 5.7 (70) 0.9 (0.6-1.6) 0.936 1.1 (0.6-1.7) 0.828 
351-500 224 11.6 (26) 2.1 (1.2-3.8) 0.010 2.2 (1.2-4.0) 0.013 
501-1512 161 9.3 (15) 1.7 (0.9-3.3) 0.133 2.0 (2.0-3.9) 0.060 
IPT=isoniazid preventive therapy; n=number of patients; ART=antiretroviral therapy; BL=baseline; WHO= World Health Organization; CD4 counts are in 
cells/mm3. 
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4.3.4 Modelling the rate of initiation of IPT  
Out of ten variables considered for inclusion in the model, three predictors - district 
category, age group and duration on ART - emerged as significant (p<0.050) predictors 
(Table 4.5a and 4.5b). Two predictors, duration on ART and district category, had 
significant (p=0.000) interactions (shown as: Duration on ART # District category in 
Table 4.5b). Based on the likelihood-ratio test, the model with the interactions was 
superior to the one without interactions (t=19.7; p<0.001).  
In the tests of proportional-hazards assumption using the Schoenfeld and scaled 
Schoenfeld residuals (phtest) test, one predictor, duration of ART, was not 
proportional. However, the variable was retained in the model after stratified analysis 
to correct for this anomaly.  
 
© Central University of Technology, Free State
   
96 
Table 4.5a Cox’s proportional hazards model for initiation of IPT by PLHIV in Lesotho 
Predictor  Outcome Unstratified model Model stratified by period of enrolment 
  2004-2016 2004-2010 2011-2016 
 Total 
(n) 
Initiation rate 
per 100 PY 
 Unadjusted  
HR (95% CI) 
p-value Adjusted  
HR (95% CI) 
p-value  Adjusted 
HR (95% CI) 
 Adjusted 
HR (95% CI) 
            
Enrolment period            
2011-2016  1 745 27.0   1 (base)  1 (base)      
2004-2010 1 210 15.8  0.60 [0.54-0.68] 0.000 0.63 [0.55-0.72] 0.000     
Duration of pre-ART            
<1 2 127 20.7  1 (base)  1 (base)      
1-2 269 21.1  1.02 [0.86-1.20] 0.851 1.01 [0.85-1.20] 0.909     
3-5 344 19.2  1.06 [0.91-1.23] 0.491 0.99 [0.85-1.16] 0.905     
>5 215 21.6  0.96 [0.76-1.20] 0.706 0.84 [0.66-1.06] 0.137     
Baseline WHO stage             
I 1 049 24.4  1 (base)  1 (base)      
II 1 219 18.7  0.81 [0.72-0.91]  0.000 0.87 [0.77-0.98] 0.023     
III 516 19.6  0.83 [0.72-0.96]  0.011 0.92 [0.79-1.06] 0.255     
IV 171 19.1  0.88 [0.68-1.13]   0.333 0.92 [0.72-1.19] 0.538     
Adherence             
Good 2 219 21.7  1 (base)  1 (base)      
Poor 615 17.5  0.96 [0.85-1.07]  0.432 0.96 [0.85-1.07] 0.462     
District category             
Sparse 1 042 16.9  1 (base)  1 (base)   1 (base)  1 (base) 
Dense 1 913 15.4  0.77 [0.69-0.86]  0.000 0.58 [0.42-0.78] 0.000  1.03 (0.46-2.30)  0.59 [0.38-0.94] 
Duration on ART*          
0-4 1 454 16.0  1 (base)  1 (base)  1 (base)   
>=5 1 501 15.8  0.76 [0.67-0.86]  0.000 1.40 [1.16-1.70] 0.001 3.34 [2.06-5.43]  1.33 [1.00-1.76] 
*Predictors insignificant when controlled for baseline WHO clinical stage, duration of ART, district category and adherence to ART; WHO=World Health 
Organization, ART= Antiretroviral therapy;  n=number of patients; PLHIV=People living with HIV; # denotes interaction of terms. 
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Table 4.5b Cox’s proportional hazards model for initiation of IPT by PLHIV in Lesotho (continued) 
Predictor  Outcome Unstratified model Model stratified by period of enrolment 
  2004-2016 2004-2010 2011-2016 
 Total 
(n) 
Initiation rate 
per 100 PY 
 Unadjusted  
HR (95% CI) 
p-value Adjusted  
HR (95% CI) 
p-value  Adjusted 
HR (95% CI) 
 Adjusted 
HR (95% CI) 
            
Geographic location # Duration of ART    1 (base)  1 (base)   
Sparse 1 042 16.9    0.81 [0.83-0.95] 0.000 0.86 [0.77-0.96]  0.95 [0.85-1.06] 
Dense 1 913 15.4    0.86 [0.79-0.89] 0.000 0.86 [0.81-0.90]  1.01 [0.89-1.14] 
Gender*        
Female 1 942 16.1   1 (base)  1 (base)  
Male 1 013 15.4  0.97 [0.87-1.08]  0.568 0.97 [0.88-1.07] 0.579 
Age*         
Child/ Adolescent 107 9.7  1 (base)  1 (base)  1 (base) 1 (base) 
Adult 2 848 16.1  1.63 [1.13-2.33]  0.008 1.71 [1.20-2.47] 0.003 1.64 [1.02-2.61]  1.78 [1.00-3.15] 
Baseline CD4 count*        
1-100 639 15.9  1 (base)  1 (base)  
101-350 1 714 15.9  1.10 [0.98-1.25]  0.116 1.08 [0.95-1.22] 0.231 
351-500 357 17.3  1.25 [1.03-1.52]  0.024 1.11 [0.91-1.35] 0.316 
501-1572 245 14.6  1.07 [0.85-1.36]  0.553 1.02 [0.81-1.30] 0.841 
Patient status*        
Drop-out 265 14.6  1 (base)  1 (base)  
Dead 121 14.2  0.83 [0.54-129]  0.416 0.79 [0.51-1.22] 0.288 
Transfer out 76 15.1  1.19 [0.83-1.70]  0.355 1.16 [0.81-1.67] 0.417 
Art cont. 2 493 16.1  1.28 [1.06-1.55]  0.012 1.27 [1.05-1.55] 0.014 
Treatment failure*        
No 2 909 18.2  1 (base)  1 (base)  
Yes 46 15.9  0.74 [0.53-1.04]  0.083 0.79 [0.56-1.11] 0.176 
*Predictors insignificant when controlled for baseline WHO clinical stage, duration of ART, district category and adherence to ART; Patient status=patient status 
at study exit time; n=number of patients; PLHIV=People living with HIV; # denotes interaction of terms.
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In the final model stratified by period of enrolment into HIV care (Table 4.5a and 4.5b), 
considering the patients enrolled on ART before 2011, the following findings were 
noted: (1) adults had 64% higher probability of receiving IPT (HR=1.64; 95% CI: 1.02-
2.61) relative to children and adolescents; (2) The likelihood of receiving IPT did not 
statistically differ between patients in the densely populated districts (HR = 1.03; 95% 
CI: 0.46–2.30) and those in the sparsely populated regions; and (3) longer durations 
on ART were associated with higher chances of IPT uptake. For example, patients on 
ART for five or more years were three times more likely to receive IPT, compared to 
patients on ART for less than five years (HR=3.34; 95% CI: 2.06-5.43). However, 
comparing two subjects on ART for five or more years in the densely populated 
districts, and considering the interaction terms, having five or more years of ART was 
20% more likely to receive IPT compared to patients on ART for less than five years. 
Considering patients enrolled in the 2011-2016 period, notable trends were as follows 
(1) adults had 78% higher probability of receiving IPT (HR=1.78; 95% CI: 1.00-3.15) 
relative to children and adolescents; (2) patients in the densely populated districts had 
59% lower likelihood of receiving IPT (HR=0.59; 95% CI: 0.38-0.94) compared to the 
sparsely populated districts; and (4) longer durations on ART were still associated with 
higher chances of IPT initiation. For instance, patients on ART for five or more years 
were 33% more likely to receive IPT, compared to patients on ART for less than five 
years (HR=1.33; 95% CI: 1.00-1.76). However, comparing two subjects on ART for five 
or more years in the densely populated districts, and taking into account the interaction 
terms, having five or more years of ART was 34% more likely to receive IPT, compared 
to patients on ART for less than five years. 
These results may be summarised as follows: (1) children and adolescents in the 2004-
2010 and the 2011-2016 cohorts had lower chances of receiving IPT; (2) while IPT 
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initiation did not differ much by district category in the 2004-2010 cohort, IPT initiation 
in the densely populated districts was much lower in the 2004-2010 cohort; and (3) 
longer durations on ART were associated with a higher chance of receiving IPT in the 
2004-2010 and the 2011-2016 cohorts, with the effect of duration being more influential 
in the 2004-2010 cohort. 
4.4 DISCUSSION 
The study found a fairly high IPT uptake (68.8%), but generally a slow initiation rate of 
20.6 per 100 person-years. The slow initiation, even among patients enrolled into HIV 
care after IPT was launched in the country, indicates a slow scale-up exercise for this 
programme considering the high TB burden in this setting, which is estimated at 
852/100,000 in Lesotho (WHO 2015). The 20.6 per 100 person-years rate of IPT 
initiation in this study is comparable to the one reported in Brazil, where IPT initiation 
was 20.0 per 100 person-years (Dowdy et al. 2014).   
One model of the impact of tuberculosis incidence on IPT effectiveness projects that 
IPT is more effective in high TB-burden countries, given an optimum initiation of the 
IPT intervention (Ragonnet, Trauer, McBryde, Houben, Denholm, Handel & Sumner 
2017). This study highlights that the rate of IPT initiation is slow in Lesotho despite the 
high TB-burden status which places the country in the top three nations with annual 
incidences exceeding 700 cases/100,000 alongside South Africa and Swaziland 
(Ragonnet et al. 2017). Therefore, this study suggests that, while current scale-up 
efforts need to be appreciated, intensification of the scale-up efforts is needed.  
The median time to IPT for the 2004-2010 cohort was almost twice as high as that of 
the 2011-2016 cohort, implying that the patients enrolled on ART after IPT was 
launched have a higher initiation rate in this setting. Possible explanations of this 
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finding as cited in the literature include resistance by patients enrolled on ART before 
IPT was launched. The challenge of reviewing the files for patients enrolled on ART 
before IPT was launched to identify those qualifying for IPT may be another 
contributing factor. 
The fact that children and adolescents had a lower chance of IPT initiation compared 
to adults in both the 2004-2010 and 2011-2016 cohorts, emphasises the need for 
scale-up efforts for this patient group. Tadesse et al. (2016) and Triasih, Padmawati, 
Duke, Robertson, Sawyer and Graham (2016) in Ethiopia and Indonesia, respectively, 
note that children in resource-limited high TB-burden settings have a low initiation rate 
of IPT, despite the fact that a six-month course of IPT reduces the risk of childhood TB 
by the same margin of about 60% as adults. The same authors attribute the problem 
to poor access to HIV and TB diagnostic tools in these countries, particularly for early 
HIV detection. Lesotho therefore needs to scale up TB contact screening as 
recommended by the WHO (2015). Deficiencies for the identification of children in 
need of IPT have been noted by other authors, including in Brazil, Benin and Indonesia 
(Mendonca, Kritski & Sant'Anna 2015; Adjobimey, Masserey, Adjonou, Gbenagnon, 
Schwoebel, Anagonou & Zellweger 2016; Triasih et al. 2016). Triasih et al. (2016) 
observe that barriers to IPT initiation and adherence to this intervention among children 
in limited-resource settings also include healthcare worker and health facility-related 
factors, including social support and access.  
IPT initiation in the densely populated districts was much lower in the 2004-2010 
cohort, compared to the 2011-2016 cohort. Access to HIV/TB services, including IPT, 
in the densely populated districts have generally been slow due to a number of 
reasons, including resource limitations for scale-up efforts in these areas, which have 
an estimated 72% of the country’s population (PEPFAR Lesotho 2016). The lower 
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initiation rates in the densely populated districts indicate that IPT initiation scale-up 
efforts, currently supported by PEPFAR Lesotho (2016), need to be intensified in these 
districts.  
It is important to note that IPT initiation in this setting is expected to improve, following 
the adoption and implementation of the new HIV treatment guidelines for the intensified 
‘Test and Treat’ programme of the WHO in Lesotho (WHO 2016). However, studies 
are required to assess the effect of the new guidelines on IPT initiation. Although 
Nachega, Uthman, Del Rio, Mugavero, Rees and Mills (2014) affirm the benefits of the 
‘Test and Treat’ programme, the authors reiterate that this new programme can only 
improve IPT initiation if linkage to care, acceptability of HIV/TB services, retention and 
monitoring strategies are well taken care of. 
Defaulting of IPT was associated with staying in the sparsely populated districts, being 
male, having baseline CD4 count category 351-500 cells/mm3 and baseline WHO 
clinical stage IV. Patients in the sparsely populated districts, particularly those who are 
bed ridden and in WHO clinical stage IV, may be defaulting due to long distances from 
the hospitals and the mountainous terrain associated with these geographic locations. 
Upscaling healthcare delivery in these areas is therefore needed to reduce defaulting. 
In South Africa, Jacobson, Niccolai, Mtungwa, Moll and Shenoi (2017) report that 
inefficient health service delivery, ineffective communication with healthcare workers, 
and the financial burden of obtaining transport to clinics were among the most 
important determinants for defaulting IPT. These factors point to the need for 
interventions to address these challenges. Higher rates of defaulting among males 
emphasise the need for intensified patient education in this group. In Botswana, males 
also defaulted IPT more than females (Mokwena & Motsamai 2015). 
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A qualitative assessment of the factors contributing to low IPT initiation is required in 
this setting - particularly for assessing factors contributing to the low IPT initiation of 
healthcare workers. It is also important to note that barriers to IPT implementation in 
some areas have included healthcare workers themselves (Lester, Hamilton, 
Charalambous, Dwadwa, Chandler, Churchyard & Grant 2010). Lack of knowledge 
and experience, unawareness of the benefits of IPT, a lack of clarity about the IPT 
guidelines, and the belief that TB screening tools are inaccurate in HIV-infected people 
were the main barriers among the healthcare workers (Lester et al. 2010). Thus, there 
is a need to assess the effect of healthcare worker factors on the implementation of 
IPT.  
It is important to note that in some African countries such as the Ivory Coast, the 
national guidelines had not recommended the use of IPT by 2014, citing that IPT could 
lead to resistant TB bacilli in patients with undiagnosed TB (Temprano ANRS 12136 
Study Group 2015). This highlights the magnitude of the challenge of scaling up health 
interventions in developing countries.  
This study is not without limitations, one of which is the lack of data on patient views. 
As Ostermann et al. (2017) note, interventions must factor in the preferences of the 
intended target populations to improve initiation and adherence to the intervention. 
Therefore, investigations on patient preferences and concerns about IPT are needed 
in Lesotho. However, the main strength of this study is the reporting of IPT initiation in 
person-years, which allows comparisons with other settings outside of Lesotho. This 
study also demonstrates that routine data in ART programmes of developing countries 
can be assembled into useful datasets for inferential modelling. 
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4.5 CONCLUSION 
This study investigated the rate of IPT initiation since the IPT progamme was launched 
in 2011 in a high TB-burden setting of Lesotho. A fairly high overall coverage, but with 
a slow initiation rate, was observed. Clearly, Lesotho’s efforts to implement the IPT 
programme is commendable considering its economic challenges. However, the slow 
initiation of IPT, particularly for children, patients leaving in sparsely populated districts 
and those enrolled before the intervention was launched, remains a concern given the 
scale of the TB burden the country faces. Furthermore, the slower initiation of IPT in 
the densely populated districts compared to the sparsely populated districts evokes 
debates on the need to further decentralise health service delivery. The high rates of 
defaulting IPT in the sparsely inhabited districts indicates the need for improving the 
monitoring of this programme. Clearly, the implementation of this health intervention in 
a high TB-burden setting of Lesotho needs further scale up.   
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CHAPTER FIVE: THE EFFECT OF ISONIAZID PREVENTIVE 
THERAPY ON THE OCCURRENCE OF 
TUBERCULOSIS IN LESOTHO 
ABSTRACT 
Background: Little is known about the effectiveness of isoniazid preventive therapy 
(IPT) for the prevention of TB in people living with HIV (PLHIV) in high TB-burden 
settings. This study assessed the treatment effect of IPT and the risk conferred by 
patient characteristics, including time to IPT initiation relative to ART commencement 
on the occurrence of TB in the high TB-burden setting of Lesotho in southern Africa. 
Methods: The study was based on Cox’s proportional hazards regression analyses of 
2 955 HIV-positive medical records randomly selected from eight health institutions in 
six districts of Lesotho. Factor selection into the model was based on univariate 
Kaplan-Meier survival functions, Wilcoxon’s log-rank test, and Cox’s regression 
analysis. Two patient cohorts, one enrolled into antiretroviral therapy (ART) before 
(2004-2010 cohort) and the other one after the launch of IPT (2011-2016 cohort), were 
included in the study.  
Results: The overall TB incidence rate was 2.0 per 100 person-years in 12 208 
person-years. Thirty-nine (15.9%, n = 246) patients developed TB after IPT. TB 
incidences per 100 person-years by timing of IPT were: (a) IPT before ART (1.7); (b) 
IPT after ART (1.8); (c) no IPT (2.6); (d) IPT within one year of ART commencement 
(1.3); and (e) IPT 3-5 years after ART initiation (2.3). IPT effectiveness rapidly 
deteriorated after four years in patients given IPT within one year of ART 
commencement. The most common side effects to IPT were skin rash (37.2%), 
peripheral neuropathy (25.4%) and liver toxicity (9.4%). Gender, baseline WHO clinical 
stage, district category and time to IPT relative to ART commencement emerged as 
significant predictors of TB occurrence. Increasing time to IPT by one six-month 
interval increased the risk of contracting TB by between 6% and 59%, depending on 
the cohort. 
Conclusion: Delayed IPT after ART commencement significantly affects the 
effectiveness of this intervention. Patient characteristics associated with higher risk of 
contracting TB in this study are important for policy making. The need to consider 
booster doses of IPT cannot be overemphasised. 
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5.1 INTRODUCTION 
5.1.1 Background 
Tuberculosis (TB) is the most frequent life-threatening opportunistic disease in people 
living with human immunodeficiency virus (HIV) (WHO 2014). Mycobacterium 
tuberculosis poses a serious threat to HIV-positive people. The organism is known to 
reactivate and cause tuberculosis when the immune system is weakened by HIV virus 
(Gengenbacher & Kaufmann 2012). Of the 1.5 million people who died from the 
disease in 2013 alone, 360 000 were people living with HIV (WHO 2014). Lesotho is 
one of the countries that are worst affected by TB, having the second highest estimated 
TB incidence in the world (WHO 2014).  
The effectiveness of the drug isoniazid, also known as isonicotinylhydrazine (INH), and 
recommended by the WHO in 2004 for the prevention of TB in people living with HIV 
(PLHIV), has been demonstrated to be effective in many TB high-burden settings, 
including but not limited to Ethiopia, Brazil, Botswana, Cambodia and South Africa 
(Dowdy, Golub, Saraceni, Moulton, Cavalcante, Cohn, Pacheco, Chaisson & Durovni 
2014; Hanrahan, Martinson, Link-Barnes, Msandiwa, Chaisson & Golub 2015; Tedla, 
Nguyen, Sibanda, Nyirenda, Agizew, Girde, Rose & Samandari 2015; Van Griensven, 
Choun, Chim, Thai, Lorent & Lynen 2015; Ayele, Mourik & Bonten 2016). One key 
recommendation from these previous studies was that concurrent IPT and ART were 
more effective than the individual therapies (Rangaka, Wilkinson, Boulle, Glynn, 
Fielding, Van Cutsem, Wilkinson, Goliath, Mathee & Goemaere 2014).  
The optimal timing of IPT relative to ART for optimal reduction of TB incidence in PLHIV 
has, however, remained unclear since the WHO 2010 policy guidelines on IPT were 
released (WHO 2011). Houben, Sumner, Grant and White (2014) note that more 
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evidence of optimal timing for IPT relative to ART is required in limited resource 
settings where IPT uptake is slow. More so, the effect of IPT when prescribed many 
years after ART commencement to individuals living in high TB-burden settings where 
chances of reinfection are high, also remains obscure.  
Lesotho is a small independent country of about two million people, and is completely 
surrounded by the Republic of South Africa (GoL 2013). The United Nations (2009) 
notes that Lesotho is a poor country, with 40% of its population living below the official 
poverty line of US$1.25 per day. With a 23.5% adult HIV prevalence rate, Lesotho has 
the second highest prevalence rate of HIV worldwide (UNAIDS 2016). Furthermore, 
with an incidence rate of TB which is estimated at 852 per 100 000 population in the 
general population (WHO 2015), the country ranks third highest globally, after South 
Africa and Swaziland, with Swaziland topping the list (Ragonnet, Trauer, McBryde, 
Houben, Denholm, Handel & Sumner 2017). IPT was introduced to Lesotho in 2011, 
and delayed commencement of IPT relative to ART has continued since the 
programme was launched (GoL 2013).  
Not much is known about the effectiveness of IPT and the risk factors for the 
occurrence of TB in the high TB-burden setting of Lesotho, given the slow initiation of 
IPT relative to ART commencement. The country’s policy on IPT recommends that the 
drug be prescribed, subject to exclusion of TB symptoms, to all PLHIV - including 
children and adolescents (GoL 2013) - regardless of time of enrolment into HIV care. 
This study evaluated the associations between patient characteristics and the 
effectiveness of IPT while in HIV care. The main aim of the study was to establish the 
optimal timing of IPT initiation relative to ART commencement in the high TB-burden 
setting of Lesotho. In addition, this study also reports the common side effects of IPT 
in Lesotho.  
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5.2 METHODS 
5.2.1 Study design  
This longitudinal retrospective cohort study modelled the relative risk of developing TB 
conferred by patient characteristic in PLHIV in Lesotho, considering time to TB as the 
dependent variable, using Cox’s proportional hazards regression function. The study 
is based on quasi-experimental quantitative analysis of ART records of PLHIV 
randomly sampled from the study population. The study assessed the effect of patient 
characteristics, including the duration of time between ART commencement and IPT 
uptake, on the occurrence of TB. 
5.2.2 Study population  
The target population for the study was HIV-positive people enrolled for HIV care 
between 2004 and 2016 in the eight district hospitals. The target population of PLHIV 
excluded patients with past TB, those on TB treatment at enrolment, and transfer-in 
patients with insufficient information. For purposes of analyzing the effect of the 
duration of ART on the occurrence of TB, patients were categorised into two groups, 
with the first group comprising patients enrolled on ART before IPT was launched in 
Lesotho in 2011 (2004-2010 cohort), and the second group consisting of the patients 
enrolled on ART from 2011 onwards (2011-2016 cohort). ART records of HIV-positive 
children, adolescents, adults, including geriatric patients and pregnant women, were 
selected using stratified systematic random sampling across eight health facilities to 
ensure proportional representation of all patient categories including gender, age and 
period of enrolment. 
5.2.3 Sample size calculation 
The minimum sample size was calculated following standard guidelines for studies 
estimating incidences of disease conditions with a preset relative precision (Lwanga & 
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Lemeshow 1991). The minimum number of patients’ records, based on a minimum 
relative precision of 10% and a significance level of 5% (Lwanga & Lemeshow 1991) 
was 385 at each hospital, or 3 080 in the eight hospitals. However, more patient 
records were required to account for data attrition due to exclusion criteria and 
incomplete records. A sufficient buffer for this loss was estimated at 40%, implying that 
at least 4 620 patient files were required. In addition, the minimum sample size per 
hospital was proportionally adjusted for slight differences in the study populations at 
the hospitals, following rules for stratified systematic random sampling.  
Data were collected from January 2016 to October 2016 from the paper-based 
registers for ART, IPT and TB. To improve the quality of data entry, a Microsoft Access 
database application tool was used to capture data from the files. Data were captured 
into the database tool in six-month discrete intervals.  
5.2.4 Patient sampling and data collection 
File selection was based on a sampling frame. The sampling frame was prepared from 
the ART attendance registers by drawing a list of all the patients enrolled into HIV care 
since 2004. The total number of files to be sampled per hospital was obtained by 
dividing the total number of patients enrolled in HIV care by the proportional target 
sample size for the hospital. For example, in a hospital with 2 000 patients enrolled 
and a target sample size of 350, one in six patients was systematically selected by 
sampling every 6th patient from the patient register.  
5.2.5 Final sample selection criteria 
Overall, 4 122 patient files were collected. Of the 4 122 patients, 1 167 were excluded 
because they were transfer-in (118), past TB cases (337 were on TB treatment at 
enrolment or were diagnosed with TB within one month of enrolment (482), had less 
than six months of follow-up time, had died before the IPT programme was launched 
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(131), or had insufficient information (99) (see Figure 5.1). Therefore, the final sample 
size was 2 955. 
 
Figure 5.1  Exclusion criteria for the patients  
Insufficient information referred to patient files with grossly missing data; past TB= 
having a diagnosis of TB before enrolment into HIV care; TB=tuberculosis. 
 
5.2.6 Patient data and outcome measures 
For purposes of evaluating the associations between patient characteristics and the 
occurrence of TB, duration of ART, time to TB (in years), demographic, baseline clinical 
data and ART, follow-up information were required. Thus, demographic information 
including gender, date of birth and marital status of the patients meeting the selection 
criteria were collected from the records. Their clinical data - including dates of HIV 
diagnosis; enrolment into HIV care; ART commencement and IPT initiation; baseline 
indicators including CD4 count, viral load, patient ART status, TB status, and WHO 
clinical stage; ART and IPT regimens; side effects to IPT and check-up information at 
each visit; adherence records; and laboratory monitoring data - were also extracted 
from the records. Time-variant variables, including age, were calculated according to 
the time at enrolment into HIV care. Poor adherence was defined as an overall score 
Total sample 
size = 4 122 
4 004 
3 667 Transfer-in=118 
3 185 Past TB =337 
TB at enrolment 
/ TB within 1 
month after 
enrolment =482 <6 months follow up 
/died before 
IPT launch 
 =131 
3 054 
Final cohort=    
2 955 
Insufficient 
information  
=99 Analysis 
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below ≤75% of the doses prescribed, where 100% denoted perfect adherence. 
Patients late for their scheduled appointments by more than a month, and those who 
did not return for ART services, were classified as drop-outs. 
Time to IPT relative to ART commencement was obtained by subtracting the date ART 
was first prescribed from the date IPT was first prescribed. Of note is the fact that a 
negative difference signified that IPT was given before ART, whilst a zero difference 
indicated that IPT and ART were prescribed simultaneously. Time to TB diagnosis was 
calculated by subtracting the date of enrolment into HIV care from the date the patient 
was diagnosed with TB. Patient treatment outcomes were assessed by median CD4 
and viral load values. The duration of the period before ART commencement (in years), 
known as the Pre-ART period in this study, was calculated by subtracting the date of 
HIV diagnosis from the date of ART commencement. 
5.2.7 Data preparation and verification  
Data captured in the Microsoft Access (Microsoft, Richmond, USA) database were 
verified, and for further cleaning and analysis, data were exported to Stata version 13.1 
(StataCorp, Texas, USA). Data were formatted for survival analysis as discrete-time 
data with interval date as the time variable, and the occurrence of TB event as the 
‘failure’ outcome. For purposes of calculating Cox’s proportional hazards ratios, entry 
time into the risk set was delayed by one month to correct for inconsistencies at first 
entry into the risk set. The date of enrolment into HIV care and the exit date marked 
the left and right censoring times, respectively.  
5.2.8 Modelling patient characteristics associated with TB outcome 
This analysis modelled the incidence of TB and identified patient characteristics 
associated with the occurrence of TB through the Cox’s hazard regression function. 
The method was applied taking the hazard as a probability of a TB event in a specified 
© Central University of Technology, Free State
 117 
time for an individual with given characteristics. Breslow’s correction for tied data was 
used to correct the assumption that survival times in the study were distinct (Kleinbaum 
& Klein 2005). Follow-up times were subdivided into six-month discrete intervals due 
to the inevitable observation gaps for the patients (Singer & Willett 2003). 
To assess the patient characteristics associated with the occurrence of TB, descriptive 
statistics of the data were summarised by cross-tabulating the patient characteristics 
with the occurrence of TB outcome. Chi-square values indicated the magnitude of the 
significance of the differences. Patient characteristics were further analysed using 
cumulative probability distribution plots and univariate Kaplan-Meier curves to 
determine their suitability in the model. Further, Wilcoxon’s log-rank test and Cox’s 
regression analysis were used to determine equality across strata for categorical 
variables and continuous variables, respectively. Predictors with p-values <0.3 were 
included in the test model. 
Nine predictors namely, gender, patient status, treatment failure, baseline CD4 count, 
time to IPT relative to ART, duration of pre-ART, baseline WHO clinical stage, 
geographic location, and duration on ART were selected into the test model and 
successively excluded using the stepwise method. The variable, period of enrolment, 
was selected a priori as a strata variable. Four variables, namely time to IPT relative 
to ART, gender, geographic location, and baseline WHO clinical stage remained in the 
model.  
The model was tested for predictor interaction and resultantly, baseline WHO clinical 
stage was found to have a significant (p<0.05) interaction with time to IPT relative to 
ART. The model with and without the interaction variables was compared using the 
likelihood ratio (Lrtest), and the difference was found to be significant (Chi(3)=19.7 and 
p=0.002), implying that the bigger model with the interaction variables was superior to 
the one without. The analysis therefore proceeded with the interaction-inclusive model.  
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The model was checked for proportionality using the Schoenfeld and scaled 
Schoenfeld residuals (Phtest) test. One categorical variable, district category 
(p=0.045), significantly violated the proportionality assumption. To correct for this 
anomaly, stratified analysis with period of enrolment as the strata variable was 
adopted.  
5.2.9 Ethical aspects and ethical clearance 
Ethical approval was granted by the Institutional Review Board of the National 
University of Lesotho and the Ethics Committee of the Ministry of Health of Lesotho. 
Permission to collect data was also granted by the relevant hospital authorities. To 
protect patient privacy, computer-generated identification numbers were used instead 
of patient names. Patient data in the medical records were treated with confidentiality. 
Furthermore, all data are presented as overall anonymised summaries.  
5.3 RESULTS 
5.3.1 Associations between patient characteristics and the occurrence of TB 
In total, 2 955 patients were included in the final analysis. The overall follow-up time 
ranged from 0.5 to 12 years [median=4.5; interquartile range (IQR): 2.5–6.5]. Table 
5.1a –5.1d present the characteristics of the 2 955 patients considered in the final 
analysis, and their TB outcomes. Overall, 246 (8.3%) developed TB during follow up 
(Table 5.1a). More males developed TB compared to females (11.5% of the males 
versus 6.6% of the females; p<0.001). However, the rates of TB did not differ 
significantly (p=0.839) by age group and marital status (p=0.476). 
The rates of TB significantly varied (p<0.001) by district. Maseru district (14.8%) had 
the highest TB rates, while Qacha’s Nek (1.0%), a sparsely populated district, had the 
lowest rate (Table 5.1a). Overall, the densely populated districts, which constituted 
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64.7%, had significantly (p<0.001) higher rates of TB compared to the sparsely 
inhabited ones. 
TB rates for the patients enrolled on ART before IPT was launched in Lesotho (2004-
2011 period) (14.9%) were significantly higher (p<0.001) than those enrolled after 2011 
(4.2%) (Table 5.1a). The most common entry point into HIV care was the outpatient 
department (77.7%) (Table 5.1b). Mother and child health (MCH) (9.1%), self-refer 
(7.9%), and the HIV testing and counselling centres within the hospital (4.0%) were the 
other notable entry points into HIV care. Rates of TB significantly (p= 0.012) varied by 
entry point into HIV care.  
Tenofovir/lamivudine/efavirenz, with 58.6%, was the most common baseline ART 
regimen (Table 5.1b). At the time the study was terminated, 84.4% patients were still 
continuing ART; the remaining were drop-outs (9.0%), or they had died (4.1%) or being 
transferred out (2.6%) (Table 5.1b). The drop-outs category had the highest rate of TB 
(17.0%); the group continuing ART had the lowest rate (7.1%). Overall, the rates of TB 
significantly (p<0.000) varied by patient status at study exit time.  
The majority (79.1%) of patients had a good rating of adherence to ART; those with 
poor adherence had insignificantly (t=2.8; p=0.061) higher rates of TB (10.2%) 
compared to those with good adherence (7.8%) (Table 5.1b).  
Out of only 1.6% patients who had their ART baseline regimens changed due to 
treatment failure, 26.1% developed TB compared to those with no failure (8.0%) (Table 
5.1b). Treatment failure was significantly (t=19.3; p<0.000) associated with the TB 
outcome.  
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Table 5.1a Associations between patient characteristics and the occurrence of TB 
in PLHIV in Lesotho 
Patient characteristic Total  Developed TB while in HIV care  
Sub-category   No Yes  
 Column% (n)  Row% (Freq) Row% (Freq) Chi-square; 
p-value 
Total 100 (2 955)  91.7 (2 709) 8.3 (246)  
Gender      
Female 65.7 (1 942)  93.4 (1 813) 6.6 (129) 21 (0.000) 
Male 34.3 (1 013)  88.5 (896) 11.5 (117)  
Age      
0-9 1.8 (52)  88.5 (46) 11.5 (6) 2.3 (0.941) 
9-18 1.3 (38)  92.1 (35) 7.9 (3)  
18-25 9.1 (269)  93.3 (251) 6.7 (18)  
25-35 34.8 (1 027)  91.5 (940) 8.5 (87)  
35-45 27.9 (824)  91.9 (757) 8.1 (67)  
45-55 16.1 (477)  91.4 (436) 8.6 (41)  
55-65 7.6 (224)  91.5 (205) 8.5 (19)  
65-84 1.5 (44)  88.6 (39) 11.4 (5)  
Marital status      
Married 59.3 (1 752)  91.4 (1 602) 8.6 (150) 5.5 (0.476) 
Divorced 0.4 (11)  81.8 (9) 18.2 (2)  
Separated 6.5 (193)  93.3 (180) 6.7 (13)  
Widowed 15.5 (458)  93.4 (428) 6.6 (30)  
Cohabiting 0.2 (6)  83.3 (5) 16.7 (1)  
Single 14.9 (440)  90.9 (400) 9.1 (40)  
(-) 3.2 (95)  89.5 (85) 10.5 (10)  
District      
Berea 18.3 (540)  95.4 (515) 4.6 (25) 111 (0.000) 
Maseru 38.7 (1 145)  85.2 (975) 14.8 (170)  
Mohale’s Hoek 7.7 (228)  96.9 (221) 3.1 (7)  
Mokhotlong 11.4 (336)  95.2 (320) 4.8 (16)  
Qacha’s Nek 10.2 (302)  99 (299) 1 (3)  
Thaba Tseka 13.7 (404)  93.8 (379) 6.2 (25)  
Geographic location      
Dense 64.7 (1 913)  89.4 (1711) 10.6 (202) 35.5 (0.000) 
Sparse 35.3 (1 042)  95.8 (998) 4.2 (44)  
Period enrolled into HIV care   
2011-2016 59.1 (1 745)  96.2 (1 679) 3.8 (66) 115.2 
(0.000) 
2004-2010 40.9 (1 210)  85.1 (1 030) 14.9 (180)  
(-)=missing information; ART=antiretroviral therapy; IPT=isoniazid preventive therapy; n=number of 
patients; TB=tuberculosis; tnd=target not detected; WHO=World Health Organization. 
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Table 5.1b Associations between patient characteristics and the occurrence of TB 
in PLHIV in Lesotho (continued) 
Patient characteristic Total  Developed TB while in HIV care  
Sub-category   No Yes  
 Column% (n)  Row% (Freq) Row% (Freq) Chi-square; 
p-value 
Total 100 (2 955)  91.7 (2 709) 8.3 (246)  
Entry      
Adolescent clinic 0.4 (12)  100 (12) 0 (0) 15.8 (0.015) 
HTC 4 (118)  91.5 (108) 8.5 (10)  
MCH 9.1 (268)  94 (252) 6 (16)  
OPD 77.7 (2 295)  91 (2 089) 9 (206)  
Self-refer 7.9 (232)  96.1 (223) 3.9 (9)  
Under-5 clinic 0.2 (6)  100 (6) 0 (0)  
Hospital ward 0.8 (24)  79.2 (19) 20.8 (5)  
Baseline regimen      
TDF+3TC+EFV 58.6 (1 732)  94.5 (1 636) 5.5 (96) 71.5 (0.000) 
AZT+3TC+EFV 23.8 (704)  85.5 (602) 14.5 (102)  
AZT+3TC+NVP 5.9 (173)  97.1 (168) 2.9 (5)  
D4T+3TC+NVP 4.1 (120)  85 (102) 15 (18)   
D4T+3TC+EFV 2.8 (84)  86.9 (73) 13.1 (11)  
TDF+3TC+NVP 2.2 (65)  92.3 (60) 7.7 (5)  
ABC+3TC+NVP 1.1 (32)  84.4 (27) 15.6 (5)  
ABC+3TC+EFV 1 (29)  93.1 (27) 6.9 (2)  
ABC+3TC+kaletra 0.5 (16)  87.5 (14) 12.5 (2)  
Patient status      
Drop-outs 9 (265)  83 (220) 17 (45) 34.5 (0.000) 
Dead 4.1 (121)  86.8 (105) 13.2 (16)  
Transfer out 2.6 (76)  90.8 (69) 9.2 (7)  
ART continuing 84.4 (2 493)  92.9 (2315) 7.1 (178)  
Adherence to ART      
Good 79.1 (2 336)  92.2 (2 153) 7.8 (183) 3.5 (0.061) 
Poor 20.9 (619)  89.8 (556) 10.2 (63)  
Treatment failure      
No 98.4 (2 909)  92 (2 675) 8 (234) 19.3 (0.000) 
Yes 1.6 (46)  73.9 (34) 26.1 (12)  
Duration of Pre-ART    
<1 72 (2 127)  91.5 (1 947) 8.5 (180) 6.1 (0.108) 
01-Feb 9.1 (269)  89.2 (240) 10.8 (29)  
03-May 11.6 (344)  92.2 (317) 7.8 (27)  
>5 7.3 (215)  95.3 (205) 4.7 (10)  
ART=antiretroviral therapy; ABC=abacavir; AZT=zidovudine; 3TC=lamivudine; NVP=nevirapine; 
kaletra=lopinavir/ritonavir; EFV=efavirenz; TDF=tenofovir; BL=baseline; HBsAg=Hepatitis B surface 
antigen; HTC=HIV testing and counselling; IPT=isoniazid preventive therapy; MCH=mother and child 
health; OPD=outpatient department; n=number of patients; TB=tuberculosis 
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Table 5.1c Associations between patient characteristics and the occurrence of TB 
in PLHIV in Lesotho (continued) 
Patient characteristic Total  Developed TB while in HIV care  
Sub-category   No Yes  
 Column% (n)  Row% (Freq) Row% (Freq) Chi-square; 
p-value 
Total 100 (2 955)  91.7 (2 709) 8.3 (246)  
BL CD4 count   
1-100 21.6 (639)  87.8 (561) 12.2 (78) 19.7 (0.000) 
101-350 58 (1714)  92.1 (1 579) 7.9 (135)  
351-500 12.1 (357)  95 (339) 5 (18)  
501-1512 8.3 (245)  93.9 (230) 6.1 (15)  
Median viral load     
Tnd 9.1 (268)  89.9 (241) 10.1 (27) 25.4 (0.000) 
Low 1.3 (38)  89.5 (34) 10.5 (4)  
High 2.1 (61)  91.8 (56) 8.2 (5)  
Very high 2.8 (84)  77.4 (65) 22.6 (19)  
(-) 84.7 (2 504)  92.4 (2 313) 7.6 (191)  
BL WHO clinical stage     
I 35.5 (1 049)  96.9 (1 016) 3.1 (33) 145.7 
(0.000) 
II 41.3 (1219)  92.3 (1 125) 7.7 (94)  
III 17.5 (516)  79.1 (408) 20.9 (108)  
IV 5.8 (171)  93.6 (160) 6.4 (11)  
Oral thrush at BL      
No 89.4 (2 642)  92.3 (2 438) 7.7 (204) 11.9 (0.001) 
Yes 10.6 (313)  86.6 (271) 13.4 (42)  
Hrpes zoster at BL      
No 93.6 (2 767)  91.9 (2 543) 8.1 (224) 3 (0.083) 
Yes 6.4 (188)  88.3 (166) 11.7 (22)  
Cryptocococcal meningitis at BL     
No 98.5 (2 910)  91.8 (2 671) 8.2 (239) 3.1 (0.077) 
Yes 1.5 (45)  84.4 (38) 15.6 (7)  
HTN diagnosis      
No 96.3 (2 845)  91.7 (2 610) 8.3 (235) 0.4 (0.517) 
Yes 3.7 (110)  90 (99) 10 (11)  
DM diagnosis      
No 99.5 (2 939)  91.7 (2 695) 8.3 (244) 0.4 (0.544) 
Yes 0.5 (16)  87.5 (14) 12.5 (2)  
Abnormal LFTs      
No 66.9 (1 976)  93.4 (1 846) 6.6 (130) 23.8 (0.000) 
Yes 33.1 (979)  88.2 (863) 11.8 (116)  
      
BL=baseline; HBsAg=Hepatitis B surface antigen; n=number of patients; TB=tuberculosis; CD4 counts 
are in cells/mm3; 
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Table 5.1d Associations between patient characteristics and the occurrence of TB 
in PLHIV in Lesotho (continued) 
Patient characteristic Total  Developed TB while in HIV care  
Sub-category   No Yes  
 Column% (n)  Row% (Freq) Row% (Freq) Chi-square; 
p-value 
Total 100 (2 955)  91.7 (2 709) 8.3 (246)  
Abnormal serum creatinine (renal disease)    
No 70.2 (2 075)  93.6 (1 942) 6.4 (133) 33.5 (0.000) 
Yes 29.8 (880)  87.2 (767) 12.8 (113)  
HBsAg positive     
No 99.5 (2 940)  91.6 (2 694) 8.4 (246) 1.4 (0.242) 
Yes 0.5 (15)  100 (15) 0 (0)  
Anaemia at BL      
No 28.1 (831)  94.7 (787) 5.3 (44) 69.7 (0.000) 
Yes 49.9 (1 474)  87.5 (1 290) 12.5 (184)  
(-) 22 (650)  97.2 (632) 2.8 (18)  
Number of IPT interventions received     
0 31 (917)  92 (844) 8 (73) 15.6 (0.001) 
1 64.3 (1 900)  92.2 (1 751) 7.8 (149)  
2 4.5 (132)  82.6 (109) 17.4 (23)  
3 0.2 (6)  83.3 (5) 16.7 (1)  
Time to IPT from date of enrolment (years)   
<1 24.6 (727)  97 (705) 3 (22) 71.6 (0.000) 
1-2 9.1 (268)  94.4 (253) 5.6 (15)  
3-5 21.8 (644)  89 (573) 11 (71)  
>5 12.9 (381)  83.2 (317) 16.8 (64)  
No IPT 31.6 (935)  92.1 (861) 7.9 (74)  
Number of TB sign events     
none 85.9 (2 539)  93.7 (2 379) 6.3 (160) 96.7 (0.000) 
once 11.3 (334)  79.3 (265) 20.7 (69)  
>2 2.8 (82)  79.3 (65) 20.7 (17)  
      
(-)=missing information; ART=antiretroviral therapy; BL=baseline; HBsAg=Hepatitis B surface antigen; 
IPT=isoniazid preventive therapy; n=number of patients; TB=tuberculosis 
Overall, the range of pre-ART period was 0-8 years (median=3 months; interquartile 
range (IQR): 0–1 year). The majority of the patients (72.0%) received ART within one 
year of testing positive for HIV, while the 11.6% had delayed ART commencement by 
3-5 years (Table 5.1b). By proportion, 7.3% had delayed ART by more than 5 years. 
The rates of TB significantly (t=17.9; p<0.000) varied with the length of pre-ART time, 
with the highest rate (10.8%) of TB occurring in those exposed to ART within 1-2 years 
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of testing positive, and the lowest rate (7.8%) occurring in those who delayed ART by 
three to five years. 
Overall, the baseline CD4 count ranged from 3 to 1512 cells/mm3 (median=223; 
interquartile range (IQR): 115–330) (Table 5.1c). The most common (58.0%) range of 
baseline CD4 count was 100-350 cells/mm3, followed by 1-100 cells/mm3 with 21.6%. 
The 1-100 cells/mm3 had the highest rate (12.2%) of TB. The overall median viral load 
ranged from below the detectable range (<50 copies/mm3) to very high (>10,000 
copies/mm3) (Table 5.1c). Patients with a very high median viral load had the highest 
rate of TB, while those with the median viral load below the detectable range had the 
lowest rate (22.6%).  
Baseline WHO clinical stage II (41.3%) was the most common baseline WHO stage. 
While baseline stage III had the highest rate of TB (20.9%), whilst the lowest rate was 
baseline stage I with only 3.1% developing TB while in HIV care (Table 5.1c). Oral 
thrush (10.6%), herpes zoster (6.4%) and cryptococcal meningitis (1.5%) were the 
most common opportunistic infections at baseline (Table 5.1c). By proportion, oral 
thrush at baseline (t=11.9; p=0.001); herpes zoster and cryptococcal meningitis were 
not significantly (p>0.050) associated with higher TB outcomes while in HIV care.  
The majority (95.6%) of the patients had missing information about the diagnosis of 
chronic non-communicable diseases (NCDs), particularly hypertension and diabetes 
(Table 5.1c). Nearly half (49.9%) of the patients had anaemia at baseline (Table 5.1d). 
More than a third (33.1%) of patients were diagnosed with liver disease at least once 
during HIV care through liver function tests; a third (29.8%) were diagnosed with renal 
disease at some point during follow-up tests, while only 0.5% were diagnosed with 
hepatitis B viral infection (Table 5.1d). Of these conditions, having a diagnosis of 
anaemia, liver or renal disease was significantly (p<0.050) associated with the 
occurrence of TB. Hepatitis B viral infection was insignificantly (t=1.4; p=0.242) 
© Central University of Technology, Free State
 125 
associated with TB outcome. Defaulting IPT was insignificantly (t=2.5; p=0.282) 
associated with the development of TB. 
Overall, time to IPT from date of enrolment ranged from four years before ART to 
eleven years after ART commencement (median=1.5; IQR: 0.5–3.6) (Table 5.1d). 
Almost a third (31.6%) of the patients had not received IPT at the exit time of the study; 
24.6% received IPT within a year of enrolment. Patients who received IPT more than 
five years after enrolment had the higher rates of TB (16.8%); whilst only 3.0% patients 
who received IPT within a year of enrolment developed TB. 
The occurrence of TB was insignificantly (t=96.7; p<0.001) associated with the number 
of times TB signs were detected in a patient during checkup visits (Table 5.1d). Only 
6.3% of the patients who had no TB signs developed TB while in HIV care. 
5.3.2 The effectiveness of TB screening criteria and IPT intervention 
outcomes 
Out of the 246 patients who developed TB, 68 (27.6%) patients had TB signs that were 
ruled out in the previous visit (see Figure 5.2A). Of the 68 patients miss-diagnosed for 
TB, 17 (25.0%) were erroneously given IPT after TB had been ruled out incorrectly. 
Skin rash (37.2%) and peripheral neuropathy (25.4%) were the most common side 
effects associated with the use of IPT (Figure 5.2B & 5.2C). However, 9.4% had raised 
liver function tests results indicative of liver disease during the IPT course or within one 
month of completing the course.  
Only 0.7% were stopped from taking IPT due to side effects (Figure 5.2D). In addition, 
only 6.6% defaulted IPT (Figure 5.2E). Out of the 246 patients who developed TB while 
in HIV care, 39 (15.9%) patients developed TB after receiving IPT, irrespective of the 
time the patient had developed TB (Figure 5.2F). Time from TB post exposure to IPT 
(Figure 5.3) ranged from 0 to 49 months (median=14; IQR: 6–30). Of the 39 patients 
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who developed TB after receiving IPT, 12.8% developed TB during the six-month 
course of IPT; whilst 25% developed TB one to six months after taking IPT. 
  
Figure 5.2 IPT treatment outcomes  
Miss-diagnosed for TB in the previous visit=patient diagnosed of TB on the following 
visit after the previous visit erroneously ruled out TB based on the WHO TB screening 
tool; Developed TB after receiving IPT=patient developed TB during or after finishing 
the IPT course (irrespective of the time the TB developed); n=number of patients; 
INH=isonicotinylhydrazine (isoniazid); TB=tuberculosis.  
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 Figure 5.3 Time to TB during or after IPT 
Developed TB at time zero means the patient developed TB during IPT; post 
exposure=after; INH=isonicotinylhydrazine (isoniazid); TB=tuberculosis; n=number of 
patients who developed TB after exposure to IPT. 
5.3.3 The occurrence of TB by predictor variables 
Table 5.2a – 5.2c present the occurrence of TB by predictor variables. The total 
number of incident TB cases was 246 (8.3%, n = 2 955) in 12,208 person-years (PY) 
of observation. Relapse TB cases occurred in 43 (17.5%) of the 246 patients who 
developed TB. Overall, the incidence rate was 2.0 per 100 PY of follow-up (Table 5.2a). 
Compared to the incidence rate of the patients who received IPT before ART (1.7 per 
100 PY), patients who received IPT after starting ART had an incidence rate of 1.8 per 
100 PY, while that of patients who received no IPT was 2.6 per 100 PY (Table 5.2b).  
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Table 5.2a Stratified model of the associations between predictors and the occurrence of TB in PLHIV in Lesotho 
 Overall Enrolment period 2004-2010 Enrolment period 2011-2016
Predictor % TB cases 
(n) 
Incidence 
per 100 
person- 
years 
Total 
(n) 
Incident TB 
Row% (n) 
Per-
son 
years 
TB 
incidence 
per 100 
person-
years 
Chi-value  
(p-value) 
Total 
(n) 
Incident TB 
Row% (n) 
Person
-years 
TB 
incidence 
per 100 
person- 
years 
Chi-value     
(p-value) 
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3 1 745 3.8 (66) 4 223 1.6  
Age    
Children 11.5 (52) 2.4 31 19.4 (6) 189 3.2 2.3 (0.510) 21 0.0 (0) 61 0 1.4 (0.708) 
Adolescent 5.5 (55) 2.2 12 16.7 (2) 61 3.3  43 2.3 (1) 74 1.3  
Adult 8.4 (2 703) 2.0 1 116 15.1 (168) 7 416 2.3  1 587 3.8 (60) 3 849 1.6  
Elderly 6.2 (145) 1.6 51 7.8 (4) 318 1.3  94 5.3 (5) 239 2.1  
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3  1745 3.8 (66) 4 223 1.6  
Gender    
Female 6.6 (1 942) 1.6 798 12.3 (98) 5 330 1.8 11.8 (0.001) 1 144 2.7 (31) 2 856 1.1 12.4 
(0.000) 
Male 11.5 (1 013) 2.9 412 19.9 (82) 2 656 3.1  601 5.8 (35) 1 367 2.6  
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3  1 745 3.8 (66) 4 223 1.6  
District population density    
Sparse 4.2 (1 042) 1.2 288 8.7 (25) 1 749 1.4 8.1 (0.005) 754 2.5 (19) 1 772 1.1 4.3 (0.039) 
Dense 10.6 (1 913) 2.3 922 16.8 (155) 6 237 2.5  991 4.7 (47) 2 452 1.9  
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3  1 745 3.8 (66) 4 223 1.6  
Baseline CD4 count    
1-100 12.2 (639) 2.7 321 19.0 (61) 2 168 2.8 5.7 (0.160) 318 5.7 (18) 757 2.4 4.5 (0.290) 
101-350 7.9 (1 714) 1.8 757 13.2 (100) 4 957 2.0  957 3.6 (34) 2 603 1.3  
351-500 5 (357) 1.8 81 12.3 (10) 531 1.9  276 2.9 (8) 477 1.7  
501-1572 6.1 (245) 2.1 51 17.6 (9) 329 2.7  194 3.1 (6) 387 1.5  
Total 8.3 (2 955) 2.0 1 210 14.8 (180) 7 985 2.3  1 745 3.8 (66) 4 223 1.6  
Incident TB cases are expressed as row percentages of row totals; ART=antiretroviral therapy; BL=baseline; IPT=isoniazid preventive therapy; TB=tuberculosis; WHO= World Health Organization; CD4 counts are in cells/mm3; n=number of patients. 
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Table 5.2b Stratified model of the associations between predictors and the occurrence of TB in PLHIV in Lesotho (continued) 
 Overall Enrolment period 2004-2010 Enrolment period 2011-2016
Predictor % TB cases 
(n) 
Incidence 
per 100 
person- 
years 
Total 
(n) 
Incident TB 
Row% (n) 
Per-
son 
years 
TB 
incidence 
per 100 
person-
years 
Chi-value  
(p-value) 
Total 
(n) 
Incident TB 
Row% (n) 
Person
-years 
TB 
incidence 
per 100 
person- 
years 
Chi-value     
(p-value) 
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3   1 745 3.8 (66) 4 223 1.6  
Timing of IPT               
<ART 6 (83) 1.8 11 9.1 (1) 77 1.3 7 (0.219)  72 5.6 (4) 206 1.9 5 (0.415) 
0-1>ART 3.6 (811) 1.3 47 12.8 (6) 299 2   764 3.0 (23) 1 861 1.2  
2-3>ART 8.6 (509) 1.7 262 10.7 (28) 1 608 1.7   247 6.5 (16) 961 1.7  
3-5>ART 15 (321) 2.3 287 15.3 (44) 1 956 2.3   34 11.8 (4) 156 2.6  
6-11>ART 16.1 (279) 2.0 278 16.2 (45) 2 239 2   1 0.0 (0) 6 0  
No IPT 7.9 (952) 2.6 325 17.2 (56) 1 806 3.1   627 3.0 (19) 1 034 1.8  
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3   1745 3.8 (66) 4 223 1.6  
BL WHO clinical stage            
I 3.1 (1 049) 1.0 246 7.3 (18) 1 578 1.1 46.7 (0.000)  803 1.9 (15) 1 813 0.8 40.1 
(0.000) 
II 7.7 (1 219) 1.6 609 11.7 (71) 4 061 1.8   610 3.8 (23) 1 664 1.4  
III 20.9 (516) 4.2 295 27.8 (82) 1 985 4.1   221 11.8 26) 577 4.5  
IV 6.4 (171) 2.1 60 15 (9) 362 2.5   111 1.8 (2) 169 1.2  
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3   1745 3.8 (66) 4 223 1.6  
Adherence to ART             
Good 7.8 (2 336) 2.1 843 15.5 (129) 5 502 2.3 0.6 (0.443)  1 493 3.6 (54) 3421 1.6 0.1 (0.737) 
Poor 10.2 (619) 1.9 367 13.9 (51) 2 483 2.1   252 4.8 (12) 803 1.5  
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3   1 745 3.8 (66) 4 223 1.6  
             
Incident TB cases are expressed as row percentages of row totals; timing of IPT is in relation to ART commencement. ART=antiretroviral therapy; BL=baseline; IPT=isoniazid preventive therapy; TB=tuberculosis; WHO= World Health Organization; n=number of patients. 
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Table 5.2c Stratified model of the associations between predictors and the occurrence of TB in PLHIV in Lesotho (continued)   
 Overall Enrolment period 2004-2010 Enrolment period 2011-2016
Predictor % TB cases 
(n) 
Incidence 
per 100 
person- 
years 
Total 
(n) 
Incident TB 
Row% (n) 
Per-
son 
years 
TB 
incidence 
per 100 
person-
years 
Chi-value  
(p-value) 
Total 
(n) 
Incident TB 
Row% (n) 
Person
-years 
TB 
incidence 
per 100 
person- 
years 
Chi-value     
(p-value) 
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3   1 745 3.8 (66) 4 223 1.6  
Median viral load             
tnd 10.1 (268) 2.0 150 13.3 (20) 1 017 2 6.8 (0.080)  118 5.9 (7) 360 1.9 2.2 (0.537) 
Low 10.5 (38) 2.1 22 9.1 (2) 149 1.3   16 12.5 (2) 42 4.7  
High 8.2 (61) 1.5 35 11.4 (4) 261 1.5   26 3.8 (1) 71 1.4  
Very high 22.6 (84) 3.6 54 29.6 (16) 443 3.6   30 10.0 (3) 82 3.7  
Total 12.2 (451) 2.2 261 16.1 (42) 1 870 2.3   190 6.8 (13) 556 2.3  
Duration on ART (years)             
0-2 2.2 (737) 2.7 59 11.9 (7) 83 8.4 6.6 (0.007)  678 1.3 (9) 514 1.8 2.0 (0.417) 
3-4 6.7 (717) 2.2 63 28.6 (18) 306 5.9   654 4.6 (30) 1 830 1.1  
5-6 9.1 (701) 1.8 313 12.1 (38) 1 790 2.1   388 6.7 (26) 1 745 1.1  
>6 14.8 (800) 2.0 775 15.1 (117) 5 806 2.0   25 4.0 (1) 134 0.8  
Total 8.3 (2 955) 2.0 1 210 14.9 (180) 7 985 2.3   1 745 3.8 (66) 4 223 1.6  
Duration on pre-ART             
<1 8.5 (2 127) 2.0 892 14.1 (126) 5 786 2.1 2.7 (0.442)  1 235 4.4 (54) 3 049 1.8 4.1 (0.320) 
1-2 10.8 (269) 2.4 121 20.7 (25) 816 3.0   148 2.7 (4) 377 1.1  
3-5 7.8 (344) 1.9 135 15.6 (21) 465 2.2   209 2.9 (6) 538 1.1  
>5 4.7 (215) 1.6 62 12.9 (8) 168 2.0   153 1.3 (2) 258 0.8  
Total 8.3 (2 955) 2.0 1 095 14.9 (180) 7 236 2.3   1 745 3.8 (66) 4 223 1.6  
             
Incident TB cases are expressed as row percentages of row totals; ART=antiretroviral therapy; TB=tuberculosis; viral load ranges in copies/mm3are as follows; tnd (0-50); low (50-500); high (500-10 000); and very high (>10 000); n=number of patients. 
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The length of time to IPT relative to starting ART was an important variable. For 
example, compared to those who received IPT three to five years after starting ART, 
and who had a rate of 2.3 per 100 PY, those who received IPT within one year of 
starting ART had a rate of 1.3 per 100 PY. Incident rates of TB also varied from 1.2 to 
2.6 by time to IPT from date of enrolment (Table 5.2b).  
The category of patients who received timeous IPT intervention, particularly before 
ART and within one year of starting ART was higher in the group of patients who did 
not develop TB, compared to those who developed TB during follow up (Table 5.2b). 
Median viral load, duration on ART and duration on pre-ART were not significantly 
associated with TB outcome (Table 5.2c) 
Figures 5.4 and 5.5 present the predictor effect of selected categorical predictor 
variables with significant (p<0.2) effect in Table 5.2a – 5.2c, based on the Kaplan-Meier 
survival plots of the cumulative occurrence of TB event over the follow-up time. 
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 Figure 5.4 Cumulative occurrence of first TB event by predictor variable (A-D) 
The predictors – period of enrolment, district category, baseline WHO clinical stage and gender had clear influence on the occurrence of TB. Note that the  
follow-up time for patients enrolled before 2011 was shorter than that of patients enrolled after 2011, which justified stratified analysis of the two cohorts; 
cum=cumulative.  
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 Figure 5.5 Cumulative occurrence of first TB event by predictor variable (E-H) 
Median viral load (E), time to IPT relative to ART (G) and duration on pre-ART (H) were important predictors of TB outcome, while adherence to ART (F) was 
not a decisive factor. Note the beneficial effect of receiving IPT within one year of starting ART, and the loss of protection after four years (G); cum=cumulative; 
viral load ranges in copies/mm3 are as follows; tnd (0-50); low (50-500); high (500-10 000); and very high (>10 000). 
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5.3.4 The effect of IPT on the occurrence of tuberculosis 
Table 5.3a – 5.3c present Cox’s proportional hazards model for the effect of isoniazid 
preventive therapy (IPT) on the occurrence of TB. Out of ten variables considered in 
the model, four predictors - time to IPT relative to ART, gender, district category and 
baseline WHO clinical stage - emerged as significant (p<0.050) predictors.  
In the final model stratified by period of enrolment into HIV care (Table 5.3a), and 
considering the patients enrolled on ART before 2011 and prior to the launch of IPT in 
Lesotho, the following findings were noted: (1) patients in the densely populated 
districts had a higher relative risk (HR=1.42; 95% CI: 1.06-1.92) of developing TB 
compared to people living in the sparsely populated districts; (2) only baseline WHO 
clinical stages III and IV had a higher relative risk of developing TB compared to stage 
I [8.09; 95% CI (3.57-18.30) and 6.05; 95% CI (1.82-20.06), respectively]; (3) 
increasing time to IPT by one unit of time (equivalent to one-six month interval), and 
holding all other variables constant, increased the relative risk of developing TB by only 
6% (HR=1.06; 95% CI: 0.88-1.25); and (4) males had a higher risk of developing TB 
compared to females (HR=1.64; 95% CI: 1.35-1.98).  
Considering patients enrolled on ART after 2011, on the other hand (Table 5.3a), 
notable findings were: (1) similar to the 2004-2010 cohort with respect to geographic 
location, patients in the densely inhabited districts had a higher relative risk of 
developing TB (HR=1.11; 95% CI: 0.86-1.44); (2) similar to the 2004-2010 cohort, 
males had a higher relative risk of developing TB (HR=1.42; 95% CI: 1.14-1.77) 
compared to females; (3) slightly different to the 2004-2010 cohort, all higher baseline 
WHO clinical stages II-IV were associated with higher relative risks of developing TB 
compared to those in stage I. For example, patients in stage III had a relative risk 26 
times (HR=26.01; 95% CI: 13.27-51.02) higher than those in stage I; (4) contrary to 
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findings with the 2004-2010 cohort, comparing two subjects in baseline WHO clinical 
stage I, and increasing the time to IPT relative to ART by one year, had an overall 
effect of increasing the occurrence of TB by 59% (HR=1.59; 95% CI: 1.01-2.50). 
However, comparing two subjects in baseline WHO clinical stage II, and considering 
the interaction terms, increasing time to IPT relative to ART by one unit (equivalent to 
one six-month interval) while holding all other variables constant, yielded an overall 
relative risk of 21% compared to stage I (Table 5.3b). Furthermore, increasing the time 
interval by a year raised the relative risk by 52%. Stage III had a 22% higher relative 
risk compared to stage I, while the relative risk of patients in stage IV was 24.2% 
compared to stage I (Table 5.3b). In a nutshell, increasing time to IPT relative to ART 
had a greater effect in the 2004-2010 cohort compared to the 2011-2016 cohort.  
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Table 5.3a Cox’s proportional hazards model of the effect of IPT on the occurrence of TB in PLHIV in Lesotho 
Predictor  Outcome  Unstratified model  Model stratified by period of enrolment 
    2004-2016  2004-2010  2011-2016 
 Total 
(n) 
TB 
incidence 
per 100 
PY 
 Unadjusted  
HR (95% CI) 
p-value Adjusted  
HR (95% CI) 
p-value  Adjusted 
HR (95% CI) 
 Adjusted 
HR (95% CI) 
   
Enrolment period            
2011-2016  1 745 1.6  1 (base)  1 (base)      
2004-2010 1 210 2.3  2.37 (1.77-3.17) 36.5; 0.000  1.53 (0.98-2.41) 0.064     
Time to IPT/ART 2 955 2.0  1.18 (1.08-1.27) 15.5; 0.000 1.20 (1.07-1.36) 0.024  1.06 (0.88-1.25)  1.59 (1.01-2.50) 
Baseline WHO stage           
I 1 049 0.9  1 (base)  1 (base)   1 (base)  1 (base) 
II 1 219 1.6  1.95 (1.31-2.90) 0.007 2.62 (1.53-4.46)  0.000  1.82 (0.73-4.54)  3.61 (1.67-7.80) 
III 516 4.2  5.17 (3.50-7.64) 0.000 17.12 (10.75-
27.28) 
0.000  8.09 (3.57-18.30)  26.01 (13.27-51.02) 
IV 171 2.1  2.21 (1.12-4.38) 0.851 9.50 (4.98-18.13) 0.000  6.05 (1.82-20.06)  9.72 (3.75-25.21) 
Gender            
Female 1 942 1.6  1 (base)  1 (base)   1 (base)  1 (base) 
Male 1 013 2.9  1.84 (1.43-2.36) 0.004 1.54 (1.34-1.79) 0.000  1.64 (1.35-1.98)  1.42 (1.14-1.77) 
District population density          
Sparse 1 042 1.2  1 (base)  1 (base)   1 (base)  1 (base) 
 Dense 1 913 2.3  2.06 (1.49-2.86) 0.000 1.25 (1.04-1.52) 0.021  1.42 (1.06-1.92)  1.11 (0.86-1.44) 
*Predictor insignificant when controlled for gender, baseline WHO clinical stage, district category and time to IPT relative to ART; Hazard ratios for predictors 
remaining in the model after stepwise predictor selection process was calculated with period of enrolment as a strata variable; WHO=World Health Organization, 
time to IPT-ART =time to IPT relative to ART; ART= antiretroviral treatment; Patient status=patient status at study exit time; n=number of patients; PLHIV=people 
living with HIV. 
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Table 5.3b Cox’s proportional hazards model of the effect of IPT on the occurrence of TB in PLHIV in Lesotho (continued) 
Predictor  Outcome  Unstratified model  Model stratified by period of enrolment 
    2004-2016  2004-2010  2011-2016 
 Total 
(n) 
TB 
incidence 
per 100 
PY 
 Unadjusted  
HR (95% CI) 
p-value Adjusted  
HR (95% CI) 
p-value  Adjusted 
HR (95% CI) 
 Adjusted 
HR (95% CI) 
   
BL. WHO stage # Time to IPT-ART          
I 1 049 0.9    1 (base)   1 (base)  1 (base) 
II 1 219 1.6    0.87 (0.76-1.00) 0.058  0.93 (0.76-1.14)  0.62 (0.35-1.09) 
III 516 4.2    0.77 (0.68-0.88) 0.000  0.88 (0.73-1.058)  0.63 (0.39-1.00) 
IV 171 2.1    0.80 (0.67-0.94) 0.009  0.86 (0.66-1.11)  0.86 (0.46-1.59) 
Age*             
Children 52 2.4  1 (base)  1 (base)      
Adolescents 55 2.2  0.70 (0.18-2.91) 0.349 1.04 (0.09-11.50)  0.976     
Adult 2 703 2.0  0.79 (0.35-1.77) 0.296 1.17 (0.29-4.74) 0.828     
Elderly 145 1.6  0.60 (0.21-1.69) 0.350 0.77 (0.15-4.00) 0.758     
Baseline CD4 count*           
1-100 639 2.7 1 (base)  1 (base)      
101-350 1 714 1.8 0.62 (0.47-0.83) 0.307 0.79 (0.56-1.11) 0.179     
351-500 357 1.8 0.55 (0.32-0.93) 0.997 1.05 (0.57-1.95) 0.875     
501-1572 245 2.1 0.63 (0.37-1.10) 0.951 1.14 (0.59-2.22) 0.169     
Patient status*           
Drop-outs 265 4.1 1 (base)  1 (base)      
Dead 121 5.5 1.23 (0.70-2.19) 0.799 1.34 (0.46-3.92) 0.594     
Transfer out 76 2.1 0.52 (0.23-1.15) 0.136 0.68 (0.26-1.79) 0.437     
Art cont. 2 493 1.7 0.42 (0.30-0.58) 0.000 0.52 (0.34-0.81) 0.004           
*Predictor insignificant when controlled for gender, baseline WHO clinical stage, district category and time to IPT relative to ART; Hazard ratios for predictors 
remaining in the model after stepwise predictor selection process were calculated with period of enrolment as a strata variable; time to IPT-ART =time to IPT relative 
to ART; ART= antiretroviral treatment; Patient status=patient status at study exit time; n=number of patients; PLHIV=people living with HIV. 
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Table 5.3c Cox’s proportional hazards model of the effect of IPT on the occurrence of TB in PLHIV in Lesotho (continued) 
Predictor  Outcome  Unstratified model  Model stratified by period of enrolment 
    2004-2016  2004-2010  2011-2016 
 Total 
(n) 
TB 
incidence 
per 100 
PY 
 Unadjusted  
HR (95% CI) 
p-value Adjusted  
HR (95% CI) 
p-value  Adjusted 
HR (95% CI) 
 Adjusted 
HR (95% CI) 
   
Treatment failure*           
No 2 909 2.0 1 (base)  1 (base)      
Yes 46 3.4 2.24 (1.25-4.03) 0.000 1.54 (0.79-3.00) 0.209     
Duration on ART (years)*          
0-2 737 2.6 1 (base)  1 (base)      
3-4 717 2.2 1.28 (0.72-2.27) 0.823 2.71 (0.82-9.02) 0.103     
5-6 701 1.8 1.45 (0.83-2.53) 0.891 3.04 (0.92-10.03) 0.068     
>6 800 2.0 1.90 (1.11-3.27) 0.652 3.28 (0.963-11.16) 0.058     
Duration on pre-ART*          
<1 2 127 2.0 1 (base)  1 (base)      
1-2 269 2.4 1.22 (0.82-1.80) 0.011 1.34 (0.84-2.16) 0.223     
3-5 344 1.9 0.66 (0.36-1.21) 0.134 1.02 (0.47-2.21) 0.958     
>5 215 1.6 0.74 (0.31-1.81) 0.361 2.61 (0.93-7.39) 0.070     
Timing of IPT/ART*            
<ART 83 1.8  1 (base)  1 (base)      
0-1>ART 811 1.3  0.71 (0.27-1.82) 0.271 0.57 (0.22-1.48) 0.047      
2-3>ART 509 1.7  1.20 (0.48-3.04) 0.296 0.94 (0.37-2.37) 0.092     
3-5>ART 321 2.3  1.82 (0.72-4.57) 0.205 1.29 (0.51-3.28) 0.552     
6-11>ART 279 2.0  1.76 (0.69-4.44) 0.235 1.18 (0.46-3.02) 0.022     
No IPT 952 2.6  1.62 (0.66-4.03) 0.292 1.20 (0.48-2.98) 0.038     
*Predictor insignificant when controlled for gender, baseline WHO clinical stage, district category and time to IPT relative to ART; Hazard ratios for predictors 
remaining in the model after stepwise predictor selection process was calculated with period of enrolment as a strata variable; WHO=World Health Organization, 
time to IPT-ART =time to IPT relative to ART; ART= antiretroviral treatment; n=number of patients; PLHIV=people living with HIV. 
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5.4 DISCUSSION  
The main purpose of this study was to model the effect of patient characteristics, 
including the timing of IPT in relation to ART, on the occurrence of TB. Four predictors 
in this study influenced the occurrence of TB when adjusted for the period of enrolment 
into HIV care. Patients with delayed IPT after starting ART; higher baseline WHO 
clinical stages; living in densely populated districts; and being male were all associated 
with higher risks of developing TB while in HIV care. With respect to the timing of IPT, 
the model revealed that increasing time to IPT relative to ART increased the risk of 
contracting TB. These findings point to the need for timely IPT intervention relative to 
ART; timely initiation of ART when patients still have better immunity; intensified TB 
interventions in the densely populated districts; and closer monitoring of males.  
Studies that have modelled the effect of time to IPT relative to ART are scarce. Notably, 
one study by Yirdaw, Jerene, Gashu, Edginton, Kumar, Letamo, Feleke, Teklu, Zewdu 
and Weiss (2014), which had similar findings to this study, categorised the timing of IPT 
relative to ART as ‘IPT-before-ART’; ‘IPT-and-ART started simultaneously’; and ‘IPT-
after-ART’; but did not model the timing of IPT relative to ART as a continuous variable. 
In the study by Yirdaw et al. (2014), receiving IPT after starting ART had limited impact 
on TB incidence compared to ‘IPT-before-ART’ and simultaneous commencement of 
IPT and ART. 
Giving IPT within six months of starting ART reduced the occurrence of TB by 59% in 
this study. Although this finding is comparable to previous studies, the main difference 
is that previous studies evaluated the effect of IPT as a categorical variable. For 
example, studies on the effect of combined IPT and ART reveal that concurrent IPT 
and ART reduces the risk of contracting TB by between 37% (HR = 0.63, 95 % CI 0.41-
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0.94) and 60 % (HR = 0.40; 95 % CI 0.18 - 0.87), in comparison to ART without IPT 
(Rangaka et al. 2014; Ayele, Van Mourik & Bonten 2015a). However, the results of this 
study indicate that timing of IPT is critical to its effectiveness. Although, Golub, Cohn, 
Saraceni, Cavalcante, Pacheco, Moulton, Durovni and Chaisson (2015) note that the 
six-month IPT course reduces the risk of contracting TB for at least seven years, the 
findings of this study suggest that the effectiveness of IPT in Lesotho starts to decline 
after two years, and rapidly deteriorates after four years, which indicates the need for 
booster doses. 
Many studies also report the impact of IPT as a categorical variable. Yirdaw et al. 
(2014) report that, in Ethiopia, starting IPT before ART, or simultaneously with ART, 
reduced the risk of contracting TB by 82% (HR = 0.18, 95% CI = 0.08–0.42) and 80% 
(HR = 0.20, 95% CI = 0.10–0.42) respectively. In Brazil, receiving both ART and IPT 
reduced the risk of contracting TB by 76% (HR=0.24; 95% CI = 0.11–0.53) (Golub, 
Saraceni, Cavalcante, Pacheco, Moulton, King, Efron, Moore, Chaisson & Durovni 
2007). Semu, Fenta, Medhin and Assefa (2017) report that the TB incidence rate in 
Ethiopia was significantly lower in the IPT-treated group (0.21 per 100 person-years), 
compared to the untreated 7.18/100 per 100 person-years.  
Of note is the fact that IPT had higher benefits in the patients enrolled on ART after 
IPT was launched in this study. For patients enrolled on ART before IPT was launched, 
cutting the time to IPT relative to ART by six months reduced TB by only 6%; while in 
the patients enrolled on ART after IPT was launched, TB occurrence was reduced by 
59%. Although this difference may be due to the high TB rates in the first few months 
of ART, this result suggests that IPT may have a limited impact on patients enrolled 
into ART for many years.  
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Higher baseline clinical stages increased the risk of contracting TB. Patients in stage 
III had a relative risk 26 times (HR=26.01; 95% CI: 13.27-51.02) higher than those in 
stage I. Late testing for HIV and poor linkage to HIV care have been cited as main 
contributors to higher WHO stages at ART enrolment (Van Rooyen, Barnabas, Baeten, 
Phakathi, Joseph, Krows, Hong, Murnane, Hughes & Celum 2013). The high 
proportion of patients in WHO baseline stage III (1%), and the occurrence of TB within 
a few months of enrolment into HIV care indicate the extent of the problem of late HIV 
testing. This finding may explain why OPD was the main (77.7%) entry point into HIV 
care. Most of the patients may have entered into HIV care due to some ailment related 
to HIV infection. In addition, higher WHO baseline stages may also explain why a 
considerable proportion of patients had herpes zoster (6.4%) and oral thrush (10.6%) 
at baseline.  
Males had a higher risk of developing TB relative to females in the cohort enrolled on 
ART after IPT was launched (HR=1.42; 95% CI: 1.1-1.77), and in the cohort enrolled 
into HIV care before 2011 (1.64; 95% CI: 1.35-1.98), compared to females. This implies 
that males continue to have a higher risk of developing TB since 2004. In Ethiopia, 
Yirdaw et al. (2014) report similar findings with respect to males (HR=1.42; 95% CI: 
1.13–1.79). The higher rates of TB in males emphasise the need for targeted 
interventions, including scaling up IPT uptake in this patient group. 
A significant improvement in the relative risk of contracting TB occurrence in densely 
populated districts was found between the 2004-2010 (HR=1.42; 95% CI: 1.06-1.92) 
and the 2011-2016 cohorts (HR=1.11; 95% CI: 0.86-1.44). In one report based on data 
collected between 2013 and 2014, PEPFAR Lesotho (2016) highlights that densely 
populated districts in Lesotho had the highest overall TB notification rates compared 
to sparsely populated districts in the general population (81% versus 19%). Thus, the 
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results of this study may signify the need to intensify scale up of HIV/TB activities in 
the densely populated districts.  
A considerable proportion (15.9%; n=246) of the patients who developed TB after 
receiving IPT had the TB occurrence during the IPT course (12.8%), while 13% 
developed TB one to six months after taking IPT. Underlying TB, or lack of adherence 
to IPT, explains this occurrence of TB during or soon after IPT (Mesfin, Deribew, Yami, 
Solomon, Van Geertruyden & Colebunders 2012; Ayele, Van Mourik, Debray & Bonten 
2015b). However, these figures are relatively higher than those reported in literature. 
Griensven, Choun, Chim, Thai, Lorent and Lynen (2015) report that 3% developed TB 
while on IPT. The results of this study imply that, without the tuberculin skin test (TST) 
and efficient screening for underlying TB in high TB-burden countries, a considerable 
proportion of patients may receive IPT when it is contraindicated. Ayele et al. (2015b) 
note that the TST has benefits in countries with a high burden of TB. The fact that 
27.6% patients who developed TB had TB signs that were ruled out in the previous 
visit, and that 25.0% of those ruled out of TB were erroneously given IPT, emphasises 
the need to improve TB screening.  
Skin rash (37.2%), peripheral neuropathy (25.4%) and liver impairment (9.4%) were 
the most common side effects associated with the use of IPT. The proportion (9.4%) 
with impaired liver function tests in this study is lower than those reported in other 
studies. Griensven et al. (2015) report a higher proportion of 22%. The results of this 
study may have been affected by underreporting of liver toxicity possibly due to 
challenges with laboratory monitoring of liver function tests. Hayashi, Fontana, 
Chalasani, Stolz, Talwalkar, Navarro, Lee, Davern, Kleiner, Gu, Hoofnagle and Injury 
(2015) highlight that underreporting of liver toxicity is common in settings prescribing 
IPT, and that IPT is one of the leading causes of drug-induced liver injury. The fact that 
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only 0.7% were stopped from taking IPT due to side effects suggests that further 
research, particularly related to the side effects associated with discontinuation of IPT, 
are needed. The 15.9% occurrence of TB after taking IPT emphasises the need for 
further interventions to mitigate the occurrence of TB during HIV care.  
A limitation of this study was the inability to assess the duration of HIV infection. This 
variable has remained elusive in studies evaluating the effectiveness of IPT, including 
the study by Ayele et al. (2015a). In addition, the effect of time to IPT relative to ART 
in this study was confounded by baseline WHO clinical stage - more especially in the 
patients enrolled on ART after IPT was launched. More studies that include stratified 
analysis are therefore needed for further assessment of the effect of time to IPT relative 
to ART.  
The main strength of this study is that it presents data on IPT’s effectiveness from a 
high TB-burden setting with a fairly high follow-up time. The modelling of IPT’s 
effectiveness as a continuous variable is another important contribution to the current 
literature on this intervention. This study also demonstrates the usefulness of routine 
ART data in developing countries in the evaluation of the effectiveness of IPT. 
5.5 CONCLUSION 
This study investigated the effect of longer durations between commencing ART and 
IPT and other important predictors of TB occurrence in a setting characterised by slow 
implementation of the IPT intervention, mostly given as a once-off six-month course. 
Better outcomes of IPT with respect to its effectiveness in mitigating TB incidence in 
high TB-burden settings are realised when IPT is given in the early stages of ART 
commencement. Clearly, the IPT intervention is having a limited effect in high  
TB-burden settings such as Lesotho, with longer durations between ART and IPT 
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commencement being the biggest challenge. Besides the timing of IPT, population 
density and gender are important predictors of TB occurrence in Lesotho during and 
after IPT. More efforts are therefore needed to address these risk factors in the country.  
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CHAPTER SIX: HEALTH SYSTEM CHALLENGES AFFECTING THE 
IMPLEMENTATION OF ISONIAZID PREVENTIVE 
THERAPY IN PEOPLE LIVING WITH HIV IN 
LESOTHO 
ABSTRACT 
Background: The six-month course of isoniazid preventive therapy (IPT) has been 
demonstrated to be an effective intervention for mitigating the occurrence of 
tuberculosis (TB), particularly in high TB-burden settings. However, its implementation 
in sub-Saharan countries remains subdued. This study investigated the factors 
inhibiting IPT uptake in the high HIV/TB burden setting of Lesotho.  
Methods: Data were obtained from 46 healthcare workers, key informants at the 
Ministry of Health of Lesotho, and representatives of partner organisations, who were 
purposively selected for their roles in IPT implementation. Data were coded to identify 
themes, and the emerging themes were benchmarked to previous typologies for 
evaluating the implementation of best practices in health interventions, namely 
effectiveness; reach; sustainability and adaptation. Each main theme was further 
linked to the World Health Organization’s building blocks of national health systems. 
Results: Seven health system challenges affecting the implementation of IPT were 
identified, namely poor decentralisation of HIV services; inefficient monitoring and 
evaluation systems; ineffective service delivery; interrupted supply chains; 
undertrained and inadequate health workforce; insufficient health system financing and 
inefficient health information systems.  
Conclusion: These findings indicate that a wide spectrum of challenges has affected 
the implementation of IPT in Lesotho.  This indicates that a wider reform of the national 
health system is imperative when implementing key health interventions that need 
complex execution strategies. 
Keywords: Health system challenges; isoniazid preventive therapy; PLHIV; 
tuberculosis; uptake of health interventions 
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6.1 INTRODUCTION 
6.1.1 Background 
Tuberculosis (TB) is the most common opportunistic disease in people living with 
human immunodeficiency virus (HIV). Of the 1.5 million people who died from TB in 
2013, nearly 25% were HIV-positive (WHO 2014). Yet, preventative interventions to 
curb the incidence of TB in this subgroup often fail to take off to scale (Yamey 2012). 
One such intervention is isoniazid preventive therapy (IPT), recommended by the 
WHO (2004) as a preventative therapy against TB in people living with HIV (PLHIV). 
A number of studies have reported the uptake of IPT in a number of countries, and 
concluded that this intervention had a slow scale up (Adams, Talbot, Odato, Blunt & 
Steingart 2014; Adjobimey, Masserey, Adjonou, Gbenagnon, Schwoebel, Anagonou & 
Zellweger 2016; Ayele, Mourik & Bonten 2016; Charles, Lindegren, Wester, Blevins, 
Sterling, Dung, Dusingize, Avit-Edi, Durier, Castelnuovo, Nakigozi, Cortes, Ballif, 
Fenner & International Epidemiology 2016). However, the factors underpinning its 
implementation are not well understood.  
Examples of sluggish scale up of health interventions in developing countries are 
many, and many lessons can be drawn from these past challenges (Lengeler 2004). 
McCannon, Berwick and Massoud (2007) recount that many sound solutions exist, but 
their adoption is slow. Buekens, Keusch, Belizan and Bhutta (2004) observe that the 
main challenge lies in how new health interventions should be delivered. Yet, the task 
of evaluating the implementation of health interventions is often daunting due to the 
spectrum of challenges involved (Yamey 2012). Often such evaluations lead to 
discovering deficiencies in the healthcare systems under investigation (WHO 2007).   
The WHO (2007) recommends increasing access to new health interventions without 
compromising the quality and safety of the interventions (WHO 2007). Health 
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interventions are therefore expected to balance between access, coverage, quality and 
safety through judging how well the six building blocks of health systems, namely – 
service delivery; health workforce; information; medical products; financing; and 
leadership have been painstakingly considered in the new intervention (WHO 2007). 
Furthermore, the evaluation of health interventions should include the qualitative and 
quantitative evidence of best practices in local settings namely, effectiveness, 
accessibility, feasibility, sustainability, and transferability – where transferability refers 
to the extent to which the practice can be applied to or adapted to various contexts 
(Spencer et al. 2013). In principle, the higher the quality of evidence, the better the 
practice for the new intervention.  
Getahun, Granich, Sculier, Gunneberg, Blanc, Nunn and Raviglione (2010), in their 
investigations on the implementation of IPT in its early years of this intervention, note 
that ineffective leadership and governance, service delivery, supply chains, health 
workforce, health information system and inadequate health system financing were 
likely to affect IPT implementation, given the scale of the resources required for this 
intervention. Since then, no further information has emerged on factors affecting the 
implementation of IPT in most other countries that have implemented IPT - Lesotho 
included.  
Lesotho is a small country of about two million people.  The country is completely 
surrounded by the Republic of South Africa (GoL 2013). The country has a 
mountainous terrain with only about 10% arable land. Poverty is a problem in the 
country. The United Nations (2009) notes that Lesotho is a poor country, with 40% of 
its population living below the official poverty line of US$1.25 per day. Lesotho has the 
second highest estimated TB incidence in the world, and a high HIV coinfection rate of 
about 74% of the TB cases (WHO 2014).  
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IPT was introduced to Lesotho in 2011 (GoL 2013). Poor uptake of the drug has 
continued since the launch of the programme (GoL 2013). This paper analyses the 
contextual factors inhibiting the uptake of IPT in PLHIV in the high TB-burden setting 
of Lesotho. The aim of this study is to establish, within the context of the health system 
of Lesotho, the compelling barriers to IPT implementation that need to be addressed.   
6.2 METHODS 
6.2.1 Study design  
This qualitative study explored the contextual constraints affecting IPT implementation 
in people living with HIV in Lesotho, based on interviews with healthcare workers, 
Ministry of Health (MoH) officials and representatives of HIV/TB programmes’ 
implementing partners, purposively sampled for their roles in the provision of HIV/TB 
services.  
6.2.2 Qualitative interviews  
6.2.2.1 Interview guides 
Interview guides used to conduct the interviews with both healthcare workers and 
implementing partners were designed by the researcher, based on the theoretical 
framework for developing and implementing best practices in health interventions 
(Spencer, Schooley, Anderson, Kochtitzky, DeGroff, Devlin & Mercer 2013) (see 
Figure 6.1). The interview guide had the following sections: (i) Effectiveness – the 
extent the practice achieves the desired outcomes; (ii) Reach – the extent IPT covers 
the intended target population; (iii) Sustainability – the extent to which the practice can 
be maintained and monitored; (iv) Adaptation – the extent to which the IPT intervention 
has been applied to and adapted to the local context.  
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The interview guide was translated by a language specialist from English to vernacular 
language (Sesotho), and was validated by pilot testing it with ten selected healthcare 
workers and two key informants with experience in the implementation of health 
interventions in Lesotho. 
 
Figure 6.1  Benchmarks for evaluating the effectiveness of health interventions 
This framework was developed based on the elements of the framework for developing 
and implementing best practices in health interventions by Spencer et al. (2013). 
6.2.2.2 Data collection  
To minimise bias, healthcare workers were interviewed first, and thereafter their 
responses were cross examined with responses from representatives of partner 
organisations and the Ministry of Health (MoH) officials. All healthcare workers working 
with IPT who were willing to participate in the study, including nurses; pharmacists; 
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laboratory technicians and counsellors were interviewed individually for about 30 
minutes, until data saturation was reached. Responses were noted down manually 
during the interviews. Representatives of partner organisations were also interviewed 
individually, with each interview lasting for about an hour. Responses from all the 
interview responses were manually transcribed from vernacular (Sesotho) into English 
by a language specialist, using open coding before analysis.  
6.2.3 Analysis of interview data 
Data were coded to identify themes, and the emerging themes were benchmarked to 
previous typologies for evaluating the implementation of best practices in health 
interventions, according to the conceptual framework of Spencer et al. (2013) (see 
Figure 6.1). Each main theme was further linked to the World Health Organization’s six 
building blocks of a health system, namely: (i) leadership and governance; (ii) service 
delivery; (iii) supplies and products; (iv) training and supervision; (v) health information 
system; and (vi) health system financing (WHO 2007), for purposes of benchmarking 
the effectiveness of the implementation of health interventions. 
6.2.4 Ethical aspects 
The study was approved by the Ministry of Health of Lesotho. The researcher observed 
standard ethical principles. Interview respondents were invited to participate in the 
study. They were informed that their participation was voluntary, that they could 
withdraw from the study at any moment if they so wish. All respondents were asked to 
sign a written consent form. Information on the background of the study was availed to 
them in English and vernacular (Sesotho) languages, where appropriate. To ensure 
interviewees’ anonymity, information that would identify the interviewees was removed 
from this study. 
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6.3 RESULTS 
6.3.1 Health system challenges constraining the implementation of isoniazid 
preventive therapy in people living with HIV in Lesotho 
Table 6.1a—6.1c present the demographic information and the relevant working 
experience of the study participants. Overall, 42 healthcare workers employed by the 
Government of Lesotho comprising nurses (33), pharmacists (5), counselors (2) and 
laboratory personnel (2) were interviewed. In addition, four nurses employed by 
Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), one EGPAF senior official, two 
Ministry of Health (MoH) officials and one US President’s Emergency Plan for Aids 
Relief (PEPFAR) senior official were interviewed.  
The following sections present the themes that emerged from the interviews 
categorised according to the benchmarks for evaluating the effectiveness of health 
interventions.  
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Table 6.1a Demographic information and the relevant working experience of the study participants  
ID District Profession Relevant experience Qualification 
HCW1 Thaba Tseka Pharmacist 5-8 years dispensing ART/TB drugs  Honour's degree in pharmacy 
HCW2 Thaba Tseka Nurse 1-7 years ART/ANC  Diploma in general nursing and midwifery 
HCW3 Thaba Tseka Nurse 7 and 9 years ART  Diploma in general nursing and midwifery 
HCW8 Thaba Tseka Nurse TB officer for 3 years Diploma in general nursing 
HCW9 Thaba Tseka Laboratory personnel 5 to 7 years ART laboratory monitoring  Diploma in bio-medical technology; Certificate in 
microscopy. 
HCW10 Qacha's Nek Pharmacist 8 years dispensing ART/TB drugs  Diploma in pharmacy technician 
HCW13 Qacha's Nek Nurse assistant 6 years ART Certificate in nurse assistance 
HCW14 Qacha's Nek Nurse 4 years ART  Diploma in general nursing 
HCW15 Qacha's Nek Nurse 10 years ART Diploma in general nursing and midwifery 
HCW16 Qacha's Nek Nurse 8 years ART  Diploma in general nursing and midwifery 
HCW17 Qacha's Nek Counsellor 5-6 years adult ART patient counselling Bachelor’s degree in pastoral care and counselling  
HCW18 Mokhotlong Pharmacist 6 years dispensing ART/TB drugs Honour's degree in pharmacy 
HCW20 Mokhotlong Nurse assistant 34 years nursing experience Certificate in nurse assistance 
HCW21 Mokhotlong Nurse 3 years ART Diploma in general nursing and midwifery 
HCW22 Mokhotlong Nurse 1 year ART  Bachelor's degree in nursing 
HCW23 Mokhotlong Nurse 6 years adolescent ART Diploma in general nursing and midwifery 
HCW=healthcare worker; IPT=isoniazid preventive therapy; MOH=Ministry of Health;  
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Table 6.1b Demographic information and the relevant working experience of the study participants (continued) 
ID District Profession Relevant experience Qualification 
HCW24 Mokhotlong Nurse 7 years TB clinic Diploma in general nursing and midwifery 
HCW25 Mohale's Hoek Nurse 7 years TB clinic Certificate in nurse assistance 
HCW26 Mohale's Hoek Nurse 2 years adolescent ART Diploma in general nursing 
HCW27 Mohale's Hoek Pharmacist [unspecified] years dispensing ART/TB drugs Honours degree in pharmacy 
HCW28 Mohale's Hoek Nurse 4 years ART Diploma in general nursing 
HCW30 Mohale's Hoek Counsellor 5 years adult ART patient counselling Bachelor’s degree in pastoral care and counselling 
HCW31 Mohale’s Hoek Nurse 4 years ART/MCH Diploma in general nursing 
HCW32 Mohale’s Hoek Nurse 3 years adolescent ART Diploma in general nursing 
HCW33 Mohale’s Hoek Nurse assistant 4 years TB clinic Certificate in nurse assistance 
HCW34 Maseru Nurse 2 years ART Diploma in general nursing 
HCW35 Maseru Nurse 4 years ART Diploma in general nursing and midwifery 
HCW36 Maseru Nurse 5 years ART Bachelor's degree in nursing 
HCW37 Maseru Nurse assistant 5 years ART Certificate in nurse assistance 
HCW38 Maseru Nurse 7 years ART/MCH  Diploma in general nursing 
HCW39 Maseru Pharmacy technician 5 years assisting dispensing ART/TB drugs Diploma in pharmacy technician 
HCW40 Maseru Nurse assistant 1 year TB clinic Certificate in nurse assistance 
HCW=healthcare worker; IPT=isoniazid preventive therapy; MCH=Mother and child health;  MOH=Ministry of Health;  
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Table 6.1c  Demographic information and the relevant working experience of the study participants (continued) 
ID District Profession Relevant experience Qualification 
HCW41 Maseru Nurse 2 years ART Diploma in general nursing 
HCW42 Maseru Nurse 2 years ART Diploma in general nursing 
HCW43 Maseru Nurse 10 years ART Master's degree in nursing 
HCW44 Maseru Nurse 1 year adolescent ART Bachelor's degree in nursing 
HCW45 Maseru Nurse <1 year ART Diploma in general nursing 
HCW46 Maseru Nurse 9 years ART/TB Master's degree in nursing 
HCW47 Maseru Laboratory personnel 10 years ART laboratory monitoring Diploma in pharmacy technician 
HCW48 Berea Nurse assistant 8 years ART/MCH Certificate in nurse assistance 
HCW49 Berea Nurse assistant 11 years ART/MCH Certificate in nurse assistance 
EGPAF1 Berea Nurse 3 years EGPAF HIV/TB Clinical Mentorship team Diploma in general nursing and midwifery 
EGPAF2 Berea Nurse 5 years EGPAF HIV/TB Clinical Mentorship team Bachelor's degree in nursing 
EGPAF3 Maseru Quality Improvement officer 5 years EGPAF Quality Improvement team Bachelor's degree in nursing 
EGPAF4 Thaba Tseka Nurse (EGPAF) 2 years ART/MCH nurse Diploma in general nursing 
EGPAF5 Maseru Medical doctor 5 years EGPAF senior management, Lesotho  Medical degree; Master’s degree in public health  
PEPFAR Maseru  PEPFAR  PEPFAR Lesotho  Medical degree; Master’s degree in public health 
WHO Maseru Medical doctor Senior management, WHO country office, Lesotho  Medical degree; Master’s degree in public health 
MOH1 Maseru Public health nurse  Representative at HIV/TB Directorate Master’s degree in public health 
MOH2 Maseru Medical doctor Representative at HIV/TB Directorate Medical degree; Master’s degree in public health 
EGPAF= Elizabeth Glaser Pediatric AIDS Foundation; HCW=healthcare worker; PEPFAR= US President’s Emergency Plan for Aids Relief; MOH=Ministry of 
Health; WHO=World Health Organization.  
© Central University of Technology, Free State
 161 
Level I: Effectiveness – the extent the practice achieves the desired 
outcomes 
Most of the healthcare workers affirmed that IPT was largely effective in mitigating the 
occurrence of TB. Cases of TB had significantly gone down in patients who had taken 
IPT. However, they noted that the continued occurrence of TB after taking IPT was 
worrying. One healthcare worker mentioned that:  
“Although the number of cases of TB among HIV patients are dwindling, 
TB cases continue to occur occasionally after IPT. Three patients 
exposed to IPT developed TB last month.” [EGPAF1] 
The main barriers to the effective implementation of IPT included ineffective monitoring 
and evaluation particularly inadequate laboratory monitoring, ineffective health 
information systems, an inadequately managed patient referral system and poor 
knowledge, attitudes and practices (KAPs) of healthcare workers. For example, 
concerning monitoring and evaluation, some HCWs were not sure of IPT coverage in 
their respective centres citing that:  
“The total IPT enrolment is not known because some ART patients are not 
recorded in the register when we run out of registers and because our monthly 
reports are not analysed longitudinally. The reports are send to the MOH for 
congregate analysis but we often do not get feedback.” [HCW17] 
On cross-interviewing the representative of the MoH about the deficiency of cohort 
analysis of IPT indicators, the officials had this to say: 
“Note that due to resource constraints, it is not feasible for MOH to frequently 
assess the effectiveness of the programmes they are implementing. The major 
goal of the MOH is to increase IPT uptake alongside ARVs and TB treatment.” 
[MoH1] 
Despite the affirmation by healthcare workers that IPT was generally effective, the most 
cited concerns for IPT effectiveness included poor monitoring and evaluation resulting 
in late detection of side effects, and in some patients developing TB post exposure to 
IPT. For example, healthcare workers categorically stated that:  
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 “Timely detection of side effects to ART and co-drugs such as cotrimoxazole is important. In this 
hospital, one patient reacted to concurrent cotrimoxazole and IPT two weeks after initiation of 
TDF/3TC/EFV.” [EGPAF3] 
Underreporting of monthly statistics, a point emphasised by representatives of the 
implementing partner organisations, was another main element affecting the efficiency 
of the health information system. One source commented as follows: 
“Although the MoH has adopted 3 key indicators for monitoring IPT, the 
indicator system is paper-based. Inaccurate reporting and underreporting of 
data from health care centres is common.” [WHO] 
The paper-based monitoring system in the country is also affecting the patient referral 
system. A representative for the organisation, PEPFAR, confided that: 
“The paper-based patient referral system in the country needs more resources 
including stationery and patient registers. Confirmation of patients’ arrival at 
the referred centres is often lacking. This confounds the national monthly 
statistics.” [PEPFAR] 
Healthcare workers noted that more frequent visits of patients were required to improve 
monitoring. However, concerning the need to increase hospital visits to improve patient 
monitoring, one representative of implementing partners had a different opinion: 
“Note that the frequency of check-up dates in under-resourced countries is 
guided by the need to balance between the amount of resources the patients 
have and the need for the hospital visits.” [PEPFAR]   
Level II: Reach – the extent IPT covers the intended target population 
According to the Ministry of Health officials, IPT uptake had a slow start and a 
suboptimal trend over the years since its inception. With respect to coverage, the main 
challenge was that densely inhabited districts had a lower coverage, compared to the 
sparsely populated districts. In their own words:  
“Probably about two-thirds of patients on ART have received IPT in the sparsely 
populated districts since 2011 compared to 50% in the densely inhabited 
districts since 2011.” [MoH1] 
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According to representatives of MoH and partner organisations, the main barrier to IPT 
implementation was inadequate national planning. On this point, one of the 
representatives revealed that: 
“One may attribute the success or failure of HIV/TB interventions to lack of 
foresight at the planning stage with regard to the amount and nature of 
resources required and poor capacity to solve problems that arise.” [PEPFAR] 
Representatives of partner organisations noted that the Lesotho Government was 
doing all in its power, but that sufficient capacity was lacking. In their own words, they 
expressed that huge amounts of resources were required but were not available. 
Concerning these challenges, representatives for PEPFAR observed that: 
“The government of Lesotho is doing reasonably well… however, the MOH 
has no sufficient capacity to implement HIV/TB programmes exclusively…” 
[PEPFAR] 
“Resource constraints are a major challenge. With a population of about 2 
million, the country has an estimated 500, 000 HIV positive people. This 
number is too high and requires a massive amount of resources.” [PEPFAR] 
With respect to barriers inhibiting IPT reaching the target population, fear of side effects 
was also reiterated by healthcare workers. One commented as follows: 
“In one hospital, sporadic cases of severe side effects of liver toxicity while on 
IPT resulted in some ART nurses declining to prescribe IPT for months. IPT 
had been given to patients with compromised liver function without following 
the guidelines” [HCW32] 
Other barriers included social and economic factors such as lack of disclosure of HIV 
status, and lack of money for transport. Ineffective service delivery, particularly 
ineffective TB screening, was the main barrier to IPT uptake in many areas of the 
country:  
“Those with presumptive signs of TB; patients declining to submit sputum for 
TB screening are delayed until TB is ruled out.” [HCW49] 
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One sticking point on IPT implementation in the country is the slow scale up of IPT 
uptake in patients enrolled on ART before IPT was launched in 2011. The 
representatives of the implementing partners mentioned that:  
“There is a general perception that [patients long on ART] have a low risk of 
developing TB after taking ART for a long time. For this reason, IPT was 
prescribed mostly to new patients in the initial stages of the programme.” 
[PEPFAR] 
On the same point of delayed IPT uptake in patients on ART for a long time, one 
PEPFAR representative revealed that “technical challenges in reviewing the manual 
patient files to identify patients long on ART” was the reasons for this problem.  
One pertinent theme on the delayed IPT uptake was poor staff education. The 
representatives of partner organisations opinioned that staff education remained a 
challenge and was to blame, at least in part, for the poor uptake of IPT in the country. 
The representatives gave these insightful comments:  
“HCWs, hesitant to initiate IPT concurrently with ARVs before ruling out side 
effects of the ARVs, take too long to rule out the side effects. Inadequate 
training is the main reason behind this. In practice, the hesitation leads to loss 
of patients through the cracks.” [EGPAF5] 
Level III: Sustainability – the extent to which the practice can be maintained 
and monitored 
Concerning the sustainability of the intervention, additional resources were required, 
including human resources, particularly data clerks, file managers, nurses and 
pharmacists – for the sparsely populated districts; physical infrastructure – laboratory 
upgrades in particular, and improved registers. A stricter monitoring and evaluation 
scheme entailing changes such as increasing the frequency of hospital visits by some 
patient groups, integrating the IPT and ART registers, was viewed as a way of 
improving IPT uptake and its outcomes. In addition, some healthcare workers 
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lamented the intermittent stock outs of the necessary supplies and products. In one 
hospital, a healthcare worker had this to say:  
“We often run out of stock for vitamin B6, cotrimoxazole and dapsone … for 
adults. These drugs run out of stock more frequently than other drugs, 
sometimes for two months on end. Vitamin B6 is supplied in small quantities.” 
[HCW27] 
MoH officials expressed that health system financing needed to be increased to 
improve the sustainability of the HIV/TB programmes, including IPT. Staff shortage 
was another problem. One MoH official remarked that:  
“Staff shortages are a major challenge. Inadequate community health workers 
to oversee the implementation of the three I’s programme which includes IPT 
is a challenge.” [MoH2] 
Level IV: Adaptation – the extent to which the IPT intervention has been 
applied to and adapted to the local context. 
Lack of engagement of healthcare workers responsible for implementing IPT was a 
challenge inhibiting IPT uptake. One important point was that some nurses were not 
familiar with IPT prescription requirements for children. One healthcare worker 
observed that:  
“Nurses are not entirely familiar with IPT prescription and monitoring guidelines 
for children.” [HCW49] 
To address this gap and improve adaptation of IPT practice for local need, health 
workers needed clearer guidelines on the ideal timing of IPT relative to ART 
commencement, and the duration after which IPT should be repeated for patients 
previously exposed to IPT. For the record, one healthcare workers had this to say 
concerning repeated IPT: 
“Guidelines are not clear on the duration after which IPT should be repeated. 
Ideally, we repeat IPT every two years in some patients.” [HCW25] 
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Lack of clarity of guidelines was also echoed by other healthcare workers. Their 
concern was that there was too much room for discretional IPT prescription. This 
contributed to poor implementation of IPT. One healthcare remarked as follows 
concerning the excessive discretional IPT prescription without following the guidelines:   
“In practice, we initiate ART before IPT to unmask side effects to ARVs. 
However, this practice is discretional for prescribers.” [EGPAF2] 
6.4 DISCUSSION 
A number of challenges in the health system of Lesotho are hampering effective 
implementation of the IPT programme. The spectrum of the challenges in the health 
system is wide and spans the ‘six building blocks’ of the national health system, as 
advocated by the WHO (2007). Poor decentralisation of HIV services, an inefficient 
monitoring and evaluation system, and ineffective service delivery were some of the 
main challenges at the core of the problem of IPT uptake in Lesotho. Furthermore, 
interrupted supply chains, health workforce factors, inadequate health system 
financing and inefficient health information systems were the other challenges 
identified. The study also found that the interrelatedness of these factors called for a 
multifactorial approach to addressing them.  
In particular, poor decentralisation of HIV/TB services was found to be a barrier 
affecting the reach of IPT to some geographic locations in the country. HIV/TB 
services, including the IPT programme, remain disproportionately more concentrated 
in Maseru District, despite efforts to scale up HIV/TB services in other densely 
populated districts of the country. Another finding attributed to the unbalanced 
decentralisation of HIV/TB services is the gap in scaling up IPT in children, particularly 
in non-scale up districts. The majority of children exposed to TB have not been given 
IPT due to challenges hampering reaching out to children in their homes. This 
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emphasises the need to improve decentralisation of HIV/TB services to address this 
challenge. To illustrate the problem of decentralisation of HIV/TB services in the 
country, the majority of healthcare workers, and 75% of GeneXpert machines were still 
located in the densely populated districts in 2014 (PEPFAR Lesotho 2016). Notably, 
Tesfaye, Fiseha, Assefa, Klinkenberg, Balanco and Langley (2017) note that the 
investment cost for full implementation of GeneXpert machines remains far beyond the 
budgets of the national TB control programmes in developing countries, particularly 
those in sub-Saharan Africa, and they suggest that other cheaper alternatives may be 
needed.  
Late onset of antenatal care (ANC) by pregnant women, a problem commonly 
observed in Lesotho (Mugomeri, Musa & Chatanga 2016), is another challenge 
affecting the implementation of IPT. Tiam, Machekano, Gounder, Maama-Maime, 
Ntene-Sealiete, Sahu, Isavwa, Oyebanji, Ahimbisibwe, Mokone, Barnes, Chaisson, 
Guay and Kassaye (2014) also reported that at least 32% of pregnant women attend 
ANC for the first time in the third trimester, and can therefore only start with IPT at a 
late stage. Further decentralisation of healthcare services is therefore needed to 
improve the uptake of IPT. However, the decentralisation of Lesotho’s healthcare 
system faces many challenges, including shortages of healthcare workers 
(Bemelmans, Goux, Baert, Van Cutsem, Motsamai, Philips, Van Damme, Mwale, Biot 
& Van Den Akker 2015). 
Ineffective TB screening and poor adherence to ART further delay IPT uptake due to 
the need to rule out TB before starting IPT. Ayele, Van Mourik and Bonten (2015) note 
that lack of access to latest technologies for excluding a pre-existing TB infection prior 
to treatment initiation is a challenge in developing countries. This problem in Lesotho 
is compounded by slow uptake of GeneXpert technology. PEPFAR Lesotho (2016) 
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note that Lesotho had a total of 28 GeneXpert machines that were not yet fully utilised 
due to shortages of healthcare workers. The problem of healthcare worker shortage 
affecting TB screening and resulting in slow uptake of IPT is a typical example of factor 
interplay in the health system of Lesotho. As the WHO (2007) notes, dynamic 
interrelationships of factors in the healthcare system need to be delineated in efforts 
to address challenges in health systems.  
Poor monitoring and evaluation of HIV/TB services is a challenge affecting the 
effectiveness of IPT intervention in developing countries, Lesotho included. The need 
to rule out side effects to ART and ensure that patients are stable on ART before IPT 
is initiated, remains a challenge. Late detection of side effects is another symptom of 
poor monitoring systems and poor staff education. It is important to note that 
developing countries continue to find it difficult to meet minimum clinical and laboratory 
monitoring tests recommended by the WHO (WHO 2011). One solution for this 
problem is to intensify staff development programmes in the country, a solution also 
noted by Buchbinder and Shanks (2016). 
One notable theme which emerged from healthcare workers was the need to improve 
patient monitoring schedules. However, to improve patient adherence to ART/IPT, 
evaluation studies on the merit of stricter patient monitoring schedules - particularly the 
effectiveness of the current frequency of check-up visits - are required. PEPFAR 
representatives in the study noted that there is need for a balance between the amount 
of resources available to the patients, and the need for hospital visits.  
Healthcare worker factors, particularly poor KAPs, were a main barrier to effective IPT 
implementation. The need for intensive training of healthcare workers to remove the 
general perception that patients enrolled on ART before IPT was launched, have a 
lower risk of developing TB compared to patients enrolled on ART after IPT was 
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launched, cannot be over-emphasised. Ayele et al. (2015) and Noé, Ribeiro, Anselmo, 
Maixenchs, Sitole, Munguambe, Blanco, Souef and García-Basteiro (2017) emphasise 
the need for healthcare worker education in high TB-burden settings to improve 
healthcare workers’ perceptions and knowledge of IPT practice guidelines. 
The need to monitor adherence to ART before administering IPT is one critical factor 
hindering IPT implementation. Healthcare workers in this study delayed giving IPT to 
patients with poor adherence to ART until the patients were stable on ART. In addition, 
patients deemed too sick were also delayed. Apparently patients deemed too sick are 
at the greatest risk of developing TB (Collins, Juste, Koenig, Secours, Ocheretina, 
Bernard, Riviere, Calnan, Dunning & Hurtado Rúa 2015). Healthcare worker education 
is therefore required to address this problem.   
Poor monitoring of the effectiveness of the IPT programme, mainly due to a weak 
monitoring system, needs attention in Lesotho. Timely detection of patients getting 
infected by TB after IPT is necessary to inform IPT policy for improvement 
(Churchyard, Mametja, Mvusi, Ndjeka, Hesseling, Reid, Babatunde & Pillay 2014). 
Without a systematic collection of data providing evidence of the effectiveness or 
failure of an intervention programme such as IPT, it is difficult to convince healthcare 
workers to change or improve in certain area of practice (Saito, Howard, Chege, 
Ellman, Ahoua, Elul & Rabkin 2015). The lack of longitudinal analysis of data 
supporting the effectiveness of IPT, and poor monitoring and evaluation may be a 
symptom of a sub-optimal monitoring and evaluation system in the country. Lack of 
skills in healthcare workers involved in data gathering and analysis may be the root 
cause, while other challenges, including poor implementation of electronic medical 
records (EMR) systems and over-reliance on paper-based monitoring systems, may 
be nested in the problem of skills shortage in the country. Suggestions for improving 
© Central University of Technology, Free State
 170 
monitoring systems include providing hands-on support for data collection and use at 
facility and national levels, utilising web-based databases for data entry, and efficient 
dissemination of results (Saito et al. 2015). 
Health workforce factors are also a challenge to improving the adaptation of IPT 
practice to suit the local context. Healthcare workers do not seem to have a uniform 
approach to the implementation of IPT. Some nurses are not entirely familiar with IPT 
prescription and monitoring guidelines for children. The timing of IPT initiation relative 
to ART remains largely discretional in many hospitals, with some prescribers initiating 
IPT six months after starting the ART, and some only two weeks after ART. This points 
to a paucity in the clarity of IPT guidelines at the extent of adaptation of the guidelines 
to suit the local context. More training and supervision is therefore required. 
A number of changes to the health system are needed to maintain and sustain the IPT 
programme. Additional health system financing is needed to acquire additional 
healthcare workers, data clerks, stationery - particularly integrated ART/IPT registers 
and combined ART/IPT dosage forms. In addition, improved supply chains and 
additional resources are also needed to sustain the programme. Furthermore, physical 
infrastructure – laboratory upgrades in particular - are required.  
The incidence of TB in Lesotho is estimated at 852/100,000 in the general population, 
making the country a high TB-burden setting (WHO 2015). Although IPT is expected 
to have a high impact in Lesotho, the contextual underpinnings behind the slow uptake 
of IPT are an important research problem. The slow trend of IPT uptake is a loss of 
opportunity to leverage the existing HIV services for an intervention particularly ear-
marked for high TB-burden countries such as Lesotho. Underestimation of potential 
public health impact has been identified as the main cause of the delayed 
implementation of this intervention in the Ivory Coast (Temprano ANRS 12136 Study 
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Group 2015). Healthcare worker education is therefore needed to improve IPT 
implementation in the country. 
Out of the major barriers to the scaling up of health interventions in developing 
countries outlined by Yamey (2012) - the barriers re-echoed in this study - include: 
limited human resources; leadership challenges; poor health systems capacity; and 
lack of engagement of local implementers. Therefore, to address the problems 
hampering IPT uptake in Lesotho, there is need to examine these challenges in the 
health system reform programme of the country, as the barriers are better addressed 
through a comprehensive reform programme. 
6.5 CONCLUSION  
The spectrum of the challenges curtailing the implementation of IPT in Lesotho is 
evidently wide. As such, these challenges call for a systems approach to addressing 
them. Particular elements of the themes emanating from this study that have a direct 
effect on the implementation of IPT, and which resonate with global challenges 
inhibiting scale up of this particular intervention in developing countries, include 
ineffective TB screening, late detection of side effects due to weak monitoring systems 
and inadequate healthcare worker education. Clearly, these challenges indicate the 
need for a health systems approach to the implementation of IPT and other complex 
health interventions in developing countries.  
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CHAPTER SEVEN 
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CHAPTER SEVEN: CONCLUDING REMARKS  
7.1 BACKGROUND 
The global syndemic of HIV and TB remains a public health threat, particularly in 
people living with HIV (PLHIV) in developing countries with high TB burdens. The 
World Health Organization (WHO) recommends the use of isoniazid preventive 
therapy (IPT) to reduce TB incidence in PLHIV, and continues to appeal for member 
countries to scale up the implementation of this intervention. The WHO remains 
concerned about the slow rates of IPT initiation and inadequate reporting of IPT 
outcomes in countries with poor IPT uptake. In addition, barriers to scaling up health 
interventions in developing countries remain obscure, despite the fact that 
understanding the contextual factors underpinning these barriers is pivotal for policy 
making.  
This study set out to investigate the rate of initiation and retention on IPT, its 
effectiveness and the contextual constraints affecting its implementation in Lesotho, a 
small country in Southern Africa regarded as a high TB-burden setting, and having one 
of the highest incidences of HIV globally. IPT was introduced to Lesotho in 2011. Data 
on IPT from this setting is important to the global audience for answering at least three 
research questions: (1) Is the rate of initiation and retention on IPT in high TB-burden 
countries good enough to have a significant impact on TB incidence in these countries? 
(2) Is IPT effective in circumstances where IPT is given years after starting ART? (3) 
What health system factors are hampering the implementation of IPT in developing 
countries?  
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7.2 CONCLUDING REMARKS  
While there are challenges in the implementation and effectiveness of IPT in Lesotho, 
the IPT intervention has considerably reduced the incidence of TB in PLHIV in the 
country. The various challenges discussed in this study may contribute to policy 
discourse on preventing the occurrence of TB in PLHIV in Lesotho.   
Concerning the rate of initiation and retention on IPT, this study found a fairly high 
overall uptake, but with a slow rate of IPT initiation and low proportion of defaults (see 
Chapter Four). The problem of poor uptake of IPT was more pronounced in the patients 
enrolled before the intervention was launched. In addition, children and adolescents 
were more affected compared to adults. Furthermore, densely populated districts had 
poorer uptake of IPT compared to the sparsely populated districts, although the gap 
has been narrowing since 2011. The problem of poor uptake of IPT in these groups 
points to the need for reforming the health sector, particularly decentralising HIV/TB 
services and improving health service delivery. 
The investigations on the effect of longer durations between commencing ART and 
IPT revealed that better outcomes of IPT are achieved when IPT is given in the early 
stages of ART commencement, with the best results obtained when IPT is prescribed 
within six months of starting ART (see Chapter Five). Of note, delaying IPT after 
starting ART renders IPT less effective to a level comparable to no IPT intervention at 
all. The investigations in this study revealed that the loss of effectiveness of IPT is 
another challenge in Lesotho which calls for booster doses of IPT to prevent the 
occurrence of TB after exposure to IPT. Concerning the predictors of TB occurrence, 
lower immunity at the time of enrolment into HIV care, geographic location and gender 
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emerged as significant risk factors for contracting TB in this study, implying that these 
factors need to be considered in the policies on TB prevention in the country.  
With respect to the health systems challenges curtailing the implementation of IPT, 
(see Chapter Six), the study found that ineffective TB screening, late detection of side 
effects due to weak monitoring systems, and inadequate education of healthcare 
workers are the most critical barriers to IPT implementation of IPT. In addition, the 
range of the factors underpinning the implementation of IPT in Lesotho was wide, 
which calls for holistic reforms of the health system, particularly in the domains of 
decentralisation; monitoring and evaluation; service delivery; supply chain; health 
workforce; health system financing and health information system.  
7.3 LIMITATIONS OF THE STUDY 
The findings of this study are not without limitations, the most critical being that the 
effectiveness of the IPT intervention was evaluated in isolation, leaving out the impact 
of the other TB intervention programmes, such as the infection control (IC) and 
intensive case finding (ICF) sub-programmes of the Three I’s programme (IC). It is 
hard to establish the effectiveness of health interventions due to the complexity of the 
factors involved. Therefore, despite the importance of the findings of this study, they 
need to be interpreted with these limitations in mind.  
7.4 FURTHER RECOMMENDED RESEARCH 
Findings from this study evoked further research questions which need to be answered 
in further research. These questions include, but are not limited to, the following:  
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 The occurrence of TB after IPT poses an important research question on the need 
to find the optimal duration after which IPT should be repeated in high TB-burden 
settings where reinfection is likely. 
 Further research should also identify deficiencies in infection control programmes 
that are worsening reinfection rates in patients exposed to IPT in high TB-burden 
settings such as Lesotho. 
 The contextual constraints affecting the implementation of IPT call for further 
research on the statuses of developing countries’ national healthcare systems with 
respect to capacities for implementing health interventions. Such research may 
need to focus on debating the most critical elements of the national health systems 
that need to be reformed. Particular elements pertinent to improving the 
implementation of preventative health interventions such as IPT may include 
decentralisation and healthcare service delivery reforms. 
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APPENDICES  
Appendix A1 Interview guide 1: Policies and guidelines for IPT intervention in Lesotho 
INTERVIEW GUIDE 
ISONIAZID PREVENTIVE THERAPY ON TUBERCULOSIS OCCURRENCE IN HIV-POSITIVE PATIENTS IN LESOTHO 
1. Respondent number         2. Date of interview 
PART 1: POLICIES AND GUIDELINES FOR IPT INTERVENTION (Ministry of Health officials and support partners)  
1. Respondent information  
a. Profession b. Gender c. Job description 
   
2. Policies & guidelines on IPT implementation in Lesotho 
2A Leadership and governance-related Response (Please explain your answer or give examples) 
1. TB is still a health challenge in Lesotho despite interventions such 
as IPT. How would you rate the implementation and outcomes of 
IPT 
 
2B Service delivery-related  
1. Do you think standard TB screening algorithms for screening TB 
before IPT are adequate? What challenges are being encountered 
in the roll out of GeneXpert machines in screening TB?  
 
2C Supplies and products-related  
1. Are you aware of any challenges facing the availability of 
laboratory reagents and equipment used in the monitoring of 
TB/HIV and IPT? Examples include: Test kits for hepatitis B 
screening, liver function tests and GeneXpert. 
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2. Is IPT adequately available in the right dosages (e.g.300 mg) in all 
settings? Are we likely to see a single tablet dosage form for 
Cotrimoxazole, IPT and Vitamin B6 in the near future? 
 
2D Training and supervision  
1. What plans are there to ensure supervision of TB/HIV and IPT 
implementers?  
2. What challenges does the TB/HIV and IPT patient referral system 
face?  
2E Health information system-related  
1. What are the main weaknesses in monitoring and evaluation of 
TB/HIV programmes, including IPT implementation? 
 
 
2. Is there a clear strategy for collecting and analysing the evidence 
of IPT effectiveness?  
3. Which key indicators are being used for monitoring and evaluation 
of IPT implementation, and how is the IPT programme 
performing? 
 
2F Health system financing-related  
1. Is there adequate funding for the IPT programme in the medium 
and long term?  
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Appendix A2 Interview guide 2: Implementation of IPT intervention in Lesotho  
INTERVIEW GUIDE 
 ISONIAZID PREVENTIVE THERAPY ON TUBERCULOSIS OCCURRENCE IN HIV-POSITIVE PATIENTS IN LESOTHO 
1. Respondent number         2. Date of interview 
 
PART 2: IMPLEMENTATION OF IPT INTERVENTION IN LESOTHO (For healthcare workers) 
1. Demographic characteristics of the respondent  
3. District # 4. Health Facility 5. Profession 6. Highest Qualification 7. Gender 8. Age 9. Experience in years 
       
 2. Implementers of IPT intervention in Lesotho 
3A Reach: Extent that the IPT intervention covers the intended 
and critical target population 
Response (Please explain your answer or give examples) 
1. Which groups of people are getting IPT in this setting?   
2. How many of these groups have been given IPT? (Please 
give an estimate)  
3. Which patients do you sometimes delay to give IPT, and 
why?  
3B Effectiveness: Extent to which IPT has achieved the desired 
outcomes 
 
1. To what extent is IPT stopping the occurrence of TB in this 
setting?  
2. Which adverse reactions to IPT do you often encounter, and 
in which groups of patients?   
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3C Barriers to implementing IPT intervention  
1. Which of the following factors do you consider as barriers 
to IPT uptake in this setting?  
Side effects; Non-adherence; fear of toxicity of IPT; fear of 
drug resistance; and social factors 
 
3D Sustainability: Extent to which the practice can be 
maintained and monitored 
 
1. What extra work does IPT add to existing ART procedures 
and processes?     
2. Have you ever run out of IPT, vitamin B6 or Cotrimoxazole 
in this setting?  
3. What additional resources are required to sustain IPT 
intervention over time?  
3E Adaptation: Extent to which IPT intervention has been 
adapted to the local context 
 
1. Describe how IPT is prescribed and monitored in this 
setting. Include in your answer how often the patients have 
to come for checkup while on IPT. 
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Appendix A3 The user interface for the database tool used to extract data from the patient records  
 
 
Note: The database tool had a module for automating the creation of the sampling frame. Also, for quality control purposes, 
data for the initiation of IPT were collected in duplicate from the ART and IPT registers.  
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Appendix B Clinical and laboratory data extraction form for phase 2 of the study 
CLINICAL & LABORATORY DATA EXTRACTION FORM 
1. Patient code                                       2. Anonymous code 
3. District # 4. Health Facility 5. Gender 6. Age 7. DOB 8. Marital 
e.g. Maseru Any of the 5 hospitals    Male/ Female  DD/MMYY  
 
9. Confirmed HIV+ 10. Enrolled in HIV care 11. Transfer-in 12. ART start 13. 1st regimen 14. 2nd-line 
regimen 
15. 3rd line 16. Dead 17. Transfer-out 
DD/MM/YY DD/MM/YY DD/MM/YY DD/MM/YY e.g. TDF/3TC/EFV e.g. TDF/3TC/EFV  Y/N Y/N 
 
18. Stop/ Lost-ART 
DD/MM/YY 
19. Reason 20. ART restart 
DD/MM/YY 
21. Stop/ Lost IPT 
DD/MM/YY 
22. Reason 23. IPT restart 
DD/MM/YY 
Wt=weight; Ht=height; Preg=pregnancy; Opp. Infection=opportunistic infection; VL=viral load; Hgb=haemoglobin; HTN=hypertension; HBsAg=hepatitis B 
surface antigen; Liver dis=diagnosis of liver disease based on clinical and laboratory liver function profile; HTN=hypertension; Kidney dis=kidney disease. 
24. 
Che
ck-u
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te
25. 
Foll
ow-
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ate
26. 
Dur
atio
n (m
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27. 
Wt (
kg)
28. 
Ht (
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29. 
Pre
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30. 
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31. 
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32. 
Side
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34. 
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35. 
Side
 effe
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36. 
IPT 
37. 
Side
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38. 
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. Inf
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39. 
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40. 
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41. 
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43. 
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44. 
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45. 
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46. 
HTN
 +/-
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Appendix C1 Information sheet for study participants: English version 
STUDY TITLE: 
ISONIAZID PREVENTIVE THERAPY ON TUBERCULOSIS OCCURRENCE IN HIV-
POSITIVE PATIENTS IN LESOTHO 
Dear respondent 
Introduction 
Tuberculosis (TB) is an important opportunistic disease in people living with human 
immunodeficiency virus (HIV). TB is caused by a bacterium known as Mycobacterium 
tuberculosis. Lesotho is one of the countries that are worst affected by TB. The 
effectiveness of the drug isoniazid preventive therapy (IPT), which was recommended in 
2004 by the World Health Organization for the prevention of TB, is of high importance to 
prevent TB infections among vulnerable groups such as HIV-positive people. However, 
the uptake and the effectiveness of IPT in Lesotho is not fully known. More importantly, 
there is little evidence to inform the process of formulating the best way of improving the 
uptake, retention and monitoring the effectiveness of IPT in HIV-positive people within the 
country. 
We intent to determine the level of coverage, uptake and retention in treatment for IPT. 
We also intend to study the extent to which isoniazid preventive therapy (IPT) is effective 
in preventing TB infection in HIV-positive patients. The occurrence of adverse reactions 
and the associated risk factors will also be studied. The study will culminate in the 
determination of the best way of improving uptake, retention and monitoring of IPT 
intervention in Lesotho.  
What the study involves 
The study will be carried out in two phases. Phase 1 will seek to evaluate the extent of 
coverage, local adaptation of the guidelines and sustainability of IPT intervention among 
HIV-positive people in different settings in Lesotho. Participants will be sampled from 
among Ministry of Health officials, Government partners and health workers involved in 
© Central University of Technology, Free State
 189 
TB/HIV programmes. An interview guide designed by the researcher will be used to collect 
qualitative data. The researcher will identify patterns and themes which will emerge from 
the interviews. The themes will be analysed to identify factors affecting the coverage, 
contextual adaptation of the guidelines and sustainability of IPT intervention in Lesotho.  
Phase 2 will be based on medical records of HIV-positive patients. The study will include 
patients from the current register of ART patients at the five health institutions. The main 
outcome variables include the proportion of patients on IPT, retention records, adherence 
to IPT, occurrence of active tuberculosis, and adverse drug reactions to IPT. 
Notification of results of the study 
The study report will be submitted to the relevant authorities in the Ministry of Health and 
all the hospitals participating in the study. The results are expected to improve IPT practice 
and HIV treatment outcomes in Lesotho. The findings of the study will be sent for review 
and possible publication in suitable journals.  
Risks of being involved in the study 
No adverse events are anticipated to the patients and the participants in the study. The 
researcher will not carry out any medical procedure or administer any drug to the patients. 
The study will make use of routine clinical and laboratory data. However, some 
participants, particularly in phase 1 of the study, may face risks, including consequences 
of information disclosure during the interviews. To safeguard patient information privacy, 
the researcher will observe standard ethical principles for conducting medical research, 
including voluntary participation, the right to decline answering certain questions, and the 
right to withdraw their participation at any time. 
Benefits of participating in the study 
No financial benefits will be awarded to the participants in the study. However, participants 
will gain important information from the study outcomes. 
Participation in the study is voluntary  
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Participation in the study is entirely voluntary. The officials from the Ministry of Health and 
Government partner organisations, as well as hospital administrators included in the study 
reserve the right to deny the researcher access to the patients’ records. In addition, the 
officials and the hospital administrators can terminate participation in the study at any 
time.  
Confidentiality 
Efforts will be made to keep personal information confidential. Personal information will 
only be disclosed if required by law. The Ethics Committee of the Ministry of Health of 
Lesotho reserves the right to demand inspection of the data records if the need arises. 
However, publication of the results will not directly lead to identification of the patients 
included and individuals participating in the study.  
 
If you have questions about your rights as a research subject, you may contact the 
researcher at emugomeri@nul.ls or the Secretariat of the Ethics Committee of the Ministry 
of Health of Lesotho at telephone number (+266) 2222 6317. 
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Appendix C2 Information sheet for study participants: Sesotho version 
SEHLOHO 
PATLISISO EA LITLA-MORAO TSA TSEBELISO EA ISONIAZID (INH) THIBELONG 
EA TB BAKULING BA NANG LE HIV LESOTHO 
Ho ba tla nka Karolo 
Selelekela: 
Lefuba (TB) ke lefu le ka sehlohong le nkang monyetla ho t'soara bakuli ba koatsi ea 
bosolla hlapi (HIV), mme TB e bakoa ke Mycobacterium tuberculosis. Lesotho le oela 
hara linaha tse nang le sekhahla se phahameng sa TB. Bohlokoa ba tsebeliso ea INH ho 
thibela lefu lena la TB bathong ba nang le HIV e khothalelitsoe ka selemo sa 2004 ke 
mokhatlo oa lefatse oa bophelo (WHO) lehoja, matla a t'sebeliso ena ea INH e keneng 
t'sebetsong ka 2011 Lesotho a sa tsejoe. 
Re ikemiselitse ho ithuta tsela eo INH e thibelang TB bakuling ba HIV. Re ikemiselitse 
hape ho fumana sekhahla sa t'sebeliso ea INH thibelong ea TB. Re tla ithuta hape le ka 
litla-morao tse amanang le t'sebeliso ea INH. Boithuto bona bo tla thusa ho fumana 
t'sebeliso e nepahetseng le tatello ea t'sebeliso ea INH thibelong ea TB lesotho. 
Sekenellang ka hara boithuto: 
Boithuto bona bo tlaba mekhahlelo e mmeli. Mokhahlelong oa pele, re tla ithuta ka kanetso 
le t'sebeliso e it'sematletseng ea tataiso ea t'sebeliso ea INH litsing tse fapaneng hara 
batho ba nang le HIV Lesotho. Ba tla nka karolo ba tla khethoa hara basebetsi ba lekala 
la bophelo, mekhatlo enang le selekane le mmuso le basebeletsi ba tsa bophelo ba 
shebaneng le mananeo a HIV/TB. Mofuputsi o tla hlopha lipotso e le ho fuputsa lintla, 
moo a tla hloaea lintlha abe ali lotomanye tafolaneng khahlanong le lintlha tsa bona tse 
phethahetseng ho fumana tsetiso le liphephetso tse tobileng t'sebeliso e phethahetseng 
ea INH lesotho. 
Mokhahlelo oa bobeli o tla manolla manane a lihlopha tsa bakoli ba nang le HIV. boithuto 
bona bo tla shebana le lihlopha tsa bakoli ba ngolisitsoeng hajoale ba sebelisang litlhare 
tsa HIV litsing tse hlano tse kenelletseng boithutong. Lintlha-kholo li kenyeletsa karolo ea 
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bakoli ba sebelisang INH, poloko ea manane, ho t'sepahalla INH, boteng ba TB le litla-
morao tsa tsebeliso ea INH. 
Tsebiso ea sephetho sa boithuto: 
Tlaleho ea sephetho e tla isoa ho ba ikarabellang lekaleng la bophelo le litsing tse nkileng 
karolo boithutong bona. Sephetho se reretsoe ho ntlafatsa tsebeliso ea INH thibelong ea 
TB le ho ntlafatsa bophelo ba bakuli ba sebelisang litlhare tsa HIV. Liphuputso tsohle li tla 
hlahlojoa mme li phatlalatsoe.  
Kotsi ea ho kenella boithutong: 
Ha ho na litla-morao tse mpe tse lebeletsoeng ho bakuli ba nkang karolo boithutong bona. 
Mofuputsi a ke ke a fa motho ea nkang karolo setlhare sefeng kapa sefeng. Boithuto bo 
tla sebelisa litlaleho tsa ngaka. E le ho boloka lekunutu la bakuli, mofuputsi o tla latela 
melaoana ea bofuputsi e khothalelitsoeng ke Helsinki ka 2013. 
Melemo ea honka karolo: 
Ha ho na chelete eo mokuli eo ho sebelisitsoeng litokomane tsa hae a tla e fumana. 
Ho nka karolo ke boithaopo: 
Ho nka karolo ke boikhethelo ba motho ka mong. Bookameli ba litsi tseo boithuto bona 
bo tla etsoa ho tsona bo na le tokelo ea ho hana ka litokomane tsa bakuli kapa hona ho 
khina boithuto bona nako eohle. 
Poloko ea lekunutu: 
Lintlha tsa mokuli li tla t'sireletsoa ka hohle-hohle, li tla tsebisoa ha fela molao o lumela. 
Komiti ea molao ho tsoa lekaleng la bophelo ena le tokelo ea ho hlahloba liphuputso ha 
ho hlokahala. Le ha ho le joalo, phatlalatso ea sephetho e ke ke ea supa ba nkileng karolo 
ka kotloloho. 
Ha u na le lipotso kapa u hloka tlhakisetso mabapi le litokelo tsa hao ho nkeng karolo 
boithutong bona, u ka letsetsa lekhotlana la ketsa-molao la lekala la bophelo nomorong 
tse latelang (+266) 2222 6317. Moo o ka fumanang moetapele oa boithuto: E Mugomeri 
email e.mugomeri@nul.ls or emugomeri@yahoo.com.  
© Central University of Technology, Free State
 193 
Appendix D1 Consent form: English Version 
 
CONSENT TO PARTICIPATE IN RESEARCH 
 
You have been asked to participate in a research study. 
You have been informed about the study by the principal researcher, Mr E. Mugomeri. 
You can also contact E. Mugomeri at: e-mail address: e.mugomeri@nul.ls or 
emugomeri@yahoo.com or the Secretariat of the Ethics Committee of the Ministry of 
Health of Lesotho at +266 2222 6317 should you have questions pertaining to the 
research. 
You may contact the Secretariat of the Ethics Committee of the Faculty of Health 
Sciences, University of the Free State (UFS) at telephone number (051) 4052812 if you 
have questions about your rights as a research subject.  
Your participation in this research is voluntary, and you will not be penalised or lose 
benefits if you refuse to participate, or decide to terminate your participation in the study.  
If you agree to participate, you will be given a signed copy of this document, as well as 
the participant information sheet, which is a written summary of the research. 
The research study, including the above information, has been verbally described to me. 
I understand what my involvement in the study means, and I voluntarily agree to 
participate.  
_____________________   __________________ 
Signature of participant   Date 
_____________________   __________________ 
Signature of witness    Date 
_____________________   __________________ 
Signature of translator    Date 
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Appendix D2 Consent form: Sesotho Version 
 
Tumellano ea ho nka karolo boithutong  
U kopiloe ho nka karolo boithutong bona. 
U tsebisitsoe ka boithuto bona ke E. Mugomeri 
U ka letsetsa lekhotlana la ketsa-molao la lekala la bophelo la Lesotho linomorong tsena: 
+266 2222 6317 nako eohle ha o na le lipotso mabapi le boithuto bona. Moo o ka 
fumanang moetapele oa boithuto: email e.mugomeri@nul.ls or emugomeri@yahoo.com 
U ka letsetsa lekhotlana la ketsa-molao la lekalana la tsa mahlale a bophelo, University 
of Free State (UFS) linomorong tse latelang: (051) 4052812 ha eba o na le lipotso kapa o 
hloka tlhakisetso ka litokelo tsa hao boithutong bona. 
Ho nka karolo ha hao boithutong bona ke ka boithaopo, ha o na ho nkeloa likhato kapa 
oa lahleheloa ke letho ha o ka khetha ho se kenelle boithutong bona kapa ha o ka khetha 
ho itokolla hara nako ea boithuto. 
Ha u lumela ho kenella boithutong bona, o tla fumana tokomane ena e tekennoe le 
kakaretso ea boithuto bona ka bokhuts`oanyane. 
Ke hlaloselitsoe lintlha tse kaholimo le kakaretso ea boithuto ka mantsoe mme ke utloisisa 
karolo ea ka boithutong bona, ka hona ke ithaopela ho nka karolo boithutong bona.  
_____________________   __________________ 
Motekeno oa moithopi   Letsatsi 
_____________________   __________________ 
Motekeno oa paki    Letsatsi 
_____________________   __________________ 
Motekeno oa toloko    Letsatsi  
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Appendix E Letter of approval for ethical clearance 
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